Search

Your search keyword '"Eda K"' showing total 50 results
Start Over Author "Eda K" Database OpenAIRE
50 results on '"Eda K"'

1. Controlling cancer-induced inflammation with a nucleic acid scavenger prevents lung metastasis in murine models of breast cancer

Author

Karenia Landa, Bruce A. Sullenger, Eda K. Holl, Victoria Frazier, David Boczkowski, and Smita K. Nair

Subjects
Dendrimers, Lung Neoplasms, Breast Neoplasms, Inflammation, Proinflammatory cytokine, Metastasis, Mice, 03 medical and health sciences, 0302 clinical medicine, Immune system, Breast cancer, Cell Line, Tumor, Drug Discovery, Tumor Microenvironment, Genetics, Animals, Humans, Medicine, Molecular Biology, 030304 developmental biology, Pharmacology, 0303 health sciences, Tumor microenvironment, business.industry, Pattern recognition receptor, Cancer, medicine.disease, Xenograft Model Antitumor Assays, Treatment Outcome, 030220 oncology & carcinogenesis, Cancer research, Cytokines, Molecular Medicine, Administration, Intravenous, Female, Original Article, medicine.symptom, business, Cell-Free Nucleic Acids
Abstract

Tumor cells release nucleic acid-containing proinflammatory complexes, termed nucleic acid-containing damage-associated molecular patterns (NA DAMPs), passively upon death and actively during stress. NA DAMPs activate pattern recognition receptors on cells in the tumor microenvironment leading to prolonged and intensified inflammation that potentiates metastasis. No strategy exists to control endogenous or therapy-induced inflammation in cancer patients. We discovered that the generation 3.0 polyamidoamine dendrimer (PAMAM-G3) scavenges NA DAMPs and mitigates their proinflammatory effects. In this study, we tested if the nucleic acid scavenger (NAS) PAMAM-G3 reduces lung metastasis in murine models of breast cancer. Our data indicate that PAMAM-G3 treatment decreases cell-free DNA levels and reduces lung metastasis in the experimental intravenous tumor-injection model and the postsurgical tumor-resection model of 4T1 breast cancer. Reduction in lung metastasis is associated with reduction in inflammatory immune cell subsets and proinflammatory cytokine levels in the tumor and the periphery. This study is the first example of NAS-mediated inhibition of metastasis to the lung. The study results provide a strong rationale for inclusion of NAS therapy in women with breast cancer undergoing standard-of-care surgery.

Published
2021

2. Spatial biology analysis reveals B cell follicles in secondary lymphoid structures may regulate anti-tumor responses at initial melanoma diagnosis

Author

Aaron D. Therien, Georgia M. Beasley, Kristen E. Rhodin, Norma E. Farrow, Douglas S. Tyler, David Boczkowski, Rami N. Al-Rohil, Eda K. Holl, and Smita K. Nair

Subjects
Skin Neoplasms, Sentinel Lymph Node Biopsy, Lymphatic Metastasis, Immunology, Immunology and Allergy, Humans, Lymph Node Excision, Biology, Melanoma
Abstract

IntroductionB cells are key regulators of immune responses in melanoma. We aimed to explore differences in the histologic location and activation status of B cell follicles in sentinel lymph nodes (SLN) of melanoma patients.MethodsFlow cytometry was performed on fresh tumor draining lymph nodes (LN). Paraffin slides from a separate cohort underwent NanoString Digital Spatial Profiling (DSP)®. After staining with fluorescent markers for CD20 (B cells), CD3 (T cells), CD11c (antigen presenting cells) and a nuclear marker (tumor) was performed, regions of interest (ROI) were selected based on the location of B cell regions (B cell follicles). A panel of 68 proteins was then analyzed from the ROIs.ResultsB cell percentage trended higher in patients with tumor in LN (n=3) compared to patients with nSLN (n=10) by flow cytometry. B cell regions from a separate cohort of patients with tumor in the (pSLN) (n=8) vs. no tumor (nSLN) (n=16) were examined with DSP. Within B cell regions of the SLN, patients with pSLN had significantly higher expression of multiple activation markers including Ki-67 compared to nSLN patients. Among 4 patients with pSLN, we noted variability in arrangement of B cell follicles which were either surrounding the tumor deposit or appeared to be infiltrating the tumor. The B cell follicle infiltrative pattern was associated with prolonged recurrence free survival.ConclusionThese data suggest a role for B cell follicles in coordinating effective adaptive immune responses in melanoma when low volume metastatic disease is present in tumor draining LN.

Published
2022

3. Immune Expression in Children With Vesicoureteral Reflux: A Pilot Study

Author

J. Todd Purves, John S. Wiener, Ashley W. Johnston, Angela Sinani, Jonathan C. Routh, and Eda K. Holl

Subjects
Male, medicine.medical_specialty, Chemokine, Adolescent, Naive T cell, Urology, T cell, Urinary Bladder, 030232 urology & nephrology, Pilot Projects, Inflammation, urologic and male genital diseases, Vesicoureteral reflux, Flow cytometry, 03 medical and health sciences, 0302 clinical medicine, Immune system, Humans, Medicine, Medical history, Child, skin and connective tissue diseases, Vesico-Ureteral Reflux, medicine.diagnostic_test, biology, business.industry, medicine.disease, female genital diseases and pregnancy complications, medicine.anatomical_structure, Child, Preschool, 030220 oncology & carcinogenesis, biology.protein, Urologic Surgical Procedures, Female, Ureter, medicine.symptom, business
Abstract

Objective To perform an exploratory, descriptive pilot study of the systemic and local immune environment in patients with vesicoureteral reflux (VUR) and bladder-bowel dysfunction (BBD). Methods Consecutive children with VUR undergoing intravesical ureteral reimplantation were enrolled. Patients were assessed for presence of BBD by reported patient history and validated questionnaire. Fresh blood and bladder tissue, collected at the time of surgery, were immediately processed for analysis. Immune cell compositions were determined via flow cytometry. Immune cell activation was also defined at the time of analysis. LegendPlex assay analysis was utilized to define levels of circulating chemokines and cytokines. Results A total of 7 patients were enrolled. Although percentages of circulating immune cells in the blood of those with VUR/BBD and VUR alone were similar, within bladder tissue, VUR/BBD demonstrated increased immune infiltrates compared to VUR alone. Bladder sample analysis showed that B cells, and Effector Memory and Naive T cell percentages were significantly increased in VUR/BBD patients compared to VUR patients. T cell expression of PD1 was increased in bladder tissues of BBD/VUR. Additionally, analysis of circulating neutrophils displayed significantly increased upregulation of PDL-1 in patients with VUR/BBD vs those with VUR only. Conclusion These pilot data suggest an immune-rich microenvironment is present within VUR. Severity of inflammation appeared to correlate with presence of BBD. This implies that targeting pelvic inflammation may be a novel therapy for children with VUR- or non-VUR-related BBD. Follow-up studies are currently underway.

Published
2021

4. Dissecting the immune landscape of tumor draining lymph nodes in melanoma with high-plex spatially resolved protein detection

Author

Georgia M. Beasley, Premi Haynes, Nellie E. Farrow, Brent A. Hanks, Smita K. Nair, Maria Angelica Selim, Douglas S. Tyler, Liuliu Pan, Yan Liang, Aaron D. Therien, Rami N. Al-Rohil, and Eda K. Holl

Subjects
Male, Cancer Research, Pathology, medicine.medical_specialty, CD3, Immunology, CD11c, Article, 03 medical and health sciences, 0302 clinical medicine, Immune system, Biopsy, Tumor Microenvironment, Humans, Immunology and Allergy, Medicine, Melanoma, CD86, CD20, biology, medicine.diagnostic_test, Sentinel Lymph Node Biopsy, business.industry, Dendritic cell, medicine.disease, Oncology, Lymphatic Metastasis, biology.protein, Female, business, 030215 immunology
Abstract

BACKGROUND: In melanoma patients, microscopic tumor in the sentinel lymph node biopsy (SLN) increases the risk of distant metastases but the transition from tumor in the SLN to metastatic disease remains poorly understood. METHODS: Fluorescent staining for CD3, CD20, CD11c, and DNA was performed on SLN tissue and matching primary tumors. Regions of interest (ROI) were then chosen geometrically (e.g. tumor) or by fluorescent cell subset markers (e.g. CD11c). Each ROI was further analyzed using NanoString Digital Spatial Profiling high-resolution multiplex profiling. Digital counts for 59-panel immune related proteins were collected and normalized to account for system variation and ROI area. RESULTS: Tumor regions of SLNs had variable infiltration of CD3 cells among patients. The patient with overall survival (OS) > 8 years had the most CD11c- and CD3-expressing cells infiltrating the SLN tumor region. All patients had CD11c (dendritic cell, DC) infiltration into the SLN tumor region. Selecting ROI by specific cell subtype, we compared protein expression of CD11c cells between tumor and non-tumor/normal tissue SLN regions. Known markers of DC activation such as CD86, HLA-DR, and OX40L were lowest on CD11c cells within SLN tumor for the patient with OS < 1 year and highest on the patient with OS > 8 years. CONCLUSION: We demonstrate the feasibility of profiling the protein expression of CD11c cells within the SLN tumor. Identifying early regulators of melanoma control when the disease is microscopically detected in the SLN is beneficial and requires follow-up studies in a larger cohort of patients.

Published
2020

5. Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma

Author

Georgia M Beasley, Michael C Brown, Norma E Farrow, Karenia Landa, Rami N Al-Rohil, Maria Angelica Selim, Aaron D Therien, Sin-Ho Jung, Junheng Gao, David Boczkowski, Eda K Holl, April K S Salama, Darell D Bigner, Matthias Gromeier, and Smita K Nair

Subjects
Inflammation, Pharmacology, Receptors, CCR7, Cancer Research, Oncology, Immunology, Tumor Microenvironment, Humans, Molecular Medicine, Immunology and Allergy, Interferons, Prognosis, Melanoma
Abstract

BackgroundWe previously reported results from a phase 1 study testing intratumoral recombinant poliovirus, lerapolturev, in 12 melanoma patients. All 12 patients received anti-PD-1 systemic therapy before lerapolturev, and 11 of these 12 patients also received anti-PD-1 after lerapolturev. In preclinical models lerapolturev induces intratumoral innate inflammation that engages antitumor T cells. In the current study, prelerapolturev and postlerapolturev tumor biopsies and blood were evaluated for biomarkers of response.MethodsThe following analyses were performed on tumor tissue (n=11): (1) flow cytometric assessment of immune cell density, (2) NanoString Digital Spatial profiling of protein and the transcriptome, and (3) bulk RNA sequencing. Immune cell phenotypes and responsiveness to in vitro stimulation, including in vitro lerapolturev challenge, were measured in peripheral blood (n=12).ResultsThree patients who received anti-PD-1 therapy within 30 days of lerapolturev have a current median progression-free survival (PFS) of 2.3 years and had higher CD8+T cell infiltrates in prelerapolturev tumor biopsies relative to that of 7 patients with median PFS of 1.6 months and lower CD8+T cell infiltrates in prelerapolturev tumor biopsies. In peripheral blood, four patients with PFS 2.3 years (including three that received anti-PD-1 therapy within 30 days before lerapolturev and had higher pretreatment tumor CD8+T cell infiltrates) had significantly higher effector memory (CD8+, CCR7-, CD45RA-) but lower CD8+PD-1+ and CD4+PD-1+ cells compared with eight patients with median PFS 1.6 months. In addition, pretreatment blood from the four patients with median PFS 2.3 years had more potent antiviral responses to in vitro lerapolturev challenge compared with eight patients with median PFS 1.6 months.ConclusionAn inflamed pretreatment tumor microenvironment, possibly induced by prior anti-PD-1 therapy and a proficient peripheral blood pretreatment innate immune response (antiviral/interferon signaling) to lerapolturev was associated with long term PFS after intratumoral lerapolturev in a small cohort of patients. These findings imply a link between intratumoral T cell inflammation and peripheral immune function.Trial registration numberNCT03712358.

Published
2022

6. Diminished noncanonical NF-κB signaling induces colitis-associated colorectal cancer susceptibility upon de-differentiation of epithelial cells

Author

Holly Morrison, Audrey Rowe, Kristin Eden, Katherine Baumgarner, Stephan L Brown, Eda K Holl, and Irving Coy Allen

Subjects
Immunology, Immunology and Allergy
Abstract

Patients with a medical history of Inflammatory Bowel Disease are predisposed to developing colitis-associated colorectal cancer (CAC), with greater than 20% developing CAC within 30 years of disease onset. CAC is a form of inflammation-induced tumorigenesis, where unregulated inflammation causes cells in the colon to accumulate mutations poising them for neoplasia. We demonstrate that NF-κB inducing kinase (NIK) is a critical regulator of intestinal epithelial cell (IEC) regeneration. We hypothesize that IECs exposed to chronic inflammatory conditions mitigated by dysregulated noncanonical NF-κB signaling are most prone to mutagenesis and cancer-initiating events termed Top-down tumorigenesis. In CAC, NIK depletion results in the accumulation of mature IECs that are increasingly susceptible to mutation and neoplastic transformation. This suggests that terminally differentiated IECs dedifferentiate into a stem-like phenotype. Our work has clinical relevancy, where human CAC biopsy samples have diminished noncanonical NF-κB signaling and NIK (MAP3K14) gene expression. Murine models with NIK deletion in IECs have increased susceptibility to inflammation-induced tumorigenesis following the chemical induction of AOM/DSS to induce colitis. Our mechanistic studies evaluating crypts demonstrate accumulation of mature, non-dividing IECs, which are more susceptible to mutations and malignant transformation. Here, we present a novel role for noncanonical NF-κB signaling in regulating intestinal epithelial cell turnover in protecting against CAC development. Focusing on the key niche signaling interplay following noncanonical NF-κB dysregulation gives greater insight into the CAC tumor microenvironment. Supported by grants from the iTHRIVE Pilot Translational and Clinical Studies Program, VCOM Center for One Health Research, Virginia Tech Carilion Research Acceleration Program, and the Virginia-Maryland College of Veterinary Medicine.

Published
2022

7. Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling

Author

Smita K. Nair, E. Shelley Hwang, Zachary P. McKay, Jonathan P. Kastan, Malte Mohme, Michael C. Brown, David M. Ashley, Matthias Gromeier, Mubeen Mosaheb, Yuanfan Yang, Darell D. Bigner, Eda K. Holl, and Georgia M. Beasley

Subjects
0301 basic medicine, Interferon-Induced Helicase, IFIH1, Cancer therapy, viruses, medicine.medical_treatment, General Physics and Astronomy, Priming (immunology), CD8-Positive T-Lymphocytes, Mice, 0302 clinical medicine, Tumor Microenvironment, Melanoma, Mice, Knockout, Oncolytic Virotherapy, Multidisciplinary, Pattern recognition receptor, NF-kappa B, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Interferon Type I, Tumour immunology, Female, Immunotherapy, Signal Transduction, Science, T cell, Breast Neoplasms, Biology, Protein Serine-Threonine Kinases, General Biochemistry, Genetics and Molecular Biology, Article, 03 medical and health sciences, Lymphocytes, Tumor-Infiltrating, medicine, Animals, Humans, Virotherapy, Tumor microenvironment, Innate immune system, General Chemistry, biochemical phenomena, metabolism, and nutrition, Th1 Cells, Immunity, Innate, Oncolytic virus, Mice, Inbred C57BL, 030104 developmental biology, Cancer research, Interferon Regulatory Factor-3
Abstract

Activating intra-tumor innate immunity might enhance tumor immune surveillance. Virotherapy is proposed to achieve tumor cell killing, while indirectly activating innate immunity. Here, we report that recombinant poliovirus therapy primarily mediates antitumor immunotherapy via direct infection of non-malignant tumor microenvironment (TME) cells, independent of malignant cell lysis. Relative to other innate immune agonists, virotherapy provokes selective, TBK1-IRF3 driven innate inflammation that is associated with sustained type-I/III interferon (IFN) release. Despite priming equivalent antitumor T cell quantities, MDA5-orchestrated TBK1-IRF3 signaling, but not NFκB-polarized TLR activation, culminates in polyfunctional and Th1-differentiated antitumor T cell phenotypes. Recombinant type-I IFN increases tumor-localized T cell function, but does not mediate durable antitumor immunotherapy without concomitant pattern recognition receptor (PRR) signaling. Thus, virus-induced MDA5-TBK1-IRF3 signaling in the TME provides PRR-contextualized IFN responses that elicit functional antitumor T cell immunity. TBK1-IRF3 innate signal transduction stimulates eventual function and differentiation of tumor-infiltrating T cells., Innate intratumoral immunity might be important in enhancing oncolytic tumor immunotherapy. Here, the authors show that recombinant poliovirus signalling through TBK-IRF3 enhances tumor-infiltrating T cell activity and multi-cytokine function.

Published
2021

8. Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma

Author

Sin-Ho Jung, Paul J. Mosca, Junheng Gao, Eda K. Holl, Norma E. Farrow, Smita K. Nair, Georgia M. Beasley, Scott J. Antonia, Douglas S. Tyler, Rami N. Al-Rohil, David W. Ollila, Jeanne Jung, and Maria Angelica Selim

Subjects
Oncology, medicine.medical_specialty, Skin Neoplasms, Sentinel lymph node, Risk Assessment, Article, 03 medical and health sciences, 0302 clinical medicine, TIGIT, Surgical oncology, Internal medicine, Biopsy, medicine, Adjuvant therapy, Humans, Melanoma, Retrospective Studies, medicine.diagnostic_test, Proportional hazards model, business.industry, Sentinel Lymph Node Biopsy, medicine.disease, Immune checkpoint, 030220 oncology & carcinogenesis, Lymphatic Metastasis, Lymph Node Excision, 030211 gastroenterology & hepatology, Surgery, Lymph Nodes, Neoplasm Recurrence, Local, Sentinel Lymph Node, business
Abstract

Although sentinel lymph node (SLN) biopsy is a standard procedure used to identify patients at risk for melanoma recurrence, it fails to risk-stratify certain patients accurately. Because processes in SLNs regulate anti-tumor immune responses, the authors hypothesized that SLN gene expression may be used for risk stratification. The Nanostring nCounter PanCancer Immune Profiling Panel was used to quantify expression of 730 immune-related genes in 60 SLN specimens (31 positive [pSLNs], 29 negative [nSLNs]) from a retrospective melanoma cohort. A multivariate prediction model for recurrence-free survival (RFS) was created by applying stepwise variable selection to Cox regression models. Risk scores calculated on the basis of the model were used to stratify patients into low- and high-risk groups. The predictive power of the model was assessed using the Kaplan–Meier and log-rank tests. During a median follow-up period of 6.3 years, 20 patients (33.3%) experienced recurrence (pSLN, 45.2% [14/31] vs nSLN, 20.7% [6/29]; p = 0.0445). A fitted Cox regression model incorporating 12 genes accurately predicted RFS (C-index, 0.9919). Improved RFS was associated with increased expression of TIGIT (p = 0.0326), an immune checkpoint, and decreased expression of CXCL16 (p = 0.0273), a cytokine important in promoting dendritic and T cell interactions. Independent of SLN status, the model in this study was able to stratify patients into cohorts at high and low risk for recurrence (p

Published
2020

9. Application of independent component analysis to the iKAGRA data

Author

Akutsu, T., Ando, M., Arai, K., Arai, Y., Araki, S., Araya, A., Aritomi, N., Asada, H., Aso, Y., Atsuta, S., Awai, K., Bae, S., Bae, Y., Baiotti, L., Bajpai, R., Barton, M. A., Cannon, K., Capocasa, E., Chan, M., Chen, C., Chen, K., Chen, Y., Chu, H., Chu, Y. -K., Craig, K., Creus, W., Doi, K., Eda, K., Eguchi, S., Enomoto, Y., Flaminio, R., Fujii, Y., Fujimoto, M. -K., Fukunaga, M., Fukushima, M., Furuhata, T., Ge, G., Hagiwara, A., Haino, S., Hasegawa, K., Hashino, K., Hayakawa, H., Hayama, K., Himemoto, Y., Hiranuma, Y., Hirata, N., Hirobayashi, S., Hirose, E., Hong, Z., Hsieh, B. H., Huang, G. -Z., Huang, P., Huang, Y., Ikenoue, B., Imam, S., Inayoshi, K., Inoue, Y., Ioka, K., Itoh, Y., Izumi, K., Jung, K., Jung, P., Kaji, T., Kajita, T., Kakizaki, M., Kamiizumi, M., Kanbara, S., Kanda, N., Kanemura, S., Kaneyama, M., Kang, G., Kasuya, J., Kataoka, Y., Kawaguchi, K., Kawai, N., Kawamura, S., Kawasaki, T., Kim, C., Kim, J. C., Kim, W. S., Kim, Y. -M., Kimura, N., Kinugawa, T., Kirii, S., Kita, N., Kitaoka, Y., Kitazawa, H., Kojima, Y., Kokeyama, K., Komori, K., Kong, A. K. H., Kotake, K., Kozakai, C., Kozu, R., Kumar, R., Kume, J., Kuo, C., Kuo, H. -S., Kuroyanagi, S., Kusayanagi, K., Kwak, K., Lee, H. K., Lee, H. M., Lee, H. W., Lee, R., Leonardi, M., Lin, C., Lin, C. -Y., Lin, F. -L., Liu, G. C., Liu, Y., Luo, L., Majorana, E., Mano, S., Marchio, M., Matsui, T., Matsushima, F., Michimura, Y., Mio, N., Miyakawa, O., Miyamoto, A., Miyamoto, T., Miyazaki, Y., Miyo, K., Miyoki, S., Morii, W., Morisaki, S., Moriwaki, Y., Morozumi, T., Musha, M., Nagano, K., Nagano, S., Nakamura, K., Nakamura, T., Nakano, H., Nakano, M., Nakao, K., Nakashima, R., Narikawa, T., Naticchioni, L., Negishi, R., Quynh, L. N., W. -T., Ni, Nishizawa, A., Obuchi, Y., Ochi, T., Ogaki, W., J. J., Oh, S. H., Oh, Ohashi, M., Ohishi, N., Ohkawa, M., Okutomi, K., Oohara, K., Ooi, C. P., Oshino, S., Pan, K., Pang, H., Park, J., Arellano, F. E. P., Pinto, I., Sago, N., Saijo, M., Saito, S., Saito, Y., Sakai, K., Sakai, Y., Sakuno, Y., Sasaki, M., Sasaki, Y., Sato, S., Sato, T., Sawada, T., Sekiguchi, T., Sekiguchi, Y., Seto, N., Shibagaki, S., Shibata, M., Shimizu, R., Shimoda, T., Shimode, K., Shinkai, H., Shishido, T., Shoda, A., Somiya, K., Son, E. J., Sotani, H., Suemasa, A., Sugimoto, R., Suzuki, T., Tagoshi, H., Takahashi, H., Takahashi, R., Takamori, A., Takano, S., Takeda, H., Takeda, M., Tanaka, H., Tanaka, K., Tanaka, T., Tanioka, S., Martin, E. N. T. S., Tatsumi, D., Telada, S., Tomaru, T., Tomigami, Y., Tomura, T., Travasso, F., Trozzo, L., Tsang, T., Tsubono, K., Tsuchida, S., Tsuzuki, T., Tuyenbayev, D., Uchikata, N., Uchiyama, T., Ueda, A., Uehara, T., Ueki, S., Ueno, K., Ueshima, G., Uraguchi, F., Ushiba, T., Van Putten, M. H. P. M., Vocca, H., Wada, S., Wakamatsu, T., Wang, J., Wu, C., Wu, H., Wu, S., W. -R., Xu, Yamada, T., Yamamoto, A., Yamamoto, K., Yamamoto, S., Yamamoto, T., Yokogawa, K., Yokoyama, J., Yokozawa, T., Yoon, T. H., Yoshioka, T., Yuzurihara, H., Zeidler, S., Zhao, Y., Zhu, Z. -H., KAGRA Collaboration, Laboratoire d'Annecy de Physique des Particules (LAPP/Laboratoire d'Annecy-le-Vieux de Physique des Particules), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), KAGRA, Laboratoire d'Annecy de Physique des Particules (LAPP), and Centre National de la Recherche Scientifique (CNRS)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)

Subjects
Gravitational-wave observatory, General Physics and Astronomy, FOS: Physical sciences, General Relativity and Quantum Cosmology (gr-qc), 01 natural sciences, GRAVITATIONAL-WAVES, General Relativity and Quantum Cosmology, 0103 physical sciences, Continuous signal, [PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det], F30 Instrumentation and technique, Environmental noise, 010303 astronomy & astrophysics, Instrumentation and Methods for Astrophysics (astro-ph.IM), Physics, Strain (chemistry), 010308 nuclear & particles physics, Gravitational wave, Independent component analysis, E02 Gravitational waves, SEPARATION, [PHYS.GRQC]Physics [physics]/General Relativity and Quantum Cosmology [gr-qc], Correlation method, Astrophysics - Instrumentation and Methods for Astrophysics, Algorithm, Communication channel
Abstract

We apply the independent component analysis (ICA) to the real data from a gravitational wave detector for the first time. Specifically we use the iKAGRA data taken in April 2016, and calculate the correlations between the gravitational wave strain channel and 35 physical environmental channels. Using a couple of seismic channels which are found to be strongly correlated with the strain, we perform ICA. Injecting a sinusoidal continuous signal in the strain channel, we find that ICA recovers correct parameters with enhanced signal-to-noise ratio, which demonstrates usefulness of this method. Among the two implementations of ICA used here, we find the correlation method yields the optimal result for the case environmental noises act on the strain channel linearly., 27 pages, 12 figures : published in PTEP with added discussion about the relation between ICA and Wiener filtering

Published
2020

10. Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer

Author

E. Shelley Hwang, Smita K. Nair, Georgia M. Beasley, Karenia Landa, Victoria Frazier, and Eda K. Holl

Subjects
Male, lcsh:Immunologic diseases. Allergy, 0301 basic medicine, Oncology, medicine.medical_specialty, immune monitoring, medicine.medical_treatment, Immunology, 03 medical and health sciences, 0302 clinical medicine, Immune system, Breast cancer, Cancer immunotherapy, Neoplasms, immune biomarkers, Internal medicine, Leukocytes, Humans, Immunology and Allergy, Medicine, Original Research, Immunity, Cellular, cellular immunome, Tumor microenvironment, cancer immunotherapy, business.industry, flow cytometry, Melanoma, Cancer, Immunotherapy, medicine.disease, 3. Good health, Radiation therapy, cell subsets, 030104 developmental biology, Female, lcsh:RC581-607, business, 030215 immunology
Abstract

Immunotherapies are rapidly being integrated into standard of care (SOC) therapy in conjunction with surgery, chemotherapy, and radiotherapy for many cancers and a large number of clinical studies continue to explore immunotherapy alone and as part of combination therapies in patients with cancer. It is evident that clinical effectiveness of immunotherapy is limited to a subset of patients and improving immunotherapy related outcomes remains a major scientific and clinical effort. Understanding the immune cell subset phenotype and activation/functional status (cellular immunome) prior to and post therapy is therefore critical to develop biomarkers that (1) will predict if a patient will respond to immunotherapy and (2) are a result of immunotherapy. In this study, we investigated local (tumor) and peripheral (blood) cellular immunome of patients with melanoma, breast cancer, and brain cancer using a rapid and reliable standardized, multiparameter flow cytometry assay. We used this approach to monitor changes in the peripheral cellular immunome in women with breast cancer undergoing SOC therapy. Our analysis is unique because it is conducted using matched fresh tumor tissue and blood from patients in real-time, within 2-3 h of sample acquisition, and provides insight into the innate and adaptive immune cell profile in blood and tumor. Specific to blood, this approach involves no manipulation and evaluates all immune subsets such as T cells, B cells, natural killer (NK) cells, monocytes, dendritic cells (DCs), neutrophils, eosinophils, and basophils using 0.5 ml of blood. Analysis of the corresponding tumor provides much needed insight into the phenotype and activation status of immune cells, especially T and B cells, in the tumor microenvironment vs. the periphery. This analysis will be used to assess baseline and therapy-mediated changes in local and peripheral cellular immunome in patients with glioblastoma, breast cancer, and melanoma in planned immunotherapy clinical studies.

Published
2019

11. Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients

Author

Raoul S. Concepcion, Andrew J. Armstrong, Yuan Wu, Michael R. Harrison, Monika Anand, Megan Ann McNamara, Neal D. Shore, Ron Tutrone, Daniel J. George, Igor Dumbudze, Joe A. Wallace, Patrick Healy, Coleman D. Breland, and Eda K. Holl

Subjects
Oncology, Male, Cancer Research, medicine.medical_specialty, Time Factors, Cancer therapy, Urology, 030232 urology & nephrology, Castration resistant, Asymptomatic, Cancer Vaccines, Article, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Internal medicine, medicine, Overall survival, Humans, Progression-free survival, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Tissue Extracts, Disease progression, Retrospective cohort study, Middle Aged, Prostate-Specific Antigen, medicine.disease, Prognosis, Progression-Free Survival, Sipuleucel-T, Prostatic Neoplasms, Castration-Resistant, 030220 oncology & carcinogenesis, Disease Progression, Kallikreins, Immunotherapy, medicine.symptom, business, medicine.drug
Abstract

Background Sipuleucel-T is an autologous cellular immunotherapy that is FDA approved for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC). The IMPACT registry trial demonstrated a 4.1 month survival benefit, but not a consistent PSA response or improvement in progression-free survival. Based upon several factors, including this lack of objective treatment response, sipuleucel-T has been under-utilized in this patient population, despite current NCCN recommendations. Methods In order to explore if delayed treatment response occurs in a subset of patients, we performed a single institutional retrospective analysis of mCRPC patients treated with sipuleucel-T and ongoing ADT alone. Within that group, we then identified a subset of sipuleucel-T-treated men with long-term disease control and no additional interventions. To independently confirm this finding, we evaluated a total of 336 patients from 4 large urology group practices treated with sipuleucel-T between 2010 and 2014 and identified 44 patients who met the same criteria and demonstrated evidence of PSA stabilization post sipuleucel-T treatment. Results For this subgroup of patients, 79% (95% CI: 64.5%, 88.1%) survived 36 months with a median time to subsequent therapy of 17.8 months (95% CI 10.3, 25.3). Conclusions Although patient selection could account for some or all of these results, these data support the utilization of sipuleucel-T alone in select mCRPC patients that is associated with a delay in disease progression and a good overall prognosis.

Published
2018

12. Scavenging nucleic acid debris to combat autoimmunity and infectious disease

Author

Angela D. Burnette, Eda K. Holl, Christopher J. Sample, Elizabeth Ramsburg, Bruce A. Sullenger, Luke B. Borst, and Kara L. Shumansky

Subjects
Male, 0301 basic medicine, Dendrimers, Autoimmunity, Mice, Transgenic, Inflammation, Biology, medicine.disease_cause, Corrections, Mice, 03 medical and health sciences, 0302 clinical medicine, Immune system, Nucleic Acids, Lupus Erythematosus, Cutaneous, medicine, Animals, Humans, Immunologic Factors, DNA Cleavage, Skin, RNA Cleavage, Autoimmune disease, Multidisciplinary, Innate immune system, Effector, Pattern recognition receptor, food and beverages, medicine.disease, Mice, Inbred C57BL, 030104 developmental biology, Antibodies, Antinuclear, 030220 oncology & carcinogenesis, Physical Sciences, Immunology, Nucleic acid, medicine.symptom, Protein Binding
Abstract

Nucleic acid-containing debris released from dead and dying cells can be recognized as damage-associated molecular patterns (DAMPs) or pattern-associated molecular patterns (PAMPs) by the innate immune system. Inappropriate activation of the innate immune response can engender pathological inflammation and autoimmune disease. To combat such diseases, major efforts have been made to therapeutically target the pattern recognition receptors (PRRs) such as the Toll-like receptors (TLRs) that recognize such DAMPs and PAMPs, or the downstream effector molecules they engender, to limit inflammation. Unfortunately, such strategies can limit the ability of the immune system to combat infection. Previously, we demonstrated that nucleic acid-binding polymers can act as molecular scavengers and limit the ability of artificial nucleic acid ligands to activate PRRs. Herein, we demonstrate that nucleic acid scavengers (NASs) can limit pathological inflammation and nucleic acid-associated autoimmunity in lupus-prone mice. Moreover, we observe that such NASs do not limit an animal's ability to combat viral infection, but rather their administration improves survival when animals are challenged with lethal doses of influenza. These results indicate that molecules that scavenge extracellular nucleic acid debris represent potentially safer agents to control pathological inflammation associated with a wide range of autoimmune and infectious diseases.

Published
2016

13. Abstract B16: The immune profile of sentinel lymph nodes in melanoma

Author

Norma E. Farrow, Smita K. Nair, Eda K. Holl, Margaret Leddy, Georgia M. Beasley, Brent A. Hanks, and April K.S. Salama

Subjects
Oncology, Cancer Research, medicine.medical_specialty, medicine.diagnostic_test, business.industry, Melanoma, Sentinel lymph node, Cancer, medicine.disease, Immune profiling, Immune system, Internal medicine, Biopsy, medicine, Adjuvant therapy, Lymph, business
Abstract

Background: Immune cell composition and immune-mediated processes occurring in the sentinel lymph node (SLN) of melanoma patients regulate generation of tumor-specific effector T-cell responses and ultimately tumor control. We hypothesized that comprehensive analysis of these immune-associated processes in the SLN biopsy may identify patients at high risk of melanoma recurrence. Methods: We analyzed 38 formalin-fixed, paraffin-embedded sentinel lymph nodes from melanoma patients undergoing SLN biopsy from 2009-2012 using the NanoString nCounter® PanCancer Immune Profiling panel. The panel included 770 immune related genes. Results: Of 38 patients, 19 were SLN negative and 19 were SLN positive. Among SLN-negative patients (n=19), the median Breslow depth was 1.25 mm, and 21% (n=4) had developed recurrence at median follow-up of 6.2 years. Among SLN-positive patients, the median Breslow depth was 3.35 mm and 37% (n=7) had developed recurrence at median follow-up of 6.5 years. There were 31 genes significantly differentially expressed (P Conclusion: In this retrospective series, we found the immunologic gene expression profile of melanoma SLNs was significantly different in SLN negative versus SLN positive. There were also significant differences in the profile between patients who developed melanoma recurrence versus no recurrence regardless of SLN status. We aim to build on these pilot data. The goal is to use this profile to predict patients at high risk of recurrence after SLNB who may benefit from adjuvant therapy. Citation Format: Georgia M. Beasley, Eda K. Holl, Norma E. Farrow, Margaret G. Leddy, April K. Salama, Brent A. Hanks, Smita K. Nair. The immune profile of sentinel lymph nodes in melanoma [abstract]. In: Proceedings of the AACR Special Conference on Melanoma: From Biology to Target; 2019 Jan 15-18; Houston, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(19 Suppl):Abstract nr B16.

Published
2020

14. Abstract P3-01-03: Modulating inflammation with nucleic acid scavengers to prevent breast cancer metastasis

Author

Victoria Frazier, Rachel E. Rempel, Elias O.U. Eteshola, David Boczkowski, Karenia Landa, Smita K. Nair, Eda K. Holl, Shelley Hwang, and Bruce A. Sullenger

Subjects
Cancer Research, business.industry, medicine.medical_treatment, Cancer, Inflammation, medicine.disease, Metastasis, Breast cancer, Immune system, Cytokine, Oncology, Tumor progression, Cancer cell, Cancer research, Medicine, medicine.symptom, business
Abstract

Rationale: Chronic inflammation is a hallmark of cancer. Inflammation, whether it is an underlying baseline condition or induced/exacerbated due to treatment, is a major hurdle that ultimately impacts the efficacy of standard of care therapy. However, no strategy exists to effectively control endogenous or therapy-induced inflammation in women with breast cancer. Moreover, there is limited information on how endogenous or therapy-induced inflammation modulates immune cells in women with breast cancer. Nucleic acid-containing pro-inflammatory complexes, termed Nucleic Acid-containing Damage Associated Molecular Patterns (NA-DAMPs), are released from dead or dying cancer cells or activated immune cells. NA-DAMPs activate nucleic acid sensing toll-like receptors (TLR) and other pattern recognition receptors (PRR). NA-DAMPs promote tumor progression and metastasis by inducing pro-tumorigenic signaling in cancer cells. Excessive and persistent NA-DAMP-mediated PRR signaling in immune cells is associated with immune dysfunction. Nucleic acid binding polymers have been used as vehicles for DNA/RNA delivery. We have discovered that a subset of nucleic acid binding polymers, termed nucleic acid scavengers (NAS), act as anti-inflammatory agents by capturing cancer-promoting pro-inflammatory NA-DAMPs. Therefore, we investigated if a NAS could limit cancer progression and metastasis by capturing and mitigating the effects of NA-DAMPs in immunocompetent murine models of breast cancer. Methods: We tested the use of the NAS PAMAM-G3 in the 1] orthotopic surgical resection 4T1 breast cancer model; 2] intravenous experimental metastasis 4T1 breast cancer model; 3] MMTV-PyMT spontaneous breast cancer model. We also measured changes in inflammation/inflammatory cell profile in tumor and in blood. Next, we investigated the relationship between therapy, NA-DAMPs and immune cell profile in blood from women with breast cancer. We also examined if NA-DAMPs in patient serum induces tumor invasion and if the NAS PAMAM-G3 prevents tumor invasion using an in vitro assay. Results: We have determined that the NAS PAMAM-G3 controls lung metastasis in immunocompetent murine models of breast cancer and our data indicate that: 1] chronic inflammation and inflammatory cells in the tumor and periphery promote cancer invasion and metastasis; 2] modulating inflammation by removing excessive NA-DAMPs using the NAS PAMAM-G3 limits cancer metastasis; 3] scavenging inflammation-associated NA-DAMPs significantly alters immune cell and cytokine/chemokine profile in the tumor and periphery, promotes T cell infiltration in the tumor and induces antitumor CD8+ T cell responses. In experiments conducted using blood collected longitudinally from women undergoing standard of care therapy, we observed that: 1] NA-DAMPs and inflammatory monocytes are elevated in women undergoing standard of care therapy; 2] Post-chemotherapy breast cancer patient serum increases invasion/migration of human breast cancer cells in vitro; 3] PAMAM-G3 abrogates increase in invasion/migration of human breast cancer cells in vitro in response to post-chemotherapy breast cancer patient serum. Conclusions: These results highlight the potential utility of NAS to treat cancer associated inflammation and thereby inhibit cancer metastasis by 1) limiting extracellular NA-DAMP-induced persistent activation of pro-inflammatory signaling, and 2) promoting full engagement of both the innate and adaptive immune systems. These principles will aid in the development of a novel anti-metastatic therapy for women with breast cancer. This work is supported by Department of Defense Breast Cancer Research Program Awards W81XWH-16-1-0512 (Nair) and W81XWH-16-1-0513 (Sullenger). Citation Format: Smita Nair, Eda Holl, Karenia Landa, Victoria Frazier, Elias Eteshola, David Boczkowski, Rachel Rempel, Shelley Hwang, Bruce Sullenger. Modulating inflammation with nucleic acid scavengers to prevent breast cancer metastasis [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-01-03.

Published
2020

15. RNA-Based Vaccines in Cancer Immunotherapy

Author

Smita K. Nair, Eda K. Holl, and Megan Ann McNamara

Subjects
lcsh:Immunologic diseases. Allergy, Cytotoxicity, Immunologic, medicine.medical_treatment, Immunology, Antigen presentation, Review Article, Biology, Lymphocyte Activation, Cancer Vaccines, Immune system, Cancer immunotherapy, Antigen, Antigens, Neoplasm, Neoplasms, medicine, Animals, Humans, Immunology and Allergy, RNA, Messenger, Polymerase, Antigen Presentation, Clinical Trials as Topic, Messenger RNA, RNA, Dendritic Cells, General Medicine, Acquired immune system, Virology, Disease Models, Animal, biology.protein, lcsh:RC581-607
Abstract

RNA vaccines traditionally consist of messenger RNA synthesized byin vitrotranscription using a bacteriophage RNA polymerase and template DNA that encodes the antigen(s) of interest. Once administered and internalized by host cells, the mRNA transcripts are translated directly in the cytoplasm and then the resulting antigens are presented to antigen presenting cells to stimulate an immune response. Alternatively, dendritic cells can be loaded with either tumor associated antigen mRNA or total tumor RNA and delivered to the host to elicit a specific immune response. In this review, we will explain why RNA vaccines represent an attractive platform for cancer immunotherapy, discuss modifications to RNA structure that have been developed to optimize mRNA vaccine stability and translational efficiency, and describe strategies for nonviral delivery of mRNA vaccines, highlighting key preclinical and clinical data related to cancer immunotherapy.

Published
2015

16. Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen–specific CTLs

Author

Eda K. Holl, Matthias Gromeier, Smita K. Nair, David Boczkowski, Vidya Chandramohan, Michael C. Brown, Elena Y. Dobrikova, Mubeen Mosaheb, and Darell D. Bigner

Subjects
0301 basic medicine, Proteome, Rhinovirus, Neutrophils, medicine.medical_treatment, T cell, Biology, Article, 03 medical and health sciences, 0302 clinical medicine, Immune system, Cancer immunotherapy, Antigens, Neoplasm, Cell Line, Tumor, medicine, Animals, Humans, Cytotoxic T cell, Melanoma, RNA, Double-Stranded, Immunosuppression Therapy, Recombination, Genetic, Tumor microenvironment, Macrophages, Immunity, Dendritic Cells, General Medicine, Dendritic cell, Immunotherapy, Tumor antigen, Mice, Inbred C57BL, Disease Models, Animal, Oncolytic Viruses, Poliovirus, Editorial, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Immunology, Interferons, T-Lymphocytes, Cytotoxic
Abstract

Tumors thrive in an immunosuppressive microenvironment that impedes antitumor innate and adaptive immune responses. Thus, approaches that can overcome immunosuppression and engage antitumor immunity are needed. This study defines the adjuvant and cancer immunotherapy potential of the recombinant poliovirus/rhinovirus chimera PVSRIPO. PVSRIPO is currently in clinical trials against recurrent World Health Organization grade IV malignant glioma, a notoriously treatment-refractory cancer. Cytopathogenic infection of neoplastic cells releases the proteome and exposes pathogen- and damage-associated molecular patterns. At the same time, sublethal infection of antigen-presenting cells, such as dendritic cells and macrophages, yields potent, sustained type I interferon-dominant activation in an immunosuppressed microenvironment and promotes the development of tumor antigen-specific T cell responses in vitro and antitumor immunity in vivo. PVSRIPO's immune adjuvancy stimulates canonical innate anti-pathogen inflammatory responses within the tumor microenvironment that culminate in dendritic cell and T cell infiltration. Our findings provide mechanistic evidence that PVSRIPO functions as a potent intratumor immune adjuvant that generates tumor antigen-specific cytotoxic T lymphocyte responses.

Published
2017

17. The status of KAGRA underground cryogenic gravitational wave telescope

Author

KAGRA Collaboration, Akutsu, T., Ando, M., Araya, A., Aritomi, N., Asada, H., Aso, Y., Atsuta, S., Awai, K., Barton, M. A., Cannon, K., Craig, K., Creus, W., Doi, K., Eda, K., Enomoto, Y., Flaminio, R., Fujii, Y., Fujimoto, M. -K., Furuhata, T., Haino, S., Hasegawa, K., Hashino, K., Hayama, K., Hirobayashi, S., Hirose, E., Hsieh, B. H., Inoue, Y., Ioka, K., Itoh, Y., Kaji, T., Kajita, T., Kakizaki, M., Kamiizumi, M., Kambara, S., Kanda, N., Kanemura, S., Kaneyama, M., Kang, G., Kasuya, J., Kataoka, Y., Kawai, N., Kawamura, S., Kim, C., Kim, H., Kim, J., Kim, Y., Kimura, N., Kinugawa, T., Kirii, S., Kitaoka, Y., Kojima, Y., Kokeyama, K., Komori, K., Kotake, K., Kumar, R., Lee, H., Liu, Y., Luca, N., Majorana, E., Mano, S., Marchio, M., Matsui, T., Matsushima, F., Michimura, Y., Miyakawa, O., Miyamoto, T., Miyamoto, A., Miyo, K., Miyoki, S., Morii, W., Morisaki, S., Moriwaki, Y., Morozumi, T., Musha, M., Nagano, S., Nagano, K., Nakamura, K., Nakamura, T., Nakano, H., Nakano, M., Nakao, K., Narikawa, T., Quynh, L. Nguyen, Ni, W. -T., Ochi, T., Oh, J., Oh, S., Ohashi, M., Ohishi, N., Ohkawa, M., Okutomi, K., Oohara, K., Alleano, F. E. Pe��a, Pinto, I., Sago, N., Saijo, M., Saito, Y., Sakai, K., Sakai, Y., Sasaki, Y., Sasaki, M., Sato, S., Sato, T., Sekiguchi, Y., Seto, N., Shibata, M., Shimoda, T., Shinkai, H., Shoda, A., Somiya, K., Son, E., Suemasa, A., Suzuki, T., Tagoshi, H., Takahashi, H., Takahashi, R., Takamori, A., Takeda, H., Tanaka, H., Tanaka, K., Tanaka, T., Tatsumi, D., Tomaru, T., Tomura, T., Travasso, F., Tsubono, K., Tsuchida, S., Uchikata, N., Uchiyama, T., Uehara, T., Ueki, S., Ueno, K., Ushiba, T., van Putten, M. H. P. M., Vocca, H., Wada, S., Wakamatsu, T., Yamada, T., Yamamoto, S., Yamamoto, T., Yamamoto, K., Yamamoto, A., Yokoyama, J., Yokozawa, T., Yoon, T. H., Yuzurihara, H., Zeidler, S., and Zhu, Z. -H.

Subjects
Physics, History, Gravitational wave underground cryogenic detectors, Physics - Instrumentation and Detectors, Gravitational wave, Astrophysics::Instrumentation and Methods for Astrophysics, Astronomy, FOS: Physical sciences, Cryogenics, General Relativity and Quantum Cosmology (gr-qc), Instrumentation and Detectors (physics.ins-det), General Relativity and Quantum Cosmology, Computer Science Applications, Education, law.invention, Telescope, Interferometry, law, KAGRA, Astrophysics - Instrumentation and Methods for Astrophysics, Instrumentation and Methods for Astrophysics (astro-ph.IM)
Abstract

KAGRA is a 3-km interferometric gravitational wave telescope located in the Kamioka mine in Japan. It is the first km-class gravitational wave telescope constructed underground to reduce seismic noise, and the first km-class telescope to use cryogenic cooling of test masses to reduce thermal noise. The construction of the infrastructure to house the interferometer in the tunnel, and the initial phase operation of the interferometer with a simple 3-km Michelson configuration have been completed. The first cryogenic operation is expected in 2018, and the observing runs with a full interferometer are expected in 2020s. The basic interferometer configuration and the current status of KAGRA are described., Comment: 7 pages, 2 figures. Proceedings for XV International Conference on Topics in Astroparticle and Underground Physics (TAUP2017), Sudbury, July 24-28, 2017

Published
2017
Full Text
View/download PDF

18. Immune expression in children with Wilms tumor: a pilot study

Author

Smita K. Nair, Victoria Frazier, Henry E. Rice, Eda K. Holl, Ashley W. Johnston, Elisabeth T. Tracy, and Jonathan C. Routh

Subjects
Male, T-Lymphocytes, Urology, medicine.medical_treatment, CD4-CD8 Ratio, 030232 urology & nephrology, Pilot Projects, Wilms Tumor, 03 medical and health sciences, 0302 clinical medicine, Immune system, Antigens, CD, 030225 pediatrics, Neuroblastoma, Biomarkers, Tumor, medicine, Humans, Cytotoxic T cell, Retrospective Studies, Immunity, Cellular, Tumor microenvironment, business.industry, Wilms' tumor, Immunotherapy, Prognosis, medicine.disease, Kidney Neoplasms, Immune checkpoint, Child, Preschool, Pediatrics, Perinatology and Child Health, Cancer research, Female, business, CD8, Follow-Up Studies
Abstract

Summary Background Given improvements in multimodality therapy, survival among children with Wilms tumor (WT) exceeds 90%. However, 15% of children with favorable histology and 50% of children with anaplastic WT experience recurrence or progression. Of patients with advanced disease, only 50% survive to adulthood. In adult malignancies (including renal tumors), patient survival has improved with the advent of immunotherapy. However, little is known about the immune microenvironment of WT, making the potential role of immunotherapy unclear. Objective The objective of the study is to perform an exploratory, descriptive analysis of the immune milieu in WT. Study design Between 2016 and 2017, all pediatric patients with WT, some of whom received neoadjuvant chemotherapy, underwent ex vivo wedge biopsy at the time of nephrectomy. The fresh tumor tissue and peripheral blood samples were analyzed for infiltrating immune infiltrate and effector cells using flow cytometry. Immunohistochemistry was performed for CD4, CD8, and PD-L1 expression. Matched blood samples were obtained for each patient, and circulating immune cells were analyzed by flow cytometry. Results A total of six patients were enrolled. One patient with neuroblastoma was excluded. The remaining five patients included the following: two with unilateral WT (resected before chemotherapy), two with bilateral WT (resected after neoadjuvant chemotherapy), and one with Denys–Drash syndrome, end-stage renal disease, and history of WT in the contralateral kidney. Immune analysis showed that WT were infiltrated by immune cells regardless of chemotherapy status. CD8 and CD4 T cells were present in the tumor tissue and exhibited an activated phenotype. Elevated levels of natural killer (NK) cells were observed in the tumors (Figure). Immune checkpoint PD-L1 was also found expressed in one of the tumors stained. Discussion In this pilot study, it was found that WTs were infiltrated by immune cells (CD45+) both before and after chemotherapy. Elevated levels of NK cells infiltrating the tumor specimens, which were quantitatively increased compared with levels of NK cells circulating in the blood, were noted. T cells, particularly CD4+ and CD8+ T cells, were present in tumor specimens. Tumor-infiltrating CD4 and CD8 T cells displayed an activated phenotype as defined by increased expression of human leukocyte antigen-DR isotype (HLA-DR), programmed cell death protein 1 (PD1), and CD57. Together, these findings suggest that WT microenvironment is immune engaged and may be susceptible to immunotherapy similar to other malignancies. Conclusions These pilot data suggest an immune-engaged tumor microenvironment is present within WT. This implies that WT may be susceptible to immunotherapy similar to adult renal tumors and other adult malignancies. Follow-up studies are currently underway. Download : Download high-res image (256KB) Download : Download full-size image Summary Figure

Published
2019

19. Understanding the peripheral cellular immunome in patients with breast cancer

Author

Victoria Frazier, Smita K. Nair, Karenia Landa, Eda K. Holl, and Eun-Sil Shelley Hwang

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Locally advanced, Disease, medicine.disease, Peripheral, Breast cancer, Immunome, Internal medicine, medicine, In patient, business
Abstract

7 Background: Neoadjuvant chemotherapy (NAC) for breast cancer (BC) is being increasingly used in patients with stage I/II disease. Although previously reserved for patients with locally advanced disease, its use in patients with localized disease allows for higher rates of breast-conserving procedures and provides insight into tumor biology. A complete pathologic response (pCR) to NAC correlates with better clinical outcomes; sadly, many patients do not achieve pCR. The advent of immunotherapy has provided cancer patients with additional treatment options. To optimize immunotherapy in BC we must understand the peripheral cellular immunome (immune subsets and activation status) of patients as they undergo standard of care therapy (SOC). Methods: Our population includes patients with stages I-III BC undergoing SOC. Samples were collected pre- and post-NAC, post-surgery and at 2-month follow-up (FU). Results: Flow cytometry analysis for 11 patients was performed at each time-point to examine percentages of circulating immune cells (see Table). We grouped samples in 3 categories: human epidermal growth factor receptor 2 (HER2+) positive, HER2 negative (HER2-) and triple-negative (TN) tumors. 3 out of 11 patients had pCR (1 HER2+, 1 HER2-, 1 TN); they had highest percentage of circulating CD56+ NK cells during treatment course. Conclusions: We observed striking changes in the immunome of women with stage I-III BC undergoing NAC. Although our findings are preliminary, given our sample size, we observed distinct trends within each immune cell population in specific tumor receptor subtypes. These trends could serve to guide our therapies, allow for better patient selection and predict treatment response in patients. [Table: see text]

Published
2019

20. Immune plexins and semaphorins: old proteins, new immune functions

Author

Jenny P.-Y. Ting, Kelly E. Roney, and Eda K. Holl

Subjects
Nervous system, animal structures, Nerve Tissue Proteins, Review, Semaphorins, Biology, Biochemistry, Semaphorin, Drug Discovery, medicine, Animals, Humans, Cytoskeleton, Cell adhesion molecule, Plexin, Immunity, Cell Biology, Transmembrane protein, Cell biology, medicine.anatomical_structure, nervous system, embryonic structures, biology.protein, sense organs, Signal transduction, Cell Adhesion Molecules, Intracellular, Biotechnology
Abstract

Plexins and semaphorins are a large family of proteins that are involved in cell movement and response. The importance of plexins and semaphorins has been emphasized by their discovery in many organ systems including the nervous (Nkyimbeng-Takwi and Chapoval, 2011; McCormick and Leipzig, 2012; Yaron and Sprinzak, 2012), epithelial (Miao et al., 1999; Fujii et al., 2002), and immune systems (Takamatsu and Kumanogoh, 2012) as well as diverse cell processes including angiogenesis (Serini et al., 2009; Sakurai et al., 2012), embryogenesis (Perala et al., 2012), and cancer (Potiron et al., 2009; Micucci et al., 2010). Plexins and semaphorins are transmembrane proteins that share a conserved extracellular semaphorin domain (Hota and Buck, 2012). The plexins and semaphorins are divided into four and eight subfamilies respectively based on their structural homology. Semaphorins are relatively small proteins containing the extracellular semaphorin domain and short intra-cellular tails. Plexins contain the semaphorin domain and long intracellular tails (Hota and Buck, 2012). The majority of plexin and semaphorin research has focused on the nervous system, particularly the developing nervous system, where these proteins are found to mediate many common neuronal cell processes including cell movement, cytoskeletal rearrangement, and signal transduction (Choi et al., 2008; Takamatsu et al., 2010). Their roles in the immune system are the focus of this review.

Published
2013

21. Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models

Author

Smita K. Nair, Daniel J. George, David Boczkowski, Matthias Gromeier, Darell D. Bigner, Megan Ann McNamara, Eda K. Holl, and Michael C. Brown

Subjects
0301 basic medicine, Male, Chemokine, Myeloid, Xenotransplantation, medicine.medical_treatment, Mice, Nude, Inflammation, Virus, 03 medical and health sciences, Mice, 0302 clinical medicine, Cell Line, Tumor, medicine, Animals, Humans, Transgenes, innate immunity, Oncolytic Virotherapy, Mice, Inbred BALB C, Innate immune system, biology, business.industry, PVSRIPO, Prostatic Neoplasms, Xenograft Model Antitumor Assays, humanities, Immunity, Innate, 3. Good health, Oncolytic virus, Oncolytic Viruses, Poliovirus, 030104 developmental biology, medicine.anatomical_structure, Oncology, oncolytic poliovirus, 030220 oncology & carcinogenesis, Cancer cell, Immunology, biology.protein, Female, Inflammatory Breast Neoplasms, medicine.symptom, business, HeLa Cells, Research Paper
Abstract

// Eda K. Holl 1 , Michael C. Brown 2 , David Boczkowski 1 , Megan A. McNamara 3 , Daniel J. George 3 , Darell D. Bigner 4 , Matthias Gromeier 2 , Smita K. Nair 1, 4 1 Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA 2 Department of Neurosurgery, Duke University School of Medicine, Durham, NC 27710, USA 3 Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA 4 Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA Correspondence to: Smita K. Nair, email: smita.nair@duke.edu Keywords: oncolytic poliovirus, PVSRIPO, inflammation, innate immunity Received: August 29, 2016 Accepted: October 13, 2016 Published: October 28, 2016 ABSTRACT Intratumoral inoculation of viruses with tumor-selective cytotoxicity may induce cancer cell death and, thereby, shrink neoplastic lesions. It is unlikely, however, that viral tumor cell killing alone could produce meaningful, durable clinical responses, as clinically suitable ‘oncolytic’ viruses are severely attenuated and their spread and propagation are opposed by host immunity. Thus, a more propitious event in this context is the innate antiviral response to intratumoral virus administration, in particular for recruiting durable adaptive immune effector responses. It may represent a double-edged sword, as innate immune activation may eliminate infected tumor cells early, intercept viral spread and block any meaningful therapeutic response. The innate response to viral infection of tumors may be very different from that in non-malignant target tissues, owing to the unusual composition/tissue properties of tumor stroma. In this work, we report investigations of the innate immune response to the oncolytic poliovirus recombinant, PVSRIPO, in two mouse xenotransplantation models for breast and prostate cancer. Our observations indicate short-term virus persistence in infected tumors and virus recovery indicative of modest intratumoral propagation and persistence. Yet, a powerful innate inflammatory response coincided with chemokine induction and myeloid cell infiltration into tumors that was, interestingly, dominated by neutrophils. The combined effect of PVSRIPO tumor infection and the innate response it elicits was significant tumor regression in both models.

Published
2016

22. Plexin-D1 Is a Novel Regulator of Germinal Centers and Humoral Immune Responses

Author

Eda K. Holl, T. Matt Holl, Albert G. Zimmermann, Brian P. O'Connor, Kelly E. Roney, Garnett Kelsoe, Sushmita Jha, and Jenny P.-Y. Ting

Subjects
Plasma Cells, Immunology, B-Lymphocyte Subsets, Enzyme-Linked Immunosorbent Assay, Mice, Transgenic, Nerve Tissue Proteins, Biology, Lymphocyte Activation, Article, Immunoglobulin G, Mice, Immune system, medicine, Animals, Immunology and Allergy, B cell, B-Lymphocytes, Membrane Glycoproteins, Plexin, CCL19, Intracellular Signaling Peptides and Proteins, Germinal center, Germinal Center, Acquired immune system, Chemokine CXCL13, Immunoglobulin Class Switching, Molecular biology, Chemokine CXCL12, Immunity, Humoral, Mice, Inbred C57BL, B-1 cell, medicine.anatomical_structure, biology.protein, Chemokine CCL19, Immunologic Memory
Abstract

Long-lived humoral immune responses depend upon the generation of memory B cells and long-lived plasma cells during the germinal center (GC) reaction. These memory compartments, characterized by class-switched IgG and high-affinity Abs, are the basis for successful vaccination. We report that a new member of the plexin family of molecules, plexin-D1, controls the GC reaction and is required for secondary humoral immune responses. Plexin-D1 was not required for B cell maturation, marginal zone precursor development, dark and light zone formation, Igλ+ and Igκ+ B cell skewing, B1/B2 development, and the initial extrafollicular response. Plexin-D1 expression was increased following B cell activation, and PlxnD1−/− mice exhibited defective GC reactions during T-dependent immune activation. PlxnD1−/− B cells showed a defect in migration toward the GC chemokines, CXCL12, CXCL13, and CCL19. Accordingly, PlxnD1−/− mice exhibited defective production of IgG1 and IgG2b, but not IgG3 serum Ab, accompanied by reductions in long-lived bone marrow plasmacytes and recall humoral memory responses. These data show a new role for immune plexins in the GC reaction and generation of immunologic memory.

Published
2011

23. Abstract A79: Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of antigen-presenting cells and tumor antigen-specific CTLs

Author

Vidya Chandramohan, Eda K. Holl, Smita K. Nair, Elena Y. Dobrikova, Darell D. Bigner, Matthias Gromeier, Michael C. Brown, David Boczkowski, and Mubeen Mosaheb

Subjects
Cancer Research, Tumor microenvironment, business.industry, medicine.medical_treatment, T cell, Immunology, Immunotherapy, Tumor antigen, medicine.anatomical_structure, Cancer immunotherapy, Interferon, medicine, Cancer research, Cytotoxic T cell, Antigen-presenting cell, business, medicine.drug
Abstract

The tumor microenvironment favors tumor immune escape by suppressing production, activation and/or function of antitumor T cells. Our group has developed a recombinant Rhino-Poliovirus chimera, PVSRIPO, currently being evaluated in Phase-II clinical trial against recurrent glioma. PVSRIPO therapy has afforded durable clinical responses in recurrent glioma patients. Clinical and pre-clinical findings suggest that PVSRIPO primarily acts through an immunological mechanism, rather than via cancer selective cytotoxicity. Here we define the immune adjuvant potential of intratumoral-delivered PVSRIPO that ultimately leads to the engagement/production of antitumor T cells. Sub-lethal infection of human dendritic cells (DCs) with PVSRIPO yields potent, sustained type I interferon dominant activation. PVSRIPO infection of macrophages induces similar activation; however, virus translation and the resulting type I Interferon/TNF-α production by macrophages is strongly enhanced in the presence of the Th2 cytokine IL-4. Compared to conventional adjuvants, e.g. poly(I:C) and LPS, PVSRIPO stimulation of APCs withstands tumor-associated immunosuppression, particularly in macrophages, and achieves more durable activation of DCs. Therapy of B16 melanoma tumors with PVSRIPO led to early production of type I interferon, IL-12, and IFN-γ; which was associated with the recruitment of neutrophils to the tumor site. Neutrophil influx was followed by DC and T cell infiltration. Mice treated with PVSRIPO developed tumor-antigen specific, cytotoxic T cells that were present in both tumor draining lymph nodes and spleens. These events correlated with delay in tumor growth and increase in survival following PVSRIPO therapy. Thus, PVSRIPO’s immune adjuvancy stimulates canonical innate inflammatory responses within the tumor microenvironment that culminates in tumor antigen-specific T cell responses. Citation Format: Michael C. Brown, Eda K. Holl, David Boczkowski, Elena Dobrikova, Mubeen Mosaheb, Vidya Chandramohan, Darell D. Bigner, Matthias Gromeier, Smita K. Nair. Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of antigen-presenting cells and tumor antigen-specific CTLs [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2017 Oct 1-4; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2018;6(9 Suppl):Abstract nr A79.

Published
2018

24. Abstract LB-302: Oncolytic poliovirus-mediated inflammation and immunity in breast cancer

Author

Shelley Hwang, Smita K. Nair, Darell D. Bigner, James E. Herndon, Karenia Landa, Jeremy Force, Michael C. Brown, Lars J. Grimm, Matthias Gromeier, and Eda K. Holl

Subjects
Cancer Research, business.industry, medicine.medical_treatment, Inflammation, Immunotherapy, medicine.disease, Oncolytic virus, Metastasis, Immune system, Breast cancer, Oncology, Interleukin 12, medicine, Cancer research, medicine.symptom, business, Triple-negative breast cancer
Abstract

Breast cancer is the most common malignancy among women in the United States and the second leading cause of cancer deaths in women. Disease prognosis, local recurrence rates and response to therapy are all related to receptor status of the individual cancer. Triple negative breast cancer (TNBC; ER-, PR-, and HER2-negative) is a subset of breast cancer with poor prognosis and high rate of local recurrence and metastasis with limited therapeutic options. The oncolytic poliovirus, PVSRIPO, is a recombinant polio:rhinovirus chimera that has been engineered to eliminate neuropathogenicity and has demonstrated promising responses in patients with recurrent glioblastoma. PVSRIPO is oncolytic in tumor cells and enters cells via its receptor CD155, which is overexpressed in solid malignancies, including TNBC. Treatment of primary TNBC tissue with PVSRIPO induces IFN-I and pro-inflammatory cytokines. In a murine immunotherapy model, intratumoral injection of PVSRIPO induces IFN-I, IL12 and IFN-γ and rapid recruitment of neutrophils into the tumor followed by infiltration of DCs, T cells and B cells. Treatment of orthotopic breast tumors with PVSRIPO results in delayed tumor growth and increased survival in an immunocompetent murine immunotherapy model. We have designed a pilot study to examine the effects of intratumoral injection of PVSRIPO into six women with TNBC with at least 1 cm of residual tumor after chemotherapy. The primary exploratory objective is to describe the changes in the amount of tumor infiltrating immune cells in tumor tissue pre- and post-injection of PVSRIPO. We will also collect blood at different time points during PVSRIPO treatment to evaluate inflammatory and immune signatures. We hypothesize that intratumoral administration of PVSRIPO will cause inflammation thus stimulating innate and adaptive immune activation. This study is funded by the Department of Defense Breast Cancer Research Program award W81XWH-16-1-0354 (PI, Smita Nair). Citation Format: Karenia Landa, Eda Holl, Michael Brown, James Herndon, Lars Grimm, Jeremy Force, Darell Bigner, Shelley Hwang, Matthias Gromeier, Smita Nair. Oncolytic poliovirus-mediated inflammation and immunity in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-302.

Published
2018

25. Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy

Author

Lars J. Grimm, Michael C. Brown, Matthias Gromeier, Victoria Frazier, Smita K. Nair, James E. Herndon, Jeremy Force, Eda K. Holl, Darell D. Bigner, David Boczkowski, Eun-Sil Shelley Hwang, and Paul K. Marcom

Subjects
0301 basic medicine, Metastatic breast, Cancer Research, business.industry, Poliovirus, virus diseases, medicine.disease_cause, medicine.disease, Poliomyelitis, law.invention, Blockade, Oncolytic virus, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Breast cancer, Oncology, law, 030220 oncology & carcinogenesis, medicine, Recombinant DNA, Cancer research, Rhinovirus, skin and connective tissue diseases, business
Abstract

e12641Background: Breast cancers thrive in an immunosuppressive microenvironment. Checkpoint blockade has had poor results in metastatic breast cancers. Recombinant oncolytic polio:rhinovirus (PVSR...

Published
2018

26. Targeting inflammation to prevent breast cancer metastasis

Author

Eda K. Holl, Victoria Frazier, David Boczkowski, Bruce Sullenger, and Smita K. Nair

Subjects
Immunology, Immunology and Allergy
Abstract

Biomarkers associated with systemic inflammation correlate with poor prognosis in cancer patients. Circulating cell-free DNA (cfDNA) is released passively and actively by both tumor cells and host cells and cfDNA levels in blood correlate with tumor burden in many tumor types. Notably, studies in breast cancer have shown that inhibition of cfDNA has a significant effect in reducing invasion and migration in vitro. We have previously demonstrated the ability of nucleic acid binding polymers (NABPs) to bind and inhibit the pro-inflammatory effects of cfDNA and RNA in models of systemic lupus erythematosus and influenza. Herein, we demonstrate that in tumor bearing mice, levels of cfDNA increase with tumor burden and decline post NABP in vivo administration. Using an orthotopic breast cancer murine model we demonstrate that NABP treatment, following surgical resection, results in reduced or completely absent lung metastasis. In addition, intravenous delivery of breast cancer cells in the presence of NABPs also results in decreased tumor cell lung seeding and lung metastasis. Taken together, our data suggest that NABPs can be used to target cfDNA and inhibit such DAMPs from activating pathological inflammation, an innovative approach to treat cancer progression and metastasis. In particular, NABPs may be useful in the clinical setting following standard of care surgical tumor resection.

Published
2018

27. RNA-Based Vaccines in Cancer Immunotherapy

Author

McNamara, Megan A., Nair, Smita K., and Holl, Eda K.

Subjects
Article Subject
Abstract

RNA vaccines traditionally consist of messenger RNA synthesized by in vitro transcription using a bacteriophage RNA polymerase and template DNA that encodes the antigen(s) of interest. Once administered and internalized by host cells, the mRNA transcripts are translated directly in the cytoplasm and then the resulting antigens are presented to antigen presenting cells to stimulate an immune response. Alternatively, dendritic cells can be loaded with either tumor associated antigen mRNA or total tumor RNA and delivered to the host to elicit a specific immune response. In this review, we will explain why RNA vaccines represent an attractive platform for cancer immunotherapy, discuss modifications to RNA structure that have been developed to optimize mRNA vaccine stability and translational efficiency, and describe strategies for nonviral delivery of mRNA vaccines, highlighting key preclinical and clinical data related to cancer immunotherapy.

Published
2015
Full Text
View/download PDF

28. Holding the Inflammatory System in Check: TLRs and NLRs

Author

Eda K. Holl, Irving C. Allen, and Jennifer Martinez

Subjects
Article Subject, Inflammasomes, Disease outcome, Immunology, NLR Proteins, Inflammation, Disease pathogenesis, Autoimmune Diseases, lcsh:Pathology, Animals, Homeostasis, Humans, Medicine, Receptor, business.industry, Toll-Like Receptors, NF-kappa B, Cancer, Cell Biology, medicine.disease, Asthma, Clinical trial, Disease Models, Animal, Editorial, Treatment Outcome, Signal transduction, medicine.symptom, business, lcsh:RB1-214, Signal Transduction
Abstract

Aberrant inflammation has been linked to the development of a diverse spectrum of human diseases. We now appreciate that Toll-like receptor (TLR) and Nod-like receptor (NLR) signaling pathways play an important role in the onset and/or severity of these pathologies, and targeting of these receptors has shown promise in preclinical studies of infectious diseases, autoimmune disorders, tissue injury, and cancer. Recently, clinical trials have been initiated to establish the efficacy of compounds targeting TLR and NLR pathways to improve disease outcomes. Despite advancements in the field, major challenges remain in potential ways to target these receptors at various stages of disease pathogenesis and develop effective therapeutics.

Published
2016

29. Map3K14 signaling attenuates the development of colorectal cancer through activation of the non-canonical NF-κB signaling cascade

Author

Irving C Allen, Kristin Eden, Bettina Heid, and Eda K Holl

Subjects
Immunology, Immunology and Allergy
Abstract

Dysregulation of NF-κB signaling is a common feature in Colorectal Cancer (CRC). While the canonical signaling pathway is well characterized, the non-canonical NF-κB signaling cascade is understudied. Thus, we evaluated the hypothesis that non-canonical NF-κB signaling significantly modulates CRC pathogenesis. To evaluate this hypothesis, we initially conducted a meta-analysis of human gene expression data. Using this approach, we found that non-canonical NF-κB signaling is significantly down-regulated in CRC patients and the extent of pathway attenuation is correlated with disease severity. These findings were confirmed in patient biopsy specimens, where we found significantly reduced expression of ligands, receptors, regulators, and chemokines associated with non-canonical NF-κB signaling. Notably, we observed significantly reduced CCL19, CCL21, CXCL12, and CXCL13 expression in CRC patients compared to healthy controls. To gain mechanistic insight, we utilized genetically modified mice lacking the kinase Map3K14 (NIK), which is essential for non-canonical NF-κB signaling. Nik−/− mice exhibited ablation of non-canonical NF-κB signaling and significantly increased epithelial cell proliferation in the GI tract compared to wild type mice in both in vivo and in vitro studies. Together, our data defines a protective role for non-canonical NF-κB signaling in the gut during CRC and identifies a highly protective role for Map3K14 in attenuating epithelial cell proliferation.

Published
2017

30. The nucleic acid scavenger polyamidoamine third-generation dendrimer inhibits fibroblast activation and granulation tissue contraction

Author

Tosan Ehanire, Maria Angelica Selim, Howard Levinson, Jennifer E. Bond, Eda K. Holl, and Bruce A. Sullenger

Subjects
Pathology, medicine.medical_specialty, Dendrimers, Contraction (grammar), Cellular differentiation, Real-Time Polymerase Chain Reaction, Article, Cicatrix, Mice, Cell Movement, Nucleic Acids, Polyamines, Medicine, Animals, Humans, Fibroblast, health care economics and organizations, Cells, Cultured, Wound Healing, business.industry, Toll-Like Receptors, Granulation tissue, Cell Differentiation, Fibroblasts, Immunohistochemistry, Cell biology, Mice, Inbred C57BL, Real-time polymerase chain reaction, medicine.anatomical_structure, Microscopy, Fluorescence, Nucleic acid, Granulation Tissue, Cytokines, Surgery, Signal transduction, business, Wound healing, Biomarkers, Signal Transduction
Abstract

Pathologic cutaneous scarring affects over 40 million people worldwide and costs billions of dollars annually. Understanding mechanisms of fibroblast activation and granulation tissue contraction is the first step toward preventing pathologic scarring. The authors hypothesize that nucleic acids increase fibroblast activation and cause granulation tissue contraction and that sequestration of nucleic acids by application of a nucleic acid scavenger dendrimer, polyamidoamine third-generation dendrimer, will decrease pathologic scarring.In vitro experiments were performed to assess the effect of nucleic acids on pathologic scar-associated fibroblast activity. The effect of nucleic acids on cytokine production and migration on mouse fibroblasts was evaluated. Immunofluorescence microscopy was used to determine the effect of nucleic acids on the differentiation of human primary fibroblasts into myofibroblasts. Using a murine model, the effect of polyamidoamine third-generation dendrimer on granulation tissue contraction was evaluated by gross and histologic parameters.Mouse fibroblasts stimulated with nucleic acids had increased cytokine production (i.e., transforming growth factor-β, monocyte chemotactic protein 1, interleukin-10, tumor necrosis factor-α, and interferon-γ), migration, and differentiation into myofibroblasts. Polyamidoamine third-generation dendrimer blocked cytokine production, migration, and differentiation into myofibroblasts. Using a murine model of granulation tissue contraction, polyamidoamine third-generation dendrimer decreased wound contraction and angiogenesis. Collagen deposition in polyamidoamine third-generation dendrimer-treated tissues was aligned more randomly and whorl-like compared with control tissue.The data demonstrate that nucleic acid-stimulated fibroblast activation and granulation tissue contraction are blocked by polyamidoamine third-generation dendrimer. Sequestration of pathogen-associated molecular patterns may be an approach for preventing pathologic scarring.

Published
2014

31. Generation of Bone Marrow and Fetal Liver Chimeric Mice

Author

Eda K. Holl

Subjects
Fetus, Cell type, Chimera, medicine.medical_treatment, Bone Marrow Cells, Liver transplantation, Biology, Article, Antibodies, Liver Transplantation, Mice, Haematopoiesis, Chimera (genetics), Immune system, medicine.anatomical_structure, Immunology, medicine, Cancer research, biology.protein, Animals, Humans, Bone marrow, Antibody, Bone Marrow Transplantation
Abstract

The creation of bone marrow and fetal liver chimeric mice has proven to be a valuable tool in the field of immunology. Chimeric mice are used to study the contribution of various cell types of hematopoietic versus non-hematopoietic origin in the course of an immune response. In this chapter, we describe a detailed method to obtain bone marrow or fetal liver chimeric mice and assess the efficiency of donor cells to repopulate the hematopoietic compartment of recipient mice.

Published
2013

32. Nucleic acid scavenging polymers inhibit extracellular DNA-mediated innate immune activation without inhibiting anti-viral responses

Author

George A. Pitoc, Elizabeth Ramsburg, Kara L. Shumansky, Bruce A. Sullenger, and Eda K. Holl

Subjects
B Cells, Mouse, Polymers, lcsh:Medicine, Lymphocyte Activation, Mice, 0302 clinical medicine, Receptors, Immunologic, lcsh:Science, Antigen Presentation, B-Lymphocytes, 0303 health sciences, Multidisciplinary, Animal Models, 3. Good health, medicine.anatomical_structure, Virus Diseases, Medicine, Research Article, Dendrimers, Ovalbumin, Immune Cells, T cell, Immunology, Antigen presentation, Antigen-Presenting Cells, Biology, Systemic Lupus Erythematosus, Antiviral Agents, Autoimmune Diseases, Proinflammatory cytokine, Immunomodulation, 03 medical and health sciences, Model Organisms, Immune system, Rheumatology, Phagocytosis, Antigen, medicine, Animals, Antigens, Cell Proliferation, 030304 developmental biology, Innate immune system, Lupus Erythematosus, lcsh:R, Histocompatibility Antigens Class II, Autoantibody, DNA, Dendrites, Immunity, Innate, Mice, Inbred C57BL, Antibody Formation, Nucleic acid, Clinical Immunology, lcsh:Q, Extracellular Space, 030215 immunology
Abstract

Toll-like receptor (TLR) family members, 3, 7 and 9 are key components in initiation and progression of autoimmune disorders such as systemic lupus erythematosus (SLE). These TLRs are often referred to as nucleic acid-sensing TLRs based on their ability to recognize DNAs or RNAs produced by pathogens or damaged cells. During autoimmune disease progression these receptors recognize self nucleic acids as well as self nucleic acid-containing complexes and contribute to inflammatory cytokine production and subsequent enhancement of serum autoantibody levels. We have recently discovered that nucleic-acid scavenging polymers (NASPs) can neutralize the proinflammatory effects of nucleic acids. Here, we begin to explore what effects such NASPs have on normal immune function. We show that such NASPs can inhibit TLR activation without affecting nucleic acid-independent T cell activation. Moreover, we observe that stimulation of immune cells by encapsulated nucleic acids, such as those found in viral particles, is unaffected by NASPs. Thus NASPs only limit the activation of the immune system by accessible extra-cellular nucleic acid and do not engender non-specific immune suppression. These important findings suggest that NASPs represent a new approach toward anti-inflammatory drug development as these agents can potentially be utilized to block overt autoimmune disorders and inflammation while allowing normal immune responses to occur.

Published
2013

33. Abstract A032: Using oncolytic polio expressing tumor as a cancer vaccine

Author

Matthias Gromeier, Christopher J. Pirozzi, Michael C. Brown, Elena Y. Dobrikova, Mubeen Mosaheb, Vidyalakshmi Chandramohan, Smita K. Nair, and Eda K. Holl

Subjects
Cancer Research, medicine.medical_treatment, Immunology, Dendritic cell, Vector vaccine, Biology, Virology, Oncolytic virus, Antigen, Cancer immunotherapy, cardiovascular system, medicine, Cytotoxic T cell, Cancer vaccine, Antigen-presenting cell
Abstract

Background: The recent clinical success of immune checkpoint inhibitors in melanoma revealed the therapeutic potential of an anti-tumor T cell response. Previous studies using peptide vaccines to elicit anti tumor T cell response have been limited in efficacy. We have discovered that an oncolytic poliovirus leads to persistent IFN dominant activation of antigen presenting cells. Based upon these findings, we propose to use a recombinant poliovirus (PVS-RIPO) expressing tumor antigens to activate antigen presenting cells and elicit an anti tumor T cell response. PVS-RIPO is the live attenuated vaccine (SABIN) type 1 containing a foreign human rhinovirus IRES. Preliminary studies in our lab showed that PVS-RIPO is a potent human dendritic cell and CD8 T cell activator. In addition, PVS-RIPO has recently achieved breakthrough status following a very promising phase I clinical trial targeting recurrent glioblastoma (GBM). The efficacy of PVS-RIPO against GBM is thought to be mediated mainly by an anti-tumor CD8 T cells response. The potent activation of dendritic cells as well as the promising results of the phase I clinical trial makes PVS-RIPO a prime candidate for use as a therapeutic tumor vaccine. The PVS-RIPO vector technology can be adapted to multiple tumor mutations, we are planning to target 2 glioma mutations at this stage: IDH1R132H and EGFRviii mutations. IDH1R132H is a point mutation in the enzyme isocitrate dehydrogenase 1, the mutation is present at high frequency (>70%) in low grade glioma. EGFRviii is a deletion in exon 2-7 of the EGFR gene, it is present in 67% of patients with GBM. Results: Adjuvancy of PVS-RIPO We first tested the immune adjuvancy of PVS-RIPO in an in vitro human system. PVS-RIPO was found to sub lethally infect and activate dendritic cells leading to pro inflammatory cytokine production. In addition, dendritic cell incubated with tumor cell lysate, PVS-RIPO and autologous T cells produced an anti tumor CD8 T cell response. Designing stable PVS-RIPO Vectors Previous attempts to use poliovirus as a vaccine vector were unsuccessful because of its notorious genetic instability. Our lab has developed a novel strategy to generate stable poliovirus vectors: we use the relative genetic plasticity of the IRES (the dispensable stem-loop Domain VI) to encode tumor antigens. We have successfully made stable PVS-RIPO vectors expressing EGFRviii and IDH1R132H antigens. Mouse models to study efficiency of vaccine in vivo Because PVS-RIPO has a rhinovirus IRES, it is incompetent in mouse cells and first had to be adapted for mouse competency. Through murine cell passaging, we have successfully generated a mouse adapted PVS-RIPO virus (mPVS-RIPO) with 5 point mutations in the IRES. We also generated 3 different transgenic (expressing the human poliovirus receptor, CD155) mouse tumor models: 1. Chemically induced model: CT2A-CD155 (C57BL/6-CD155), 2. Genetic model: Neuro Stem Cell-P53fl/fl-mPDGFB-CD155 (C57BL/6-CD155) and 3. Spontaneous tumor model: SMA560-CD155 (VM/DK-CD155). Conclusion: Here we have put together all the required tools to test the antitumor efficacy of a PVS-RIPO vector vaccine in vivo. Given that PVS-RIPO has some replication competence in muscle cells and also in tumor cells, we are planning to administer the mPVS-RIPO vector intramuscularly as well as intratumorally in mice and monitor its anti tumor efficacy. Citation Format: M Mubeen Mosaheb, Elena Dobrikova, Michael C. Brown, Christopher Pirozzi, Vidyalakshmi Chandramohan, Eda Holl, Smita Nair, Matthias Gromeier. Using oncolytic polio expressing tumor as a cancer vaccine [abstract]. In: Proceedings of the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; 2016 Sept 25-28; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(11 Suppl):Abstract nr A032.

Published
2016

34. Abstract A157: Oncolytic poliovirus mediated immune events

Author

David Boczkowski, Eda K. Holl, Michael C. Brown, Matthias Gromeier, Darell D. Bigner, and Smita K. Nair

Subjects
Cancer Research, business.industry, medicine.medical_treatment, Immunology, Immunotherapy, Acquired immune system, Oncolytic virus, Immune system, Cancer immunotherapy, Antigen, medicine, Interleukin 12, Cytotoxic T cell, business
Abstract

Introduction: Tumor-targeted therapies that efficiently eliminate malignant cells and in the process engage the innate and adaptive immune system are desirable for preventing cancer recurrence. We have pioneered an oncolytic poliovirus therapy, PVSRIPO, which selectively targets and eliminates malignant cells. PVSRIPO is a recombinant polio:rhinovirus chimera, engineered to eliminate neuronal competence and is devoid of neuropathogenicity after intracerebral inoculation in non-human primates and in humans. PVSRIPO has cancer tropism due to widespread ectopic expression of the poliovirus receptor, CD155, in solid cancers. PVSRIPO kills tumor cells with no effect on normal cells. Unlike other oncolytic viruses, PVSRIPO is effective in the presence of neutralizing antibodies and an innate antiviral response. A first-in-human Phase-1 study with PVSRIPO at Duke University has shown remarkable promise in patients with recurrent glioblastoma (GBM), a uniformly lethal disease. PVSRIPO tumor cell killing is associated with the induction of danger- and pathogen-associated molecular patterns (DAMPs and PAMPs) via antiviral type I interferons (IFNs) and simultaneous non-lethal infection of antigen-presenting cells (APCs) such as monocytes and dendritic cells (DCs) via CD155. Type I IFNs are known to inhibit tumor proliferation, activate innate immune cells and bridge innate and adaptive immunity among other functions. Methods: To understand immune events associated with poliovirus infection of APCs, we examined the effects of PVSRIPO treatment on the human macrophage cell line (THP1) and primary human monocyte-derived DCs. PVSRIPO-treated DCs were evaluated for expression of maturation/activation markers and compared to untreated immature and mature DCs. To investigate if DCs exposed to PVSRIPO-induced dying tumor cells are capable of presenting tumor antigens to T cells, we performed an in vitro human immunotherapy assay. Human DCs generated from HLA-A2+ donor cells were incubated with PVSRIPO-induced tumor cell lysate and then used to stimulate autologous T cells in vitro followed by a cytotoxic T lymphocyte (CTL) assay. All tumor cell lines used for the human immunotherapy experiments were positive for HLA-A2 expression. The following tumor cell lines were used for this analysis: DM6 (MART+) melanoma cell line, MDA-MB231 (CEA+) triple-negative breast cancer cell line, SUM149 (EGFR+) inflammatory breast cancer cell line and LNCaP (PSA+) prostate cancer cell line. Results: PVSRIPO infection of THP1 macrophages induces Mda5/Stat1 and Stat1 phosphorylation as well as TNFα and IFNβ release. Coculturing of DCs with PVSRIPO-induced tumor cell lysate stimulates DC activation and IL12 production. Human DCs loaded with PVSRIPO-induced tumor cell lysate are capable of stimulating tumor antigen-specific cytotoxic T cells in vitro. Autologous DCs transfected with RNA that encodes for CEA, EGFR, MART or PSA (tumor antigen-expressing cells) and human tumor cell lines were used as targets to assess tumor antigen-specificity of T cells. Conclusion: Our data suggests that along with destruction of the primary tumor, oncolytic poliovirus mediates immune events. Importantly, we demonstrate that human DCs co-incubated with PVSRIPO-induced tumor cell lysate stimulate tumor antigen-specific cytotoxic T cells in an in vitro human immunotherapy assay. In ongoing studies we are analyzing oncolytic poliovirus mediated immune events in syngeneic, immunocompetent murine models of breast cancer and prostate cancer. Citation Format: Michael C. Brown, Eda K. Holl, David Boczkowski, Darell D. Bigner, Matthias Gromeier, Smita K. Nair. Oncolytic poliovirus mediated immune events. [abstract]. In: Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(1 Suppl):Abstract nr A157.

Published
2016

35. Nucleic acid scavengers inhibit thrombosis without increasing bleeding

Author

Eda K. Holl, George A. Pitoc, Ying Zhang, Jaewoo Lee, Kam W. Leong, Bruce A. Sullenger, Luke B. Borst, and Shashank Jain

Subjects
Multidisciplinary, Polyphosphate, RNA, Thrombosis, Biological Sciences, Calorimetry, In vitro, Thrombelastography, chemistry.chemical_compound, Mice, Biochemistry, chemistry, Fibrinolytic Agents, In vivo, Polyphosphates, Nucleic Acids, Antithrombotic, Nucleic acid, Animals, Carotid Artery Injuries, Pulmonary Embolism, Blood Coagulation, Fibrinolytic agent, DNA
Abstract

Development of effective, yet safe, antithrombotic agents has been challenging because such agents increase the propensity of patients to bleed. Recently, naturally occurring polyphosphates such as extracellular DNA, RNA, and inorganic polyphosphates have been shown to activate blood coagulation. In this report, we evaluate the anticoagulant and antithrombotic activity of nucleic acid-binding polymers in vitro and in vivo. Such polymers bind to DNA, RNA, and inorganic polyphosphate molecules with high affinity and inhibit RNA- and polyphosphate-induced clotting and the activation of the intrinsic pathway of coagulation in vitro. Moreover, [NH 2 (CH 2 ) 2 NH 2 ]∶(G = 3);dendri PAMAM(NH 2 ) 32 (PAMAM G-3) prevents thrombosis following carotid artery injury and pulmonary thromboembolism in mice without significantly increasing blood loss from surgically challenged animals. These studies indicate that nucleic acid-binding polymers are able to scavenge effectively prothrombotic nucleic acids and other polyphosphates in vivo and represent a new and potentially safer class of antithrombotic agents.

Published
2012

36. The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-κB

Author

Zhengmao Ye, Beverly H. Koller, Brian J. Conti, Irving C. Allen, Haitao Wen, Monika Schneider, Albert G. Zimmermann, Timothy K. Eitas, Karen V. Swanson, Reid A. Roberts, Beckley K. Davis, Jenny P.-Y. Ting, Adeeb H. Rahman, Eda K. Holl, and Lu Zhang

Subjects
Immunology, Molecular Sequence Data, Biology, Real-Time Polymerase Chain Reaction, Article, Proinflammatory cytokine, Receptors, G-Protein-Coupled, chemistry.chemical_compound, Mice, Immunology and Allergy, Animals, Humans, Amino Acid Sequence, NLRX1, Transcription factor, Feedback, Physiological, Mice, Knockout, TNF Receptor-Associated Factor 6, Toll-like receptor, Innate immune system, Reverse Transcriptase Polymerase Chain Reaction, Macrophages, Toll-Like Receptors, NF-kappa B, NF-κB, NFKB1, Molecular biology, Cell biology, Mice, Inbred C57BL, HEK293 Cells, chemistry, Signal transduction, Signal Transduction
Abstract

Several members of the NLR family of sensors activate innate immunity. In contrast, we found here that NLRC3 inhibited Toll-like receptor (TLR)-dependent activation of the transcription factor NF-κB by interacting with the TLR signaling adaptor TRAF6 to attenuate Lys63 (K63)-linked ubiquitination of TRAF6 and activation of NF-κB. We used bioinformatics to predict interactions between NLR and TRAF proteins, including interactions of TRAF with NLRC3. In vivo, macrophage expression of Nlrc3 mRNA was diminished by the administration of lipopolysaccharide (LPS) but was restored when cellular activation subsided. To assess biologic relevance, we generated Nlrc3(-/-) mice. LPS-treated Nlrc3(-/-) macrophages had more K63-ubiquitinated TRAF6, nuclear NF-κB and proinflammatory cytokines. Finally, LPS-treated Nlrc3(-/-) mice had more signs of inflammation. Thus, signaling via NLRC3 and TLR constitutes a negative feedback loop. Furthermore, prevalent NLR-TRAF interactions suggest the formation of a 'TRAFasome' complex.

Published
2012

37. Plexin-B2 and Plexin-D1 in dendritic cells: expression and IL-12/IL-23p40 production

Author

Jenny P.-Y. Ting, Adam Buntzman, Irving C. Allen, Eda K. Holl, Scott E. Plevy, Jeffrey A. Frelinger, Erin C. Steinbach, Kelly E. Roney, and Janelle C. Arthur

Subjects
Chemokine, Myeloid, lcsh:Medicine, Gene Expression, Antigen Processing and Recognition, Interleukin-23, Biochemistry, Mice, 0302 clinical medicine, Bone Marrow, Molecular Cell Biology, lcsh:Science, Cells, Cultured, 0303 health sciences, Multidisciplinary, Membrane Glycoproteins, Reverse Transcriptase Polymerase Chain Reaction, Intracellular Signaling Peptides and Proteins, Flow Cytometry, Interleukin-12, Innate Immunity, Cell biology, medicine.anatomical_structure, embryonic structures, Interleukin 12, Cytokines, Research Article, animal structures, Immune Cells, Immunology, Antigen-Presenting Cells, Enzyme-Linked Immunosorbent Assay, Nerve Tissue Proteins, Biology, Immune Activation, 03 medical and health sciences, Immune system, medicine, Animals, Protein Interactions, Immunity to Infections, B cell, 030304 developmental biology, Inflammation, Follicular dendritic cells, CCL19, Plexin, lcsh:R, Immunity, Proteins, Immunoregulation, Dendritic Cells, Mice, Inbred C57BL, Immune System, biology.protein, lcsh:Q, 030215 immunology
Abstract

Plexins are a family of genes (A,B,C, and D) that are expressed in many organ systems. Plexins expressed in the immune system have been implicated in cell movement and cell-cell interaction during the course of an immune response. In this study, the expression pattern of Plexin-B2 and Plexin-D1 in dendritic cells (DCs), which are central in immune activation, was investigated. Plexin-B2 and Plexin-D1 are reciprocally expressed in myeloid and plasmacytoid DC populations. Plasmacytoid DCs have high Plexin-B2 but low Plexin-D1, while the opposite is true of myeloid DCs. Expression of Plexin-B2 and Plexin-D1 is modulated upon activation of DCs by TLR ligands, TNFα, and anti-CD40, again in a reciprocal fashion. Semaphorin3E, a ligand for Plexin-D1 and Plexin-B2, is expressed by T cells, and interestingly, is dramatically higher on Th2 cells and on DCs. The expression of Plexins and their ligands on DCs and T cells suggest functional relevance. To explore this, we utilized chimeric mice lacking Plxnb2 or Plxnd1. Absence of Plexin-B2 and Plexin-D1 on DCs did not affect the ability of these cells to upregulate costimulatory molecules or the ability of these cells to activate antigen specific T cells. Additionally, Plexin-B2 and Plexin-D1 were dispensable for chemokine-directed in-vitro migration of DCs towards key DC chemokines, CXCL12 and CCL19. However, the absence of either Plexin-B2 or Plexin-D1 on DCs leads to constitutive expression of IL-12/IL-23p40. This is the first report to show an association between Plexin-B2 and Plexin-D1 with the negative regulation of IL-12/IL-23p40 in DCs. This work also shows the presence of Plexin-B2 and Plexin-D1 on mouse DC subpopulations, and indicates that these two proteins play a role in IL-12/IL-23p40 production that is likely to impact the immune response.

Published
2011

38. Prejunctional facilitatory effect of a thiol-alkylating agent N-Ethylmaleimide on neurogenic contractions in rat prostate smooth muscle

Author

Hacer S G, Büyüknacar, Nadire, Eser, Cemil, Göçmen, William C, de Groat, Eda K, Kumcu, Peyman U, Ertuğ, and Serpil, Onder

Subjects
Atropine, Male, Prostate, Muscle, Smooth, Muscarinic Antagonists, Prazosin, Suramin, Calcium Channel Blockers, Nitroarginine, Electric Stimulation, Rats, Verapamil, Ethylmaleimide, Adrenergic alpha-1 Receptor Antagonists, Animals, Enzyme Inhibitors, Rats, Wistar, Muscle Contraction
Abstract

The effect of a non-specific thiol-alkylating agent N-ethylmaleimide (NEM) was studied on neurogenic contractile mechanisms in rat ventral prostate gland.Male Wistar albino rats were used. The rats were killed by cervical dislocation under sevoflurane anesthesia and ventral prostate gland was removed. Two preparations were obtained from each lobe. Neurally evoked isometric contractions were induced using trains of electrical field stimulation (EFS; 0.5, 1, 4, or 8 Hz). The effect of NEM on the contractions to EFS was examined in the absence or presence of adrenergic and/or purinergic antagonists.NEM enhanced the EFS-evoked contractions without altering the basal tone. These effects were significantly suppressed by an α(1) -adrenergic receptor antagonist (prazosin), a P2-purinergic antagonist (suramin), a specific P2X-receptor antagonist pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate (PPADS), an ATP analog (α,β-methylene ATP), or a calcium channel blocker (verapamil). This facilitating effect of NEM did not occur following the administration of L-cysteine or glutathione which saturated NEM with excess thiols. However, a thiol-oxidant diamide failed to affect the contractions to EFS. An adrenergic neuron blocker (guanethidine) completely suppressed the responses to NEM. On the other hand, an α(2) -adrenergic receptor blocker (yohimbine), a nitric oxide synthase inhibitor (N(ω) -nitro-L-arginine) or a cholinergic muscarinic receptor antagonist (atropine) did not significantly affect the facilitatory response of NEM.These findings suggest that NEM has a prejunctional facilitatory action on the adrenergic nerves in rat prostate tissue to enhance release of transmitters, noradrenaline, and ATP. NEM sensitive proteins involved in transmitter release mechanisms can play a role in this effect.

Published
2011

39. Plexin-B2 negatively regulates macrophage motility, Rac, and Cdc42 activation

Author

Stephen W. Jones, Beckley K. Davis, Jenny P.-Y. Ting, Rafael Garcia-Mata, Lisa Sharek, Brian P. O'Connor, Kelly E. Roney, Haitao Wen, Elizabeth H. Guthrie, Eda K. Holl, James E. Bear, and Sushmita Jha

Subjects
Male, rac1 GTP-Binding Protein, Cell Transplantation, medicine.medical_treatment, lcsh:Medicine, CDC42, Monocytes, Mice, Cell Movement, Macrophage, cdc42 GTP-Binding Protein, lcsh:Science, Immune Response, Cells, Cultured, Mice, Knockout, Multidisciplinary, biology, Flow Cytometry, Innate Immunity, Cell biology, Cytokine, Liver, Cdc42 GTP-Binding Protein, embryonic structures, Cytokines, Female, Research Article, Protein Binding, animal structures, Immune Cells, Immunology, Blotting, Western, Motility, Bone Marrow Cells, Nerve Tissue Proteins, Mice, Congenic, Immune system, Phagocytosis, medicine, Animals, Humans, Biology, Innate immune system, Macrophages, Plexin, lcsh:R, Immunity, Molecular biology, Mice, Inbred C57BL, biology.protein, Leukocyte Common Antigens, lcsh:Q, Spleen
Abstract

Plexins are cell surface receptors widely studied in the nervous system, where they mediate migration and morphogenesis though the Rho family of small GTPases. More recently, plexins have been implicated in immune processes including cell-cell interaction, immune activation, migration, and cytokine production. Plexin-B2 facilitates ligand induced cell guidance and migration in the nervous system, and induces cytoskeletal changes in overexpression assays through RhoGTPase. The function of Plexin-B2 in the immune system is unknown. This report shows that Plexin-B2 is highly expressed on cells of the innate immune system in the mouse, including macrophages, conventional dendritic cells, and plasmacytoid dendritic cells. However, Plexin-B2 does not appear to regulate the production of proinflammatory cytokines, phagocytosis of a variety of targets, or directional migration towards chemoattractants or extracellular matrix in mouse macrophages. Instead, Plxnb2(-/-) macrophages have greater cellular motility than wild type in the unstimulated state that is accompanied by more active, GTP-bound Rac and Cdc42. Additionally, Plxnb2(-/-) macrophages demonstrate faster in vitro wound closure activity. Studies have shown that a closely related family member, Plexin-B1, binds to active Rac and sequesters it from downstream signaling. The interaction of Plexin-B2 with Rac has only been previously confirmed in yeast and bacterial overexpression assays. The data presented here show that Plexin-B2 functions in mouse macrophages as a negative regulator of the GTPases Rac and Cdc42 and as a negative regulator of basal cell motility and wound healing.

Published
2011

40. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer

Author

Jenny P.-Y. Ting, Christian Jobin, Rita Marie T Woodford, Joshua M. Uronis, Hans H Herfarth, Eda K. Holl, Arlin B. Rogers, Irving C. Allen, and Erin McElvania TeKippe

Subjects
Stromal cell, Colon, Immunology, Interleukin-1beta, 03 medical and health sciences, chemistry.chemical_compound, Mice, 0302 clinical medicine, NLRC4, Neoplasms, NLR Family, Pyrin Domain-Containing 3 Protein, Immunology and Allergy, Medicine, Animals, Humans, Colitis, 030304 developmental biology, Mice, Knockout, 0303 health sciences, business.industry, Azoxymethane, Euthanasia, Interleukin-18, Inflammasome, PYCARD, medicine.disease, Inflammatory Bowel Diseases, 3. Good health, Tumor Burden, CARD Signaling Adaptor Proteins, Gene Expression Regulation, Neoplastic, Cytoskeletal Proteins, chemistry, Tumor progression, 030220 oncology & carcinogenesis, Interleukin 18, business, Apoptosis Regulatory Proteins, Carrier Proteins, medicine.drug
Abstract

Colitis-associated cancer (CAC) is a major complication of inflammatory bowel diseases. We show that components of the inflammasome are protective during acute and recurring colitis and CAC in the dextran sulfate sodium (DSS) and azoxymethane + DSS models. Mice lacking the inflammasome adaptor protein PYCARD (ASC) and caspase-1 demonstrate increased disease outcome, morbidity, histopathology, and polyp formation. The increased tumor burden is correlated with attenuated levels of IL-1β and IL-18 at the tumor site. To decipher the nucleotide-binding domain, leucine-rich-repeat-containing (NLR) component that is involved in colitis and CAC, we assessed Nlrp3 and Nlrc4 deficient mice. Nlrp3−/− mice showed an increase in acute and recurring colitis and CAC, although the disease outcome was less severe in Nlrp3−/− mice than in Pycard−/− or Casp1−/− animals. No significant differences were observed in disease progression or outcome in Nlrc4−/− mice compared with similarly treated wild-type animals. Bone marrow reconstitution experiments show that Nlrp3 gene expression and function in hematopoietic cells, rather than intestinal epithelial cells or stromal cells, is responsible for protection against increased tumorigenesis. These data suggest that the inflammasome functions as an attenuator of colitis and CAC.

Published
2010

41. Allen, I.C. et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J. Exp. Med. 207, 1045-1056

Author

Uronis, Joshua M., Ting, Jenny P.Y., Rogers, Arlin B., Holl, Eda K., Woodford, Rita Marie T., Allen, Irving C., Herfarth, Hans H., Jobin, Christian, and Tekippe, Erin Mc Elvania

Abstract

Colitis-associated cancer (CAC) is a major complication of inflammatory bowel diseases. We show that components of the inflammasome are protective during acute and recurring colitis and CAC in the dextran sulfate sodium (DSS) and azoxymethane + DSS models. Mice lacking the inflammasome adaptor protein PYCARD (ASC) and caspase-1 demonstrate increased disease outcome, morbidity, histopathology, and polyp formation. The increased tumor burden is correlated with attenuated levels of IL-1beta and IL-18 at the tumor site. To decipher the nucleotide-binding domain, leucine-rich-repeat-containing (NLR) component that is involved in colitis and CAC, we assessed Nlrp3 and Nlrc4 deficient mice. Nlrp3(-/-) mice showed an increase in acute and recurring colitis and CAC, although the disease outcome was less severe in Nlrp3(-/-) mice than in Pycard(-/-) or Casp1(-/-) animals. No significant differences were observed in disease progression or outcome in Nlrc4(-/-) mice compared with similarly treated wild-type animals. Bone marrow reconstitution experiments show that Nlrp3 gene expression and function in hematopoietic cells, rather than intestinal epithelial cells or stromal cells, is responsible for protection against increased tumorigenesis. These data suggest that the inflammasome functions as an attenuator of colitis and CAC.

Published
2010
Full Text
View/download PDF

42. Semaphorin 6D regulates the late phase of CD4+ T cell primary immune responses

Author

Hendrick W. van Deventer, Zsuzsanna Fabry, Quing Ping Wu, Eda K. Holl, Jenny P.-Y. Ting, Kelly E. Roney, Heather A. Iocca, So-Young Eun, Zhengmao Ye, Chris B. Moore, Alla L. Zozulya, John D. Lich, and Brian P. O'Connor

Subjects
CD4-Positive T-Lymphocytes, Cell type, animal structures, T cell, Semaphorins, Lymphocyte Activation, Mice, Immune system, Semaphorin, medicine, Animals, Kinase activity, Interleukin-7 receptor, Cell Proliferation, Multidisciplinary, biology, Plexin, Immunity, Biological Sciences, Cell biology, Mice, Inbred C57BL, medicine.anatomical_structure, nervous system, embryonic structures, biology.protein, Cancer research, sense organs, Signal transduction, biological phenomena, cell phenomena, and immunity, Signal Transduction
Abstract

The semaphorin and plexin family of ligand and receptor proteins provides important axon guidance cues required for development. Recent studies have expanded the role of semaphorins and plexins in the regulation of cardiac, circulatory and immune system function. Within the immune system, semaphorins and plexins regulate cell–cell interactions through a complex network of receptor and ligand pairs. Immune cells at different stages of development often express multiple semaphorins and plexins, leading to multivariate interactions, involving more than one ligand and receptor within each functional group. Because of this complexity, the significance of semaphorin and plexin regulation on individual immune cell types has yet to be fully appreciated. In this work, we examined the regulation of T cells by semaphorin 6D. Both in vitro and in vivo T cell stimulation enhanced semaphorin 6D expression. However, semaphorin 6D was only expressed by a majority of T cells during the late phases of activation. Consequently, the targeted disruption of semaphorin 6D receptor–ligand interactions inhibited T cell proliferation at late but not early phases of activation. This proliferation defect was associated with reduced linker of activated T cells protein phosphorylation, which may reflect semaphorin 6D regulation of c-Abl kinase activity. Semaphorin 6D disruption also inhibited expression of CD127, which is required during the multiphase antigen-presenting cell and T cell interactions leading to selection of long-lived lymphocytes. This work reveals a role for semaphorin 6D as a regulator of the late phase of primary immune responses.

Published
2008

43. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA

Author

Jenny P.-Y. Ting, Margaret A. Scull, Eda K. Holl, Elizabeth H. Guthrie, Chris B. Moore, Irving C. Allen, Debra J. Taxman, Erin McElvania-TeKippe, and Raymond J. Pickles

Subjects
Neutrophils, Immunology, Biology, medicine.disease_cause, Exosomes, Article, Monocytes, Virus, Microbiology, NLR Proteins, Cell Line, 03 medical and health sciences, Mice, 0302 clinical medicine, Influenza A Virus, H1N1 Subtype, Orthomyxoviridae Infections, NLRC4, Influenza, Human, NLR Family, Pyrin Domain-Containing 3 Protein, Influenza A virus, medicine, Immunology and Allergy, Animals, Humans, MOLIMMUNO, 030304 developmental biology, Mice, Knockout, 0303 health sciences, Innate immune system, integumentary system, Influenza A Virus, H3N2 Subtype, RNA, Inflammasome, Virology, Immunity, Innate, 3. Good health, RNA silencing, Infectious Diseases, Virus Diseases, RNA, Viral, Carrier Proteins, Signal Transduction, 030215 immunology, medicine.drug
Abstract

SummaryThe nucleotide-binding domain and leucine-rich-repeat-containing (NLR) family of pattern-recognition molecules mediate host immunity to various pathogenic stimuli. However, in vivo evidence for the involvement of NLR proteins in viral sensing has not been widely investigated and remains controversial. As a test of the physiologic role of the NLR molecule NLRP3 during RNA viral infection, we explored the in vivo role of NLRP3 inflammasome components during influenza virus infection. Mice lacking Nlrp3, Pycard, or caspase-1, but not Nlrc4, exhibited dramatically increased mortality and a reduced immune response after exposure to the influenza virus. Utilizing analogs of dsRNA (poly(I:C)) and ssRNA (ssRNA40), we demonstrated that an NLRP3-mediated response could be activated by RNA species. Mechanistically, NLRP3 inflammasome activation by the influenza virus was dependent on lysosomal maturation and reactive oxygen species (ROS). Inhibition of ROS induction eliminated IL-1β production in animals during influenza infection. Together, these data place the NLRP3 inflammasome as an essential component in host defense against influenza infection through the sensing of viral RNA.

Published
2008

44. On the fundamental group of $\mathbb R^3$ modulo the Case-Chamberlin continuum

Author

Eda, K., Karimov, U. H., and Repovš, D.

Subjects
Mathematics - Geometric Topology, 54F15, 55Q52, 57M05, 54B15, 54F35, 54G15, FOS: Mathematics, Algebraic Topology (math.AT), Geometric Topology (math.GT), Mathematics - Algebraic Topology
Abstract

It has been known for a long time that the fundamental group of the quotient of $\RR ^3$ by the Case-Chamberlin continuum is nontrivial. In the present paper we prove that this group is in fact, uncountable.

Published
2007
Full Text
View/download PDF

45. Abstract 32

Author

Jennifer E. Bond, Eda K. Holl, Howard Levinson, and Bruce A. Sullenger

Subjects
chemistry.chemical_compound, Biochemistry, chemistry, business.industry, Medicine, Guanosine, Surgery, Cytidine, business, Phosphate
Published
2012

46. Construction of KAGRA: An underground gravitational-wave observatory

Author

Akutsu, T., Ando, M., Araki, S., Araya, A., Arima, T., Aritomi, N., Asada, H., Aso, Y., Atsuta, S., Awai, K., Baiotti, L., Barton, M.A., Chen, D., Cho, K., Craig, K., DeSalvo, R., Doi, K., Eda, K., Enomoto, Y., Flaminio, R., Fujibayashi, S., Fujii, Y., Fujimoto, M.-K., Fukushima, M., Furuhata, T., Hagiwara, A., Haino, S., Harita, S., Hasegawa, K., Hasegawa, M., Hashino, K., Hayama, K., Hirata, N., Hirose, E., Ikenoue, B., Inoue, Y., Ioka, K., Ishizaki, H., Itoh, Y., Jia, D., Kagawa, T., Kaji, T., Kajita, T., Kakizaki, M., Kakuhata, H., Kamiizumi, M., Kanbara, S., Kanda, N., Kanemura, S., Kaneyama, M., Kasuya, J., Kataoka, Y., Kawaguchi, K., Kawai, N., Kawamura, S., Kawazoe, F., Kim, C., Kim, J., Kim, J.C., Kim, W., Kimura, N., Kitaoka, Y., Kobayashi, K., Kojima, Y., Kokeyama, K., Komori, K., Kotake, K., Kubo, K., Kumar, R., Kume, T., Kuroda, K., Kuwahara, Y., Lee, H.-K., Lee, H.-W., Lin, C.-Y., Liu, Y., Majorana, E., Mano, S., Marchio, M., Matsui, T., Matsumoto, N., Matsushima, F., Michimura, Y., Mio, N., Miyakawa, O., Miyake, K., Miyamoto, A., Miyamoto, T., Miyo, K., Miyoki, S., Morii, W., Morisaki, S., Moriwaki, Y., Muraki, Y., Murakoshi, M., Musha, M., Nagano, K., Nagano, S., Nakamura, K., Nakamura, T., Nakano, H., Nakano, M., Nakao, H., Nakao, K., Narikawa, T., Ni, W.-T., Nonomura, T., Obuchi, Y., Oh, J.J., Oh, S.-H., Ohashi, M., Ohishi, N., Ohkawa, M., Ohmae, N., Okino, K., Okutomi, K., Ono, K., Ono, Y., Oohara, K., Ota, S., Park, J., Peña, Arellano, Pinto, I.M., Principe, M., Sago, N., Saijo, M., Saito, T., Saito, Y., Saitou, S., Sakai, K., Sakakibara, Y., Sasaki, Y., Sato, S., Sato, T., Sato, Y., Sekiguchi, T., Sekiguchi, Y., Shibata, M., Shiga, K., Shikano, Y., Shimoda, T., Shinkai, H., Shoda, A., Someya, N., Somiya, K., Son, E.J., Starecki, T., Suemasa, A., Sugimoto, Y., Susa, Y., Suwabe, H., Suzuki, T., Tachibana, Y., Tagoshi, H., Takada, S., Takahashi, H., Takahashi, R., Takamori, A., Takeda, H., Tanaka, H., Tanaka, K., Tanaka, T., Tatsumi, D., Telada, S., Tomaru, T., Tsubono, K., Tsuchida, S., Tsukada, L., Tsuzuki, T., Uchikata, N., Uchiyama, T., Uehara, T., Ueki, S., Ueno, K., Uraguchi, F., Ushiba, T., Van Putten, M.H.P.M., Wada, S., Wakamatsu, T., Yaginuma, T., Yamamoto, K., Yamamoto, S., Yamamoto, T., Yano, K., Yokoyama, J., Yokozawa, T., Yoon, T.H., Yuzurihara, H., Zeidler, S., Zhao, Y., Zheng, L., Agatsuma, K., Akiyama, Y., Arai, N., Asano, M., Bertolini, A., Fujisawa, M., Goetz, R., Guscott, J., Hashimoto, Y., Hayashida, Y., Hennes, E., Hirai, K., Hirayama, T., Ishitsuka, H., Kato, J., Khalaidovski, A., Koike, S., Kumeta, A., Miener, T., Morioka, M., Mueller, C.L., Narita, T., Oda, Y., Ogawa, T., Tamura, H., Tanner, D.B., Tokoku, C., Toritani, M., Utsuki, T., Uyeshima, M., Van Den Brand, J.F.J., Van Heijningen, J.V., Yamaguchi, S., and Yanagida, A.

Subjects
gravitational-wave detector, 11. Sustainability, seismic motion, KAGRA, Dewey Decimal Classification::500 | Naturwissenschaften::530 | Physik
Abstract

The major construction and initial-phase operation of a second-generation gravitational-wave detector, KAGRA, has been completed. The entire 3 km detector is installed underground in a mine in order to be isolated from background seismic vibrations on the surface. This allows us to achieve a good sensitivity at low frequencies and high stability of the detector. Bare-bones equipment for the interferometer operation has been installed and the first test run was accomplished in March and April of 2016 with a rather simple configuration. The initial configuration of KAGRA is called iKAGRA. In this paper, we summarize the construction of KAGRA, including a study of the advantages and challenges of building an underground detector, and the operation of the iKAGRA interferometer together with the geophysics interferometer that has been constructed in the same tunnel. © The Author(s) 2018. Published by Oxford University Press on behalf of the Physical Society of Japan.

47. The NLRP3 Inflammasome Mediates In Vivo Innate Immunity to Influenza A Virus through Recognition of Viral RNA

Author

Moore, Chris B., Holl, Eda K., Allen, Irving C., McElvania-TeKippe, Erin, Ting, Jenny P.-Y., Taxman, Debra J., Scull, Margaret A., Pickles, Raymond J., and Guthrie, Elizabeth H.

Subjects
integumentary system, 3. Good health
Abstract

NLR genes mediate host immunity to various pathogenic stimuli. However, in vivo evidence for NLR involvement in viral sensing has not been widely investigated and remains controversial. As an ultimate test of the physiologic role of NLRP3 during RNA viral infection, this work explores the in vivo role of NLRP3 inflammasome components during influenza virus infection. Mice lacking Nlrp3, ASC, or Caspase-1, but not Nlrc4, exhibit dramatically increased mortality but reduced immune response following influenza virus exposure. Utilizing analogs of dsRNA (poly(I:C)) and ssRNA (ssRNA40), we demonstrate that NLRP3-mediated response can be activated by RNA species. Mechanistically, NLRP3 inflammasome activation by influenza virus is dependent upon lysosomal maturation and reactive oxygen species. Inhibition of ROS induction eliminated IL-1β production in animals during influenza infection. Together, these data place the NLRP3 inflammasome as an essential component in host defense against influenza infection through the sensing of viral RNA.

48. Oncolytic poliovirus directs tumor antigen presentation and T cell activation in vitro

Author

Smita K. Nair, Eda K. Holl, Darell D. Bigner, Matthias Gromeier, Ross W. Walton, Michael C. Brown, and David Boczkowski

Subjects
Cancer Research, viruses, T cell, Immunology, chemical and pharmacologic phenomena, medicine.disease_cause, Bioinformatics, complex mixtures, law.invention, Chimera (genetics), law, medicine, Immunology and Allergy, Tropism, Pharmacology, business.industry, Poliovirus, virus diseases, Virology, Tumor antigen, Oncolytic virus, medicine.anatomical_structure, Oncology, Poster Presentation, Recombinant DNA, Molecular Medicine, Rhinovirus, business
Abstract

Meeting abstracts Our group has developed an oncolytic poliovirus, PVSRIPO, capable of lysing malignant cells while generating inflammation at the site of the tumor. PVSRIPO is a recombinant polio:rhinovirus chimera, engineered to eliminate neuropathogenicity, that has cancer tropism due to ectopic

Full Text
View/download PDF

49. KAGRA: 2.5 generation interferometric gravitational wave detector

Author

Hirotaka Takahashi, H. Tahara, T. Miyamoto, Kazuyuki Tanaka, Y. Saito, Mitsuhiro Fukushima, Y. Liu, Albert K. H. Kong, Yoshinori Fujii, G. Kang, Innocenzo M. Pinto, E. J. Son, Sakae Araki, Osamu Miyakawa, Hyun Lee, K. Hasegawa, B. Ikenoue, H-S. Kuo, B. H. Hsieh, Ken Ono, F. L. Lin, C. Z. Huang, Xu W. R., Takaaki Kajita, Yuki Inoue, Akiteru Takamori, Motoyuki Saijo, F. Matsushima, T. Yoshioka, Ken-ichi Nakao, Ni W. T., Kentaro Komori, M. A. Barton, T. Ushiba, R. Flaminio, Simon Zeidler, Luca Baiotti, F. Uraguchi, Y. Sakai, Ettore Majorana, K. Awai, Kieran Craig, K. Yamamoto, Daisuke Tatsumi, Atsushi Nishizawa, Yousuke Itoh, Oh S. H., K. Sakai, S. Kanbara, Kipp Cannon, R. Kozu, Jong-Dae Park, Mitsuru Musha, M. Fukunaga, S. Sato, Masashi Ohkawa, J. Kasuya, N. Uchikata, T. Matsui, Shinya Kanemura, Kyung-Suk Cho, Yutaro Enomoto, S. Wada, Hiroyuki Nakano, Y. Watanabe, Hisa-aki Shinkai, Yuta Michimura, S. Yamamoto, Katsuya Hashino, S. Ueki, Tomoya Kinugawa, J. Kim, A. Miyamoto, W. Morii, Y. Kataoka, Masatake Ohashi, Akito Araya, T. Furuhata, Tai Hyun Yoon, S. Kirii, T. Kaji, Satoshi Tsuchida, Kentaro Somiya, Sachiko Kuroyanagi, Naoki Seto, Nobutada Kimura, T. Kawasaki, Shinji Miyoki, Y. Sasaki, Naoko Ohishi, A. Suemasa, Takahiro Yamamoto, F. E. P. Arellano, T. Tomura, Nobuyuki Kanda, H. K. Tanaka, Masaki Ando, Shigeki Hirobayashi, S. Bae, M. Marchio, T. Ochi, T. Shimoda, M. Sasai, A. Yamamoto, Eiichi Hirose, Kouji Nakamura, Jun'ichi Yokoyama, H. Yuzurihara, Young-Min Kim, Yoichi Aso, Norichika Sago, Oh J. J., Y. K. Chu, M. H. P. M. van Putten, A. Shoda, Takashi Nakamura, Zong-Hong Zhu, C. Chen, Hideyuki Tagoshi, Y. Arai, T. Morozumi, Ting-Wai Chiu, Yasufumi Kojima, Rajesh Kumar, N. Sato, Chunglee Kim, Kimio Tsubono, Hyeseung Lee, C. P. Ooi, S. S. Pan, K. Miyo, K. Oohara, M. Kaneyama, M. Leonardi, Takayuki Tomaru, S. Saitou, Kazunari Eda, Takahiro Yamada, Koya Arai, Hiroki Takeda, T. Wakamatsu, Tomotada Akutsu, S. Tanioka, Kazuhiro Hayama, M. Nakano, Kohei Doi, Masako Kakizaki, Sadakazu Haino, K. Ueno, Yuichiro Sekiguchi, W. S. Kim, Norikatsu Mio, K. Izumi, Takamasa Suzuki, Seiji Kawamura, Haruki Kitazawa, Masa-Katsu Fujimoto, L. Naticchioni, T. Shishido, Naoki Aritomi, K. Yokogawa, E. Capocasa, Enzo Nicolas Tapia San Martin, Takashi Uchiyama, Kunihito Ioka, T. Uehara, T. Narikawa, Y. Moriwaki, Manami Sasaki, Ryutaro Takahashi, Keiko Kokeyama, Hyang Woon Lee, Koki Okutomi, Y. Obuchi, Jinsook Kim, T. Yokozawa, Y. Kitaoka, N. Kawai, Guo-Chin Liu, Takahiro Tanaka, W. Creus, Hideki Asada, Masaru Shibata, Shuhei Mano, Soichiro Morisaki, L. N. Quynh, S. Atsuta, C-Y. Lin, Takashi Sato, Koji Nagano, M. Kamiizumi, Shigeo Nagano, Kei Kotake, H. Vocca, F. Travasso, Laboratoire d'Annecy de Physique des Particules (LAPP/Laboratoire d'Annecy-le-Vieux de Physique des Particules), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), KAGRA, Laboratoire d'Annecy de Physique des Particules (LAPP), Akutsu, T., Ando, M., Arai, K., Arai, Y., Araki, S., Araya, A., Aritomi, N., Asada, H., Aso, Y., Atsuta, S., Awai, K., Bae, S., Baiotti, L., Barton, M. A., Cannon, K., Capocasa, E., Chen, C. -S., Chiu, T. -W., Cho, K., Chu, Y. -K., Craig, K., Creus, W., Doi, K., Eda, K., Enomoto, Y., Flaminio, R., Fujii, Y., Fujimoto, M. -K., Fukunaga, M., Fukushima, M., Furuhata, T., Haino, S., Hasegawa, K., Hashino, K., Hayama, K., Hirobayashi, S., Hirose, E., Hsieh, B. H., Huang, C. -Z., Ikenoue, B., Inoue, Y., Ioka, K., Itoh, Y., Izumi, K., Kaji, T., Kajita, T., Kakizaki, M., Kamiizumi, M., Kanbara, S., Kanda, N., Kanemura, S., Kaneyama, M., Kang, G., Kasuya, J., Kataoka, Y., Kawai, N., Kawamura, S., Kawasaki, T., Kim, C., Kim, J., Kim, J. C., Kim, W. S., Kim, Y. -M., Kimura, N., Kinugawa, T., Kirii, S., Kitaoka, Y., Kitazawa, H., Kojima, Y., Kokeyama, K., Komori, K., Kong, A. K. H., Kotake, K., Kozu, R., Kumar, R., Kuo, H. -S., Kuroyanagi, S., Lee, H. K., Lee, H. M., Lee, H. W., Leonardi, M., Lin, C. -Y., Lin, F. -L., Liu, G. C., Liu, Y., Majorana, E., Mano, S., Marchio, M., Matsui, T., Matsushima, F., Michimura, Y., Mio, N., Miyakawa, O., Miyamoto, A., Miyamoto, T., Miyo, K., Miyoki, S., Morii, W., Morisaki, S., Moriwaki, Y., Morozumi, T., Musha, M., Nagano, K., Nagano, S., Nakamura, K., Nakamura, T., Nakano, H., Nakano, M., Nakao, K., Narikawa, T., Naticchioni, L., Quynh, L. N., Ni, W. -T., Nishizawa, A., Obuchi, Y., Ochi, T., Oh, J. J., Oh, S. H., Ohashi, M., Ohishi, N., Ohkawa, M., Okutomi, K., Ono, K., Oohara, K., Ooi, C. P., Pan, S. -S., Park, J., Arellano, F. E. P., Pinto, I., Sago, N., Saijo, M., Saitou, S., Saito, Y., Sakai, K., Sakai, Y., Sasai, M., Sasaki, M., Sasaki, Y., Sato, S., Sato, N., Sato, T., Sekiguchi, Y., Seto, N., Shibata, M., Shimoda, T., Shinkai, H., Shishido, T., Shoda, A., Somiya, K., Son, E. J., Suemasa, A., Suzuki, T., Tagoshi, H., Tahara, H., Takahashi, H., Takahashi, R., Takamori, A., Takeda, H., Tanaka, H., Tanaka, K., Tanaka, T., Tanioka, S., Martin, E. N. T. S., Tatsumi, D., Tomaru, T., Tomura, T., Travasso, F., Tsubono, K., Tsuchida, S., Uchikata, N., Uchiyama, T., Uehara, T., Ueki, S., Ueno, K., Uraguchi, F., Ushiba, T., van Putten, M. H. P. M., Vocca, H., Wada, S., Wakamatsu, T., Watanabe, Y., Xu, W. -R., Yamada, T., Yamamoto, A., Yamamoto, K., Yamamoto, S., Yamamoto, T., Yokogawa, K., Yokoyama, J., Yokozawa, T., Yoon, T. H., Yoshioka, T., Yuzurihara, H., Zeidler, S., and Zhu, Z. -H.

Subjects
Physics - Instrumentation and Detectors, detector: cryogenics, 010504 meteorology & atmospheric sciences, FOS: Physical sciences, General Relativity and Quantum Cosmology (gr-qc), detector: network, 7. Clean energy, 01 natural sciences, General Relativity and Quantum Cosmology, Laser interferometry, Einstein Telescope, temperature: low, 0103 physical sciences, LCGT, Interferometric gravitational wave detector, KAGRA, laser: interferometer, [PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det], LIGO, mirror, Instrumentation and Methods for Astrophysics (astro-ph.IM), 010303 astronomy & astrophysics, detector: design, 0105 earth and related environmental sciences, Physics, COSMIC cancer database, Gravitational wave, Detector, gravitational radiation, Astronomy, Astronomy and Astrophysics, Gravitational Wave Detector, Instrumentation and Detectors (physics.ins-det), trigger, gravitational radiation detector, detector: sensitivity, VIRGO, [PHYS.GRQC]Physics [physics]/General Relativity and Quantum Cosmology [gr-qc], Astrophysics - Instrumentation and Methods for Astrophysics
Abstract

著者人数: KAGRA collaboration 198名 (所属. 宇宙航空研究開発機構宇宙科学研究所(JAXA)(ISAS): 和泉, 究), Number of authors: KAGRA collaboration 198 (Affiliation. Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency(JAXA)(ISAS): Izumi, Kiwamu), Accepted: 2018-11-19, 資料番号: SA1180423000

Published
2019

50. Prospects for observing and localizing gravitational-wave transients with Advanced LIGO, Advanced Virgo and KAGRA

Author

Abbott, B. P., Abbott, R., Abbott, T. D., Abraham, S., Acernese, F., Ackley, K., Adams, C., Adya, V. B., Affeldt, C., Agathos, M., Agatsuma, K., Aggarwal, N., Aguiar, O. D., Aiello, L., Ain, A., Ajith, P., Akutsu, T., Allen, G., Allocca, A., Aloy, M. A., Altin, P. A., Amato, A., Ananyeva, A., Anderson, S. B., Anderson, W. G., Ando, M., Angelova, S. V., Antier, S., Appert, S., Arai, K., Arai, Koya, Arai, Y., Araki, S., Araya, A., Araya, M. C., Areeda, J. S., Arene, M., Aritomi, N., Arnaud, N., Arun, K. G., Ascenzi, S., Ashton, G., Aso, Y., Aston, S. M., Astone, P., Aubin, F., Aufmuth, P., AultONeal, K., Austin, C., Avendano, V., Avila-Alvarez, A., Babak, S., Bacon, P., Badaracco, F., Bader, M. K. M., Bae, S. W., Bae, Y. B., Baiotti, L., Bajpai, R., Baker, P. T., Baldaccini, F., Ballardin, G., Ballmer, S. W., Banagiri, S., Barayoga, J. C., Barclay, S. E., Barish, B. C., Barker, D., Barkett, K., Barnum, S., Barone, F., Barr, B., Barsotti, L., Barsuglia, M., Barta, D., Bartlett, J., Barton, M. A., Bartos, I., Bassiri, R., Basti, A., Bawaj, M., Bayley, J. C., Bazzan, M., Becsy, B., Bejger, M., Belahcene, I., Bell, A. S., Beniwal, D., Berger, B. K., Bergmann, G., Bernuzzi, S., Bero, J. J., Berry, C. P. L., Bersanetti, D., Bertolini, A., Betzwieser, J., Bhandare, R., Bidler, J., Bilenko, I. A., Bilgili, S. A., Billingsley, G., Birch, J., Birney, R., Birnholtz, O., Biscans, S., Biscoveanu, S., Bisht, A., Bitossi, M., Bizouard, M. A., Blackburn, J. K., Blair, C. D., Blair, D. G., Blair, R. M., Bloemen, S., Bode, N., Boer, M., Boetzel, Y., Bogaert, G., Bondu, F., Bonilla, E., Bonnand, R., Booker, P., Boom, B. A., Booth, C. D., Bork, R., Boschi, V., Bose, S., Bossie, K., Bossilkov, V., Bosveld, J., Bouffanais, Y., Bozzi, A., Bradaschia, C., Brady, P. R., Bramley, A., Branchesi, M., Brau, J. E., Briant, T., Briggs, J. H., Brighenti, F., Brillet, A., Brinkmann, M., Brisson, V., Brockill, P., Brooks, A. F., Brown, D. A., Brown, D. D., Brunett, S., Buikema, A., Bulik, T., Bulten, H. J., Buonanno, A., Buskulic, D., Buy, C., Byer, R. L., Cabero, M., Cadonati, L., Cagnoli, G., Cahillane, C., Bustillo, J. Calderon, Callister, T. A., Calloni, E., Camp, J. B., Campbell, W. A., Canepa, M., Cannon, K., Cannon, K. C., Cao, H., Cao, J., Capocasa, E., Carbognani, F., Caride, S., Carney, M. F., Carullo, G., Diaz, J. Casanueva, Casentini, C., Caudill, S., Cavaglia, M., Cavalier, F., Cavalieri, R., Cella, G., Cerda-Duran, P., Cerretani, G., Cesarini, E., Chaibi, O., Chakravarti, K., Chamberlin, S. J., Chan, M., Chan, M. L., Chao, S., Charlton, P., Chase, E. A., Chassande-Mottin, E., Chatterjee, D., Chaturvedi, M., Chatziioannou, K., Cheeseboro, B. D., Chen, C. S., Chen, H. Y., Chen, K. H., Chen, X., Chen, Y., Chen, Y. R., Cheng, H. -P., Cheong, C. K., Chia, H. Y., Chincarini, A., Chiummo, A., Cho, G., Cho, H. S., Cho, M., Christensen, N., Chu, H. Y., Chu, Q., Chu, Y. K., Chua, S., Chung, K. W., Chung, S., Ciani, G., Ciobanu, A. A., Ciolfi, R., Cipriano, F., Cirone, A., Clara, F., Clark, J. A., Clearwater, P., Cleva, F., Cocchieri, C., Coccia, E., Cohadon, P. -F., Cohen, D., Colgan, R., Colleoni, M., Collette, C. G., Collins, C., Cominsky, L. R., Constancio, M., Jr., Conti, L., Cooper, S. J., Corban, P., Corbitt, T. R., Cordero-Carrion, I., Corley, K. R., Cornish, N., Corsi, A., Cortese, S., Costa, C. A., Cotesta, R., Coughlin, M. W., Coughlin, S. B., Coulon, J. -P., Countryman, S. T., Couvares, P., Covas, P. B., Cowan, E. E., Coward, D. M., Cowart, M. J., Coyne, D. C., Coyne, R., Creighton, J. D. E., Creighton, T. D., Cripe, J., Croquette, M., Crowder, S. G., Cullen, T. J., Cumming, A., Cunningham, L., Cuoco, E., Canton, T. Dal, Dálya, Gergely, Danilishin, S. L., D'Antonio, S., Danzmann, K., Dasgupta, A., Da Silva Costa, C. F., Datrier, L. E. H., Dattilo, V., Dave, I., Davier, M., Davis, D., Daw, E. J., DeBra, D., Deenadayalan, M., Degallaix, J., De Laurentis, M., Deleglise, S., Pozzo, W. Del, DeMarchi, L. M., Demos, N., Dent, T., De Pietri, R., Derby, J., De Rosa, R., De Rossi, C., DeSalvo, R., de Varona, O., Dhurandhar, S., Diaz, M. C., Dietrich, T., Fiore, L. Di, Giovanni, M. Di, Girolamo, T. Di, Lieto, A. Di, Ding, B., Pace, S. Di, Palma, I. Di, Renzo, F. Di, Dmitriev, A., Doctor, Z., Doi, K., Donovan, F., Dooley, K. L., Doravari, S., Dorrington, I., Downes, T. P., Drago, M., Driggers, J. C., Du, Z., Ducoin, J. -G., Dupej, P., Dwyer, S. E., Easter, P. J., Edo, T. B., Edwards, M. C., Effler, A., Eguchi, S., Ehrens, P., Eichholz, J., Eikenberry, S. S., Eisenmann, M., Eisenstein, R. A., Enomoto, Y., Essick, R. C., Estelles, H., Estevez, D., Etienne, Z. B., Etzel, T., Evans, M., Evans, T. M., Fafone, V., Fair, H., Fairhurst, S., Fan, X., Farinon, S., Farr, B., Farr, W. M., Fauchon-Jones, E. J., Favata, M., Fays, M., Fazio, M., Fee, C., Feicht, J., Fejer, M. M., Feng, F., Fernandez-Galiana, A., Ferrante, I., Ferreira, E. C., Ferreira, T. A., Ferrini, F., Fidecaro, F., Fiori, I., Fiorucci, D., Fishbach, M., Fisher, R. P., Fishner, J. M., Fitz-Axen, M., Flaminio, R., Fletcher, M., Flynn, E., Fong, H., Font, J. A., Forsyth, P. W. F., Fournier, J. -D., Frasca, S., Frasconi, F., Frei, Z., Freise, A., Frey, R., Frey, V., Fritschel, P., Frolov, V. V., Fujii, Y., Fukunaga, M., Fukushima, M., Fulda, P., Fyffe, M., Gabbard, H. A., Gadre, B. U., Gaebel, S. M., Gair, J. R., Gammaitoni, L., Ganija, M. R., Gaonkar, S. G., Garcia, A., Garcia-Quiros, C., Garufi, F., Gateley, B., Gaudio, S., Gaur, G., Gayathri, V., Ge, G. G., Gemme, G., Genin, E., Gennai, A., George, D., George, J., Gergely, L., Germain, V., Ghonge, S., Ghosh, Abhirup, Ghosh, Archisman, Ghosh, S., Giacomazzo, B., Giaime, J. A., Giardina, K. D., Giazotto, A., Gill, K., Giordano, G., Glover, L., Godwin, P., Goetz, E., Goetz, R., Goncharov, B., Gonzalez, G., Castro, J. M. Gonzalez, Gopakumar, A., Gorodetsky, M. L., Gossan, S. E., Gosselin, M., Gouaty, R., Grado, A., Graef, C., Granata, M., Grant, A., Gras, S., Grassia, P., Gray, C., Gray, R., Greco, G., Green, A. C., Green, R., Gretarsson, E. M., Groot, P., Grote, H., Grunewald, S., Gruning, P., Guidi, G. M., Gulati, H. K., Guo, Y., Gupta, A., Gupta, M. K., Gustafson, E. K., Gustafson, R., Haegel, L., Hagiwara, A., Haino, S., Halim, O., Hall, B. R., Hall, E. D., Hamilton, E. Z., Hammond, G., Haney, M., Hanke, M. M., Hanks, J., Hanna, C., Hannam, M. D., Hannuksela, O. A., Hanson, J., Hardwick, T., Haris, K., Harms, J., Harry, G. M., Harry, I. W., Hasegawa, K., Haster, C. -J., Haughian, K., Hayakawa, H., Hayama, K., Hayes, F. J., Healy, J., Heidmann, A., Heintze, M. C., Heitmann, H., Hello, P., Hemming, G., Hendry, M., Heng, I. S., Hennig, J., Heptonstall, A. W., Heurs, M., Hild, S., Himemoto, Y., Hinderer, T., Hiranuma, Y., Hirata, N., Hirose, E., Hoak, D., Hochheim, S., Hofman, D., Holgado, A. M., Holland, N. A., Holt, K., Holz, D. E., Hong, Z., Hopkins, P., Horst, C., Hough, J., Howell, E. J., Hoy, C. G., Hreibi, A., Hsieh, B. H., Huang, G. Z., Huang, P. W., Huang, Y. J., Huerta, E. A., Huet, D., Hughey, B., Hulko, M., Husa, S., Huttner, S. H., Huynh-Dinh, T., Idzkowski, B., Iess, A., Ikenoue, B., Imam, S., Inayoshi, K., Ingram, C., Inoue, Y., Inta, R., Intini, G., Ioka, K., Irwin, B., Isa, H. N., Isac, J. -M., Isi, M., Itoh, Y., Iyer, B. R., Izumi, K., Jacqmin, T., Jadhav, S. J., Jani, K., Janthalur, N. N., Jaranowski, P., Jenkins, A. C., Jiang, J., Johnson, D. S., Jones, A. W., Jones, D. I., Jones, R., Jonker, R. J. G., Ju, L., Jung, K., Jung, P., Junker, J., Kajita, T., Kalaghatgi, C. V., Kalogera, V., Kamai, B., Kamiizumi, M., Kanda, N., Kandhasamy, S., Kang, G. W., Kanner, J. B., Kapadia, S. J., Karki, S., Karvinen, K. S., Kashyap, R., Kasprzack, M., Katsanevas, S., Katsavounidis, E., Katzman, W., Kaufer, S., Kawabe, K., Kawaguchi, K., Kawai, N., Kawasaki, T., Keerthana, N. V., Kefelian, F., Keitel, D., Kennedy, R., Key, J. S., Khalili, F. Y., Khan, H., Khan, I., Khan, S., Khan, Z., Khazanov, E. A., Khursheed, M., Kijbunchoo, N., Kim, Chunglee, Kim, C., Kim, J. C., Kim, J., Kim, K., Kim, W., Kim, W. S., Kim, Y. -M., Kimball, C., Kimura, N., King, E. J., King, P. J., Kinley-Hanlon, M., Kirchhoff, R., Kissel, J. S., Kita, N., Kitazawa, H., Kleybolte, L., Klika, J. H., Klimenko, S., Knowles, T. D., Knyazev, E., Koch, P., Koehlenbeck, S. M., Koekoek, G., Kojima, Y., Kokeyama, K., Koley, S., Komori, K., Kondrashov, V., Kong, A. K. H., Kontos, A., Koper, N., Korobko, M., Korth, W. Z., Kotake, K., Kowalska, I., Kozak, D. B., Kozakai, C., Kozu, R., Kringel, V., Krishnendu, N., Krolak, A., Kuehn, G., Kumar, A., Kumar, P., Kumar, Rahul, Kumar, R., Kumar, S., Kume, J., Kuo, C. M., Kuo, H. S., Kuo, L., Kuroyanagi, S., Kusayanagi, K., Kutynia, A., Kwak, K., Kwang, S., Lackey, B. D., Lai, K. H., Lam, T. L., Landry, M., Lane, B. B., Lang, R. N., Lange, J., Lantz, B., Lanza, R. K., Lartaux-Vollard, A., Lasky, P. D., Laxen, M., Lazzarini, A., Lazzaro, C., Leaci, P., Leavey, S., Lecoeuche, Y. K., Lee, C. H., Lee, H. K., Lee, H. M., Lee, H. W., Lee, J., Lee, K., Lee, R. K., Lehmann, J., Lenon, A., Leonardi, M., Leroy, N., Letendre, N., Levin, Y., Li, J., Li, K. J. L., Li, T. G. F., Li, X., Lin, C. Y., Lin, F., Lin, F. L., Lin, L. C. C., Linde, F., Linker, S. D., Littenberg, T. B., Liu, G. C., Liu, J., Liu, X., Lo, R. K. L., Lockerbie, N. A., London, L. T., Longo, A., Lorenzini, M., Loriette, V., Lormand, M., Losurdo, G., Lough, J. D., Lousto, C. O., Lovelace, G., Lower, M. E., Lueck, H., Lumaca, D., Lundgren, A. P., Luo, L. W., Lynch, R., Ma, Y., Macas, R., Macfoy, S., MacInnis, M., Macleod, D. M., Macquet, A., Magana-Sandoval, F., Zertuche, L. Magana, Magee, R. M., Majorana, E., Maksimovic, I., Malik, A., Man, N., Mandic, V., Mangano, V., Mansell, G. L., Manske, M., Mantovani, M., Marchesoni, F., Marchio, M., Marion, F., Marka, S., Marka, Z., Markakis, C., Markosyan, A. S., Markowitz, A., Maros, E., Marquina, A., Marsat, S., Martelli, F., Martin, I. W., Martin, R. M., Martynov, D. V., Mason, K., Massera, E., Masserot, A., Massinger, T. J., Masso-Reid, M., Mastrogiovanni, S., Matas, A., Matichard, F., Matone, L., Mavalvala, N., Mazumder, N., McCann, J. J., McCarthy, R., McClelland, D. E., McCormick, S., McCuller, L., McGuire, S. C., McIver, J., McManus, D. J., McRae, T., McWilliams, S. T., Meacher, D., Meadors, G. D., Mehmet, M., Mehta, A. K., Meidam, J., Melatos, A., Mendell, G., Mercer, R. A., Mereni, L., Merilh, E. L., Merzougui, M., Meshkov, S., Messenger, C., Messick, C., Metzdorff, R., Meyers, P. M., Miao, H., Michel, C., Michimura, Y., Middleton, H., Mikhailov, E. E., Milano, L., Miller, A. L., Miller, A., Millhouse, M., Mills, J. C., Milovich-Goff, M. C., Minazzoli, O., Minenkov, Y., Mio, N., Mishkin, A., Mishra, C., Mistry, T., Mitra, S., Mitrofanov, V. P., Mitselmakher, G., Mittleman, R., Miyakawa, O., Miyamoto, A., Miyazaki, Y., Miyo, K., Miyoki, S., Mo, G., Moffa, D., Mogushi, K., Mohapatra, S. R. P., Montani, M., Moore, C. J., Moraru, D., Moreno, G., Morisaki, S., Moriwaki, Y., Mours, B., Mow-Lowry, C. M., Mukherjee, Arunava, Mukherjee, D., Mukherjee, S., Mukund, N., Mullavey, A., Munch, J., Muniz, E. A., Muratore, M., Murray, P. G., Nagano, K., Nagano, S., Nagar, A., Nakamura, K., Nakano, H., Nakano, M., Nakashima, R., Nardecchia, I., Narikawa, T., Naticchioni, L., Nayak, R. K., Negishi, R., Neilson, J., Nelemans, G., Nelson, T. J. N., Nery, M., Neunzert, A., Ng, K. Y., Ng, S., Nguyen, P., Ni, W. T., Nichols, D., Nishizawa, A., Nissanke, S., Nocera, F., North, C., Nuttall, L. K., Obergaulinger, M., Oberling, J., O'Brien, B. D., Obuchi, Y., O'Dea, G. D., Ogaki, W., Ogin, G. H., Oh, J. J., Oh, S. H., Ohashi, M., Ohishi, N., Ohkawa, M., Ohme, F., Ohta, H., Okada, M. A., Okutomi, K., Oliver, M., Oohara, K., Ooi, C. P., Oppermann, P., Oram, Richard J., O'Reilly, B., Ormiston, R. G., Ortega, L. F., O'Shaughnessy, R., Oshino, S., Ossokine, S., Ottaway, D. J., Overmier, H., Owen, B. J., Pace, A. E., Pagano, G., Page, M. A., Pai, A., Pai, S. A., Palamos, J. R., Palashov, O., Palomba, C., Pal-Singh, A., Pan, Huang-Wei, Pan, K. C., Pang, B., Pang, H. F., Pang, P. T. H., Pankow, C., Pannarale, F., Pant, B. C., Paoletti, F., Paoli, A., Papa, M. A., Parida, A., Park, J., Parker, W., Pascucci, D., Pasqualetti, A., Passaquieti, R., Passuello, D., Patil, M., Patricelli, B., Pearlstone, B. L., Pedersen, C., Pedraza, M., Pedurand, R., Pele, A., Arellano, F. E. Pena, Penn, S., Perez, C. J., Perreca, A., Pfeiffer, H. P., Phelps, M., Phukon, K. S., Piccinni, O. J., Pichot, M., Piergiovanni, F., Pillant, G., Pinard, L., Pinto, I., Pirello, M., Pitkin, M., Poggiani, R., Pong, D. Y. T., Ponrathnam, S., Popolizio, P., Porter, E. K., Powell, J., Prajapati, A. K., Prasad, J., Prasai, K., Prasanna, R., Pratten, G., Prestegard, T., Privitera, S., Prodi, G. A., Prokhorov, L. G., Puncken, O., Punturo, M., Puppo, P., Puerrer, M., Qi, H., Quetschke, V., Quinonez, P. J., Quintero, E. A., Quitzow-James, R., Raab, F. J., Radkins, H., Radulescu, N., Raffai, P., Raja, S., Rajan, C., Rajbhandari, B., Rakhmanov, M., Ramirez, K. E., Ramos-Buades, A., Rana, Javed, Rao, K., Rapagnani, P., Raymond, V., Razzano, M., Read, J., Regimbau, T., Rei, L., Reid, S., Reitze, D. H., Ren, W., Ricci, F., Richardson, C. J., Richardson, J. W., Ricker, P. M., Riles, K., Rizzo, M., Robertson, N. A., Robie, R., Robinet, F., Rocchi, A., Rolland, L., Rollins, J. G., Roma, V. J., Romanelli, M., Romano, R., Romel, C. L., Romie, J. H., Rose, K., Rosinska, D., Rosofsky, S. G., Ross, M. P., Rowan, S., Ruediger, A., Ruggi, P., Rutins, G., Ryan, K., Sachdev, S., Sadecki, T., Sago, N., Saito, S., Saito, Y., Sakai, K., Sakai, Y., Sakamoto, H., Sakellariadou, M., Sakuno, Y., Salconi, L., Saleem, M., Samajdar, A., Sammut, L., Sanchez, E. J., Sanchez, L. E., Sanchis-Gual, N., Sandberg, V., Sanders, J. R., Santiago, K. A., Sarin, N., Sassolas, B., Sathyaprakash, B. S., Sato, S., Sato, T., Sauter, O., Savage, R. L., Sawada, T., Schale, P., Scheel, M., Scheuer, J., Schmidt, P., Schnabel, R., Schofield, R. M. S., Schoenbeck, A., Schreiber, E., Schulte, B. W., Schutz, B. F., Schwalbe, S. G., Scott, J., Scott, S. M., Seidel, E., Sekiguchi, T., Sekiguchi, Y., Sellers, D., Sengupta, A. S., Sennett, N., Sentenac, D., Sequino, V., Sergeev, A., Setyawati, Y., Shaddock, D. A., Shaffer, T., Shahriar, M. S., Shaner, M. B., Shao, L., Sharma, P., Shawhan, P., Shen, H., Shibagaki, S., Shimizu, R., Shimoda, T., Shimode, K., Shink, R., Shinkai, H., Shishido, T., Shoda, A., Shoemaker, D. H., Shoemaker, D. M., ShyamSundar, S., Siellez, K., Sieniawska, M., Sigg, D., Silva, A. D., Singer, L. P., Singh, N., Singhal, A., Sintes, A. M., Sitmukhambetov, S., Skliris, V., Slagmolen, B. J. J., Slaven-Blair, T. J., Smith, J. R., Smith, R. J. E., Somala, S., Somiya, K., Son, E. J., Sorazu, B., Sorrentino, F., Sotani, H., Souradeep, T., Sowell, E., Spencer, A. P., Srivastava, A. K., Srivastava, V., Staats, K., Stachie, C., Standke, M., Steer, D. A., Steinke, M., Steinlechner, J., Steinlechner, S., Steinmeyer, D., Stevenson, S. P., Stocks, D., Stone, R., Stops, D. J., Strain, K. A., Stratta, G., Strigin, S. E., Strunk, A., Sturani, R., Stuver, A. L., Sudhir, V., Sugimoto, R., Summerscales, T. Z., Sun, L., Sunil, S., Suresh, J., Sutton, P. J., Suzuki, Takamasa, Suzuki, Toshikazu, Swinkels, B. L., Szczepanczyk, M. J., Tacca, M., Tagoshi, H., Tait, S. C., Takahashi, H., Takahashi, R., Takamori, A., Takano, S., Takeda, H., Takeda, M., Talbot, C., Talukder, D., Tanaka, H., Tanaka, Kazuyuki, Tanaka, Kenta, Tanaka, Taiki, Tanaka, Takahiro, Tanioka, S., Tanner, D. B., Tapai, M., Martin, E. N. Tapia San, Taracchini, A., Tasson, J. D., Taylor, R., Telada, S., Thies, F., Thomas, M., Thomas, P., Thondapu, S. R., Thorne, K. A., Thrane, E., Tiwari, Shubhanshu, Tiwari, Srishti, Tiwari, V., Toland, K., Tomaru, T., Tomigami, Y., Tomura, T., Tonelli, M., Tornasi, Z., Torres-Forne, A., Torrie, C. I., Toyra, D., Travasso, F., Traylor, G., Tringali, M. C., Trovato, A., Trozzo, L., Trudeau, R., Tsang, K. W., Tsang, T. T. L., Tse, M., Tso, R., Tsubono, K., Tsuchida, S., Tsukada, L., Tsuna, D., Tsuzuki, T., Tuyenbayev, D., Uchikata, N., Uchiyama, T., Ueda, A., Uehara, T., Ueno, K., Ueshima, G., Ugolini, D., Unnikrishnan, C. S., Uraguchi, F., Urban, A. L., Ushiba, T., Usman, S. A., Vahlbruch, H., Vajente, G., Valdes, G., Bakel, N. van, Beuzekom, M. van, Brand, J. F. J. van den, Broeck, C. Van Den, Vander-Hyde, D. C., Schaaf, L. van der, Heijningen, J. V. van, Putten, M. H. P. M. van, Veggel, A. A. van, Vardaro, M., Varma, V., Vass, S., Vasuth, M., Vecchio, A., Vedovato, G., Veitch, J., Veitch, P. J., Venkateswara, K., Venugopalan, G., Verkindt, D., Vetrano, F., Vicere, A., Viets, A. D., Vine, D. J., Vinet, J. -Y., Vitale, S., Vivanco, Francisco Hernandez, Vo, T., Vocca, H., Vorvick, C., Vyatchanin, S. P., Wade, A. R., Wade, L. E., Wade, M., Walet, R., Walker, M., Wallace, L., Walsh, S., Wang, G., Wang, H., Wang, J., Wang, J. Z., Wang, W. H., Wang, Y. F., Ward, R. L., Warden, Z. A., Warner, J., Was, M., Watchi, J., Weaver, B., Wei, L. -W., Weinert, M., Weinstein, A. J., Weiss, R., Wellmann, F., Wen, L., Wessel, E. K., Wessels, P., Westhouse, J. W., Wette, K., Whelan, J. T., Whiting, B. F., Whittle, C., Wilken, D. M., Williams, D., Williamson, A. R., Willis, J. L., Willke, B., Wimmer, M. H., Winkler, W., Wipf, C. C., Wittel, H., Woan, G., Woehler, J., Wofford, J. K., Worden, J., Wright, J. L., Wu, C. M., Wu, D. S., Wu, H. C., Wu, S. R., Wysocki, D. M., Xiao, L., Xu, W. R., Yamada, T., Yamamoto, H., Yamamoto, Kazuhiro, Yamamoto, Kohei, Yamamoto, T., Yancey, C. C., Yang, L., Yap, M. J., Yazback, M., Yeeles, D. W., Yokogawa, K., Yokoyama, J., Yokozawa, T., Yoshioka, T., Yu, Hang, Yu, Haocun, Yuen, S. H. R., Yuzurihara, H., Yvert, M., Zadrozny, A. K., Zanolin, M., Zeidler, S., Zelenova, T., Zendri, J. -P., Zevin, M., Zhang, J., Zhang, L., Zhang, T., Zhao, C., Zhao, Y., Zhou, M., Zhou, Z., Zhu, X. J., Zhu, Z. H., Zimmerman, A. B., Zucker, M. E., Zweizig, J., KAGRA Collaboration, [ missing ], LIGO Scientific Collaboration and Virgo Collaboration, [ missing ], The KAGRA Collaboration, The LIGO Scientific Collaboration, The Virgo Collaboration, IoP (FNWI), Faculty of Science, Gravitation and Astroparticle Physics Amsterdam, Other Research IHEF (IoP, FNWI), Astroparticle Physics (IHEF, IoP, FNWI), Van Swinderen Institute for Particle Physics and G, Lincoln Laboratory, Massachusetts Institute of Technology. Department of Mechanical Engineering, Massachusetts Institute of Technology. Department of Physics, LIGO (Observatory : Massachusetts Institute of Technology), MIT Kavli Institute for Astrophysics and Space Research, Aggarwal, Nancy, Barsotti, Lisa, Biscans, Sebastien, Brown, N. M., Buikema, Aaron, Donovan, Frederick J, Eisenstein, Robert Alan, Essick, Reed Clasey, Fernandez Galiana, Alvaro-Miguel, Fritschel, Peter K, Gras, Slawomir, Isogai, Tomoki, Katsavounidis, Erotokritos, Kontos, Antonios, Lanza Jr, Robert K, Libson, Adam A., Lynch, Ryan Christopher, MacInnis, Myron E, Martynov, Denis, Mason, Kenneth R, Matichard, Fabrice, Mavalvala, Nergis, Miller, J., Mittleman, Richard K, Ray Pitambar Mohapatra, Satyanarayan, Oelker, Eric Glenn, Shoemaker, David H, Tse, Maggie, Vitale, Salvatore, Weiss, Rainer, Yam, William, Yu, Hang, Yu, Haocun, Zucker, Michael E, Evans, Matthew J, Science and Technology Facilities Council (UK), Max Planck Society, Australian Research Council, Istituto Nazionale di Fisica Nucleare, Centre National de la Recherche Scientifique (France), Department of Science and Technology (India), Govern de les Illes Balears, Generalitat Valenciana, National Science Centre (Poland), Swiss National Science Foundation, Russian Foundation for Basic Research, European Commission, Royal Society (UK), Scottish Funding Council, Hungarian Scientific Research Fund, National Research, Development and Innovation Office (Hungary), National Research Foundation of Korea, Ministério da Ciência e Tecnologia (Brasil), National Natural Science Foundation of China, Leverhulme Trust, Ministry of Science and Technology (Taiwan), Kavli Institute for Particle Astrophysics and Cosmology, Ministry of Education, Culture, Sports, Science and Technology (Japan), Japan Society for the Promotion of Science, University of Tokyo, Academia Sinica (Taiwan), Abbott, Bp, Abbott, R, Abbott, Td, Abraham, S, Acernese, F, Ackley, K, Adams, C, Adya, Vb, Affeldt, C, Agathos, M, Agatsuma, K, Aggarwal, N, Aguiar, Od, Aiello, L, Ain, A, Ajith, P, Akutsu, T, Allen, G, Allocca, A, Aloy, Ma, Altin, Pa, Amato, A, Ananyeva, A, Anderson, Sb, Anderson, Wg, Ando, M, Angelova, Sv, Antier, S, Appert, S, Arai, K, Arai, Y, Araki, S, Araya, A, Araya, Mc, Areeda, J, Arene, M, Aritomi, N, Arnaud, N, Arun, Kg, Ascenzi, S, Ashton, G, Aso, Y, Aston, Sm, Astone, P, Aubin, F, Aufmuth, P, Aultoneal, K, Austin, C, Avendano, V, Avila-Alvarez, A, Babak, S, Bacon, P, Badaracco, F, Bader, Mkm, Bae, Sw, Bae, Yb, Baiotti, L, Bajpai, R, Baker, Pt, Baldaccini, F, Ballardin, G, Ballmer, Sw, Banagiri, S, Barayoga, Jc, Barclay, Se, Barish, Bc, Barker, D, Barkett, K, Barnum, S, Barone, F, Barr, B, Barsotti, L, Barsuglia, M, Barta, D, Bartlett, J, Barton, Ma, Bartos, I, Bassiri, R, Basti, A, Bawaj, M, Bayley, Jc, Bazzan, M, Becsy, B, Bejger, M, Belahcene, I, Bell, A, Beniwal, D, Berger, Bk, Bergmann, G, Bernuzzi, S, Bero, Jj, Berry, Cpl, Bersanetti, D, Bertolini, A, Betzwieser, J, Bhandare, R, Bidler, J, Bilenko, Ia, Bilgili, Sa, Billingsley, G, Birch, J, Birney, R, Birnholtz, O, Biscans, S, Biscoveanu, S, Bisht, A, Bitossi, M, Bizouard, Ma, Blackburn, Jk, Blair, Cd, Blair, Dg, Blair, Rm, Bloemen, S, Bode, N, Boer, M, Boetzel, Y, Bogaert, G, Bondu, F, Bonilla, E, Bonnand, R, Booker, P, Boom, Ba, Booth, Cd, Bork, R, Boschi, V, Bose, S, Bossie, K, Bossilkov, V, Bosveld, J, Bouffanais, Y, Bozzi, A, Bradaschia, C, Brady, Pr, Bramley, A, Branchesi, M, Brau, Je, Briant, T, Briggs, Jh, Brighenti, F, Brillet, A, Brinkmann, M, Brisson, V, Brockill, P, Brooks, Af, Brown, Da, Brown, Dd, Brunett, S, Buikema, A, Bulik, T, Bulten, Hj, Buonanno, A, Buskulic, D, Buy, C, Byer, Rl, Cabero, M, Cadonati, L, Cagnoli, G, Cahillane, C, Bustillo, Jc, Callister, Ta, Calloni, E, Camp, Jb, Campbell, Wa, Canepa, M, Cannon, K, Cannon, Kc, Cao, H, Cao, J, Capocasa, E, Carbognani, F, Caride, S, Carney, Mf, Carullo, G, Diaz, Jc, Casentini, C, Caudill, S, Cavaglia, M, Cavalier, F, Cavalieri, R, Cella, G, Cerda-Duran, P, Cerretani, G, Cesarini, E, Chaibi, O, Chakravarti, K, Chamberlin, Sj, Chan, M, Chan, Ml, Chao, S, Charlton, P, Chase, Ea, Chassande-Mottin, E, Chatterjee, D, Chaturvedi, M, Chatziioannou, K, Cheeseboro, Bd, Chen, C, Chen, Hy, Chen, Kh, Chen, X, Chen, Y, Chen, Yr, Cheng, Hp, Cheong, Ck, Chia, Hy, Chincarini, A, Chiummo, A, Cho, G, Cho, H, Cho, M, Christensen, N, Chu, Hy, Chu, Q, Chu, Yk, Chua, S, Chung, Kw, Chung, S, Ciani, G, Ciobanu, Aa, Ciolfi, R, Cipriano, F, Cirone, A, Clara, F, Clark, Ja, Clearwater, P, Cleva, F, Cocchieri, C, Coccia, E, Cohadon, Pf, Cohen, D, Colgan, R, Colleoni, M, Collette, Cg, Collins, C, Cominsky, Lr, Constancio, M, Conti, L, Cooper, Sj, Corban, P, Corbitt, Tr, Cordero-Carrion, I, Corley, Kr, Cornish, N, Corsi, A, Cortese, S, Costa, Ca, Cotesta, R, Coughlin, Mw, Coughlin, Sb, Coulon, Jp, Countryman, St, Couvares, P, Covas, Pb, Cowan, Ee, Coward, Dm, Cowart, Mj, Coyne, Dc, Coyne, R, Creighton, Jde, Creighton, Td, Cripe, J, Croquette, M, Crowder, Sg, Cullen, Tj, Cumming, A, Cunningham, L, Cuoco, E, Canton, Td, Dalya, G, Danilishin, Sl, D'Antonio, S, Danzmann, K, Dasgupta, A, Costa, Cfd, Datrier, Leh, Dattilo, V, Dave, I, Davier, M, Davis, D, Daw, Ej, Debra, D, Deenadayalan, M, Degallaix, J, De Laurentis, M, Deleglise, S, Pozzo, Wd, Demarchi, Lm, Demos, N, Dent, T, De Pietri, R, Derby, J, De Rosa, R, De Rossi, C, Desalvo, R, de Varona, O, Dhurandhar, S, Diaz, Mc, Dietrich, T, Fiore, Ld, Giovanni, Md, Girolamo, Td, Lieto, Ad, Ding, B, Pace, Sd, Di Palma, I, Di Renzo, F, Dmitriev, A, Doctor, Z, Doi, K, Donovan, F, Dooley, Kl, Doravari, S, Dorrington, I, Downes, Tp, Drago, M, Driggers, Jc, Du, Z, Ducoin, Jg, Dupej, P, Dwyer, Se, Easter, Pj, Edo, Tb, Edwards, Mc, Effler, A, Eguchi, S, Ehrens, P, Eichholz, J, Eikenberry, S, Eisenmann, M, Eisenstein, Ra, Enomoto, Y, Essick, Rc, Estelles, H, Estevez, D, Etienne, Zb, Etzel, T, Evans, M, Evans, Tm, Fafone, V, Fair, H, Fairhurst, S, Fan, X, Farinon, S, Farr, B, Farr, Wm, Fauchon-Jones, Ej, Favata, M, Fays, M, Fazio, M, Fee, C, Feicht, J, Fejer, Mm, Feng, F, Fernandez-Galiana, A, Ferrante, I, Ferreira, Ec, Ferreira, Ta, Ferrini, F, Fidecaro, F, Fiori, I, Fiorucci, D, Fishbach, M, Fisher, Rp, Fishner, Jm, Fitz-Axen, M, Flaminio, R, Fletcher, M, Flynn, E, Fong, H, Font, Ja, Forsyth, Pwf, Fournier, Jd, Frasca, S, Frasconi, F, Frei, Z, Freise, A, Frey, R, Frey, V, Fritschel, P, Frolov, Vv, Fujii, Y, Fukunaga, M, Fukushima, M, Fulda, P, Fyffe, M, Gabbard, Ha, Gadre, Bu, Gaebel, Sm, Gair, Jr, Gammaitoni, L, Ganija, Mr, Gaonkar, Sg, Garcia, A, Garcia-Quiros, C, Garufi, F, Gateley, B, Gaudio, S, Gaur, G, Gayathri, V, Ge, Gg, Gemme, G, Genin, E, Gennai, A, George, D, George, J, Gergely, L, Germain, V, Ghonge, S, Ghosh, A, Ghosh, S, Giacomazzo, B, Giaime, Ja, Giardina, Kd, Giazotto, A, Gill, K, Giordano, G, Glover, L, Godwin, P, Goetz, E, Goetz, R, Goncharov, B, Gonzaalez, G, Castro, Jmg, Gopakumar, A, Gorodetsky, Ml, Gossan, Se, Gosselin, M, Gouaty, R, Grado, A, Graef, C, Granata, M, Grant, A, Gras, S, Grassia, P, Gray, C, Gray, R, Greco, G, Green, Ac, Green, R, Gretarsson, Em, Groot, P, Grote, H, Grunewald, S, Gruning, P, Guidi, Gm, Gulati, Hk, Guo, Y, Gupta, A, Gupta, Mk, Gustafson, Ek, Gustafson, R, Haegel, L, Hagiwara, A, Haino, S, Halim, O, Hall, Br, Hall, Ed, Hamilton, Ez, Hammond, G, Haney, M, Hanke, Mm, Hanks, J, Hanna, C, Hannam, Md, Hannuksela, Oa, Hanson, J, Hardwick, T, Haris, K, Harms, J, Harry, Gm, Harry, Iw, Hasegawa, K, Haster, Cj, Haughian, K, Hayakawa, H, Hayama, K, Hayes, Fj, Healy, J, Heidmann, A, Heintze, Mc, Heitmann, H, Hello, P, Hemming, G, Hendry, M, Heng, I, Hennig, J, Heptonstall, Aw, Heurs, M, Hild, S, Himemoto, Y, Hinderer, T, Hiranuma, Y, Hirata, N, Hirose, E, Hoak, D, Hochheim, S, Hofman, D, Holgado, Am, Holland, Na, Holt, K, Holz, De, Hong, Z, Hopkins, P, Horst, C, Hough, J, Howell, Ej, Hoy, Cg, Hreibi, A, Hsieh, Bh, Huang, Gz, Huang, Pw, Huang, Yj, Huerta, Ea, Huet, D, Hughey, B, Hulko, M, Husa, S, Huttner, Sh, Huynh-Dinh, T, Idzkowski, B, Iess, A, Ikenoue, B, Imam, S, Inayoshi, K, Ingram, C, Inoue, Y, Inta, R, Intini, G, Ioka, K, Irwin, B, Isa, Hn, Isac, Jm, Isi, M, Itoh, Y, Iyer, Br, Izumi, K, Jacqmin, T, Jadhav, Sj, Jani, K, Janthalur, Nn, Jaranowski, P, Jenkins, Ac, Jiang, J, Johnson, D, Jones, Aw, Jones, Di, Jones, R, Jonker, Rjg, Ju, L, Jung, K, Jung, P, Junker, J, Kajita, T, Kalaghatgi, Cv, Kalogera, V, Kamai, B, Kamiizumi, M, Kanda, N, Kandhasamy, S, Kang, Gw, Kanner, Jb, Kapadia, Sj, Karki, S, Karvinen, K, Kashyap, R, Kasprzack, M, Katsanevas, S, Katsavounidis, E, Katzman, W, Kaufer, S, Kawabe, K, Kawaguchi, K, Kawai, N, Kawasaki, T, Keerthana, Nv, Kefelian, F, Keitel, D, Kennedy, R, Key, J, Khalili, Fy, Khan, H, Khan, I, Khan, S, Khan, Z, Khazanov, Ea, Khursheed, M, Kijbunchoo, N, Kim, C, Kim, Jc, Kim, J, Kim, K, Kim, W, Kim, Ym, Kimball, C, Kimura, N, King, Ej, King, Pj, Kinley-Hanlon, M, Kirchhoff, R, Kissel, J, Kita, N, Kitazawa, H, Kleybolte, L, Klika, Jh, Klimenko, S, Knowles, Td, Knyazev, E, Koch, P, Koehlenbeck, Sm, Koekoek, G, Kojima, Y, Kokeyama, K, Koley, S, Komori, K, Kondrashov, V, Kong, Akh, Kontos, A, Koper, N, Korobko, M, Korth, Wz, Kotake, K, Kowalska, I, Kozak, Db, Kozakai, C, Kozu, R, Kringel, V, Krishnendu, N, Krolak, A, Kuehn, G, Kumar, A, Kumar, P, Kumar, R, Kumar, S, Kume, J, Kuo, Cm, Kuo, H, Kuo, L, Kuroyanagi, S, Kusayanagi, K, Kutynia, A, Kwak, K, Kwang, S, Lackey, Bd, Lai, Kh, Lam, Tl, Landry, M, Lane, Bb, Lang, Rn, Lange, J, Lantz, B, Lanza, Rk, Lartaux-Vollard, A, Lasky, Pd, Laxen, M, Lazzarini, A, Lazzaro, C, Leaci, P, Leavey, S, Lecoeuche, Yk, Lee, Ch, Lee, Hk, Lee, Hm, Lee, Hw, Lee, J, Lee, K, Lee, Rk, Lehmann, J, Lenon, A, Leonardi, M, Leroy, N, Letendre, N, Levin, Y, Li, J, Li, Kjl, Li, Tgf, Li, X, Lin, Cy, Lin, F, Lin, Fl, Lin, Lcc, Linde, F, Linker, Sd, Littenberg, Tb, Liu, Gc, Liu, J, Liu, X, Lo, Rkl, Lockerbie, Na, London, Lt, Longo, A, Lorenzini, M, Loriette, V, Lormand, M, Losurdo, G, Lough, Jd, Lousto, Co, Lovelace, G, Lower, Me, Luuck, H, Lumaca, D, Lundgren, Ap, Luo, Lw, Lynch, R, Ma, Y, Macas, R, Macfoy, S, Macinnis, M, Macleod, Dm, Macquet, A, Magana-Sandoval, F, Zertuche, Lm, Magee, Rm, Majorana, E, Maksimovic, I, Malik, A, Man, N, Mandic, V, Mangano, V, Mansell, Gl, Manske, M, Mantovani, M, Marchesoni, F, Marchio, M, Marion, F, Marka, S, Marka, Z, Markakis, C, Markosyan, A, Markowitz, A, Maros, E, Marquina, A, Marsat, S, Martelli, F, Martin, Iw, Martin, Rm, Martynov, Dv, Mason, K, Massera, E, Masserot, A, Massinger, Tj, Masso-Reid, M, Mastrogiovanni, S, Matas, A, Matichard, F, Matone, L, Mavalvala, N, Mazumder, N, Mccann, Jj, Mccarthy, R, Mcclelland, De, Mccormick, S, Mcculler, L, Mcguire, Sc, Mciver, J, Mcmanus, Dj, Mcrae, T, Mcwilliams, St, Meacher, D, Meadors, Gd, Mehmet, M, Mehta, Ak, Meidam, J, Melatos, A, Mendell, G, Mercer, Ra, Mereni, L, Merilh, El, Merzougui, M, Meshkov, S, Messenger, C, Messick, C, Metzdorff, R, Meyers, Pm, Miao, H, Michel, C, Michimura, Y, Middleton, H, Mikhailov, Ee, Milano, L, Miller, Al, Miller, A, Millhouse, M, Mills, Jc, Milovich-Goff, Mc, Minazzoli, O, Minenkov, Y, Mio, N, Mishkin, A, Mishra, C, Mistry, T, Mitra, S, Mitrofanov, Vp, Mitselmakher, G, Mittleman, R, Miyakawa, O, Miyamoto, A, Miyazaki, Y, Miyo, K, Miyoki, S, Mo, G, Moffa, D, Mogushi, K, Mohapatra, Srp, Montani, M, Moore, Cj, Moraru, D, Moreno, G, Morisaki, S, Moriwaki, Y, Mours, B, Mow-Lowry, Cm, Mukherjee, A, Mukherjee, D, Mukherjee, S, Mukund, N, Mullavey, A, Munch, J, Muniz, Ea, Muratore, M, Murray, Pg, Nagano, K, Nagano, S, Nagar, A, Nakamura, K, Nakano, H, Nakano, M, Nakashima, R, Nardecchia, I, Narikawa, T, Naticchioni, L, Nayak, Rk, Negishi, R, Neilson, J, Nelemans, G, Nelson, Tjn, Nery, M, Neunzert, A, Ng, Ky, Ng, S, Nguyen, P, Ni, Wt, Nichols, D, Nishizawa, A, Nissanke, S, Nocera, F, North, C, Nuttall, Lk, Obergaulinger, M, Oberling, J, O'Brien, Bd, Obuchi, Y, O'Dea, Gd, Ogaki, W, Ogin, Gh, Oh, Jj, Oh, Sh, Ohashi, M, Ohishi, N, Ohkawa, M, Ohme, F, Ohta, H, Okada, Ma, Okutomi, K, Oliver, M, Oohara, K, Ooi, Cp, Oppermann, P, Oram, Rj, O'Reilly, B, Ormiston, Rg, Ortega, Lf, O'Shaughnessy, R, Oshino, S, Ossokine, S, Ottaway, Dj, Overmier, H, Owen, Bj, Pace, Ae, Pagano, G, Page, Ma, Pai, A, Pai, Sa, Palamos, Jr, Palashov, O, Palomba, C, Pal-Singh, A, Pan, Hw, Pan, Kc, Pang, B, Pang, Hf, Pang, Pth, Pankow, C, Pannarale, F, Pant, Bc, Paoletti, F, Paoli, A, Papa, Ma, Parida, A, Park, J, Parker, W, Pascucci, D, Pasqualetti, A, Passaquieti, R, Passuello, D, Patil, M, Patricelli, B, Pearlstone, Bl, Pedersen, C, Pedraza, M, Pedurand, R, Pele, A, Arellano, Fep, Penn, S, Perez, Cj, Perreca, A, Pfeiffer, Hp, Phelps, M, Phukon, K, Piccinni, Oj, Pichot, M, Piergiovanni, F, Pillant, G, Pinard, L, Pinto, I, Pirello, M, Pitkin, M, Poggiani, R, Pong, Dyt, Ponrathnam, S, Popolizio, P, Porter, Ek, Powell, J, Prajapati, Ak, Prasad, J, Prasai, K, Prasanna, R, Pratten, G, Prestegard, T, Privitera, S, Prodi, Ga, Prokhorov, Lg, Puncken, O, Punturo, M, Puppo, P, Purer, M, Qi, H, Quetschke, V, Quinonez, Pj, Quintero, Ea, Quitzow-James, R, Raab, Fj, Radkins, H, Radulescu, N, Raffai, P, Raja, S, Rajan, C, Rajbhandari, B, Rakhmanov, M, Ramirez, Ke, Ramos-Buades, A, Rana, J, Rao, K, Rapagnani, P, Raymond, V, Razzano, M, Read, J, Regimbau, T, Rei, L, Reid, S, Reitze, Dh, Ren, W, Ricci, F, Richardson, Cj, Richardson, Jw, Ricker, Pm, Riles, K, Rizzo, M, Robertson, Na, Robie, R, Robinet, F, Rocchi, A, Rolland, L, Rollins, Jg, Roma, Vj, Romanelli, M, Romano, R, Romel, Cl, Romie, Jh, Rose, K, Rosinska, D, Rosofsky, Sg, Ross, Mp, Rowan, S, Ruiger, A, Ruggi, P, Rutins, G, Ryan, K, Sachdev, S, Sadecki, T, Sago, N, Saito, S, Saito, Y, Sakai, K, Sakai, Y, Sakamoto, H, Sakellariadou, M, Sakuno, Y, Salconi, L, Saleem, M, Samajdar, A, Sammut, L, Sanchez, Ej, Sanchez, Le, Sanchis-Gual, N, Sandberg, V, Sanders, Jr, Santiago, Ka, Sarin, N, Sassolas, B, Sathyaprakash, B, Sato, S, Sato, T, Sauter, O, Savage, Rl, Sawada, T, Schale, P, Scheel, M, Scheuer, J, Schmidt, P, Schnabel, R, Schofield, Rm, Schonbeck, A, Schreiber, E, Schulte, Bw, Schutz, Bf, Schwalbe, Sg, Scott, J, Scott, Sm, Seidel, E, Sekiguchi, T, Sekiguchi, Y, Sellers, D, Sengupta, A, Sennett, N, Sentenac, D, Sequino, V, Sergeev, A, Setyawati, Y, Shaddock, Da, Shaffer, T, Shahriar, M, Shaner, Mb, Shao, L, Sharma, P, Shawhan, P, Shen, H, Shibagaki, S, Shimizu, R, Shimoda, T, Shimode, K, Shink, R, Shinkai, H, Shishido, T, Shoda, A, Shoemaker, Dh, Shoemaker, Dm, Shyamsundar, S, Siellez, K, Sieniawska, M, Sigg, D, Silva, Ad, Singer, Lp, Singh, N, Singhal, A, Sintes, Am, Sitmukhambetov, S, Skliris, V, Slagmolen, Bjj, Slaven-Blair, Tj, Smith, Jr, Smith, Rje, Somala, S, Somiya, K, Son, Ej, Sorazu, B, Sorrentino, F, Sotani, H, Souradeep, T, Sowell, E, Spencer, Ap, Srivastava, Ak, Srivastava, V, Staats, K, Stachie, C, Standke, M, Steer, Da, Steinke, M, Steinlechner, J, Steinlechner, S, Steinmeyer, D, Stevenson, Sp, Stocks, D, Stone, R, Stops, Dj, Strain, Ka, Stratta, G, Strigin, Se, Strunk, A, Sturani, R, Stuver, Al, Sudhir, V, Sugimoto, R, Summerscales, Tz, Sun, L, Sunil, S, Suresh, J, Sutton, Pj, Suzuki, T, Swinkels, Bl, Szczepanczyk, Mj, Tacca, M, Tagoshi, H, Tait, Sc, Takahashi, H, Takahashi, R, Takamori, A, Takano, S, Takeda, H, Takeda, M, Talbot, C, Talukder, D, Tanaka, H, Tanaka, K, Tanaka, T, Tanioka, S, Tanner, Db, Tapai, M, San Martin, Ent, Taracchini, A, Tasson, Jd, Taylor, R, Telada, S, Thies, F, Thomas, M, Thomas, P, Thondapu, Sr, Thorne, Ka, Thrane, E, Tiwari, S, Tiwari, V, Toland, K, Tomaru, T, Tomigami, Y, Tomura, T, Tonelli, M, Tornasi, Z, Torres-Forne, A, Torrie, Ci, Toyra, D, Travasso, F, Traylor, G, Tringali, Mc, Trovato, A, Trozzo, L, Trudeau, R, Tsang, Kw, Tsang, Ttl, Tse, M, Tso, R, Tsubono, K, Tsuchida, S, Tsukada, L, Tsuna, D, Tsuzuki, T, Tuyenbayev, D, Uchikata, N, Uchiyama, T, Ueda, A, Uehara, T, Ueno, K, Ueshima, G, Ugolini, D, Unnikrishnan, C, Uraguchi, F, Urban, Al, Ushiba, T, Usman, Sa, Vahlbruch, H, Vajente, G, Valdes, G, van Bakel, N, van Beuzekom, M, van den Brand, Jfj, Van Den Broeck, C, Vander-Hyde, Dc, van den Schaaf, L, van Heijningen, Jv, van Putten, Mhpm, van Veggel, Aa, Vardaro, M, Varma, V, Vass, S, Vasuth, M, Vecchio, A, Vedovato, G, Veitch, J, Veitch, Pj, Venkateswara, K, Venugopalan, G, Verkindt, D, Vetrano, F, Vicere, A, Viets, Ad, Vine, Dj, Vinet, Jy, Vitale, S, Vivanco, Fh, Vo, T, Vocca, H, Vorvick, C, Vyatchanin, Sp, Wade, Ar, Wade, Le, Wade, M, Walet, R, Walker, M, Wallace, L, Walsh, S, Wang, G, Wang, H, Wang, J, Wang, Jz, Wang, Wh, Wang, Yf, Ward, Rl, Warden, Za, Warner, J, Was, M, Watchi, J, Weaver, B, Wei, Lw, Weinert, M, Weinstein, Aj, Weiss, R, Wellmann, F, Wen, L, Wessel, Ek, Wessels, P, Westhouse, Jw, Wette, K, Whelan, Jt, Whiting, Bf, Whittle, C, Wilken, Dm, Williams, D, Williamson, Ar, Willis, Jl, Willke, B, Wimmer, Mh, Winkler, W, Wipf, Cc, Wittel, H, Woan, G, Woehler, J, Wofford, Jk, Worden, J, Wright, Jl, Wu, Cm, Wu, D, Wu, Hc, Wu, Sr, Wysocki, Dm, Xiao, L, Xu, Wr, Yamada, T, Yamamoto, H, Yamamoto, K, Yamamoto, T, Yancey, Cc, Yang, L, Yap, Mj, Yazback, M, Yeeles, Dw, Yokogawa, K, Yokoyama, J, Yokozawa, T, Yoshioka, T, Yu, H, Yu, Hc, Yuen, Shr, Yuzurihara, H, Yvert, M, Zadrozny, Ak, Zanolin, M, Zeidler, S, Zelenova, T, Zendri, Jp, Zevin, M, Zhang, J, Zhang, L, Zhang, T, Zhao, C, Zhao, Y, Zhou, M, Zhou, Z, Zhu, Xj, Zhu, Zh, Zimmerman, Ab, Zucker, Me, Zweizig, J, Apollo - University of Cambridge Repository, Laboratoire des matériaux avancés (LMA), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Laboratoire de l'Accélérateur Linéaire (LAL), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), AstroParticule et Cosmologie (APC (UMR_7164)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Astrophysique Relativiste Théories Expériences Métrologie Instrumentation Signaux (ARTEMIS), Centre National de la Recherche Scientifique (CNRS)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Institut des Fonctions Optiques pour les Technologies de l'informatiON (Institut FOTON), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-École Nationale Supérieure des Sciences Appliquées et de Technologie (ENSSAT)-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Laboratoire Kastler Brossel (LKB [Collège de France]), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Fédération de recherche du Département de physique de l'Ecole Normale Supérieure - ENS Paris (FRDPENS), Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Collège de France (CdF (institution)), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL), Institut des Hautes Etudes Scientifiques (IHES), IHES, KAGRA, LIGO Scientific, Virgo, Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-École Nationale Supérieure des Sciences Appliquées et de Technologie (ENSSAT)-Centre National de la Recherche Scientifique (CNRS), Fédération de recherche du Département de physique de l'Ecole Normale Supérieure - ENS Paris (FRDPENS), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Collège de France (CdF (institution))-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut des Hautes Études Scientifiques (IHES), Abbott, B, Abbott, T, Adya, V, Aguiar, O, Aloy, M, Altin, P, Anderson, S, Anderson, W, Angelova, S, Araya, M, Arun, K, Aston, S, Bader, M, Bae, S, Bae, Y, Baker, P, Ballmer, S, Barayoga, J, Barclay, S, Barish, B, Barton, M, Bayley, J, Berger, B, Bero, J, Berry, C, Bilenko, I, Bilgili, S, Bizouard, M, Blackburn, J, Blair, C, Blair, D, Blair, R, Boom, B, Booth, C, Brady, P, Brau, J, Briggs, J, Brooks, A, Brown, D, Bulten, H, Byer, R, Bustillo, J, Callister, T, Camp, J, Campbell, W, Carney, M, Diaz, J, Chamberlin, S, Chase, E, Cheeseboro, B, Chen, H, Chen, K, Cheng, H, Cheong, C, Chia, H, Chu, H, Chu, Y, Chung, K, Ciobanu, A, Clark, J, Cohadon, P, Collette, C, Cominsky, L, Cooper, S, Corbitt, T, Corley, K, Costa, C, Coughlin, M, Coughlin, S, Coulon, J, Countryman, S, Covas, P, Cowan, E, Coward, D, Cowart, M, Coyne, D, Creighton, J, Creighton, T, Crowder, S, Cullen, T, Canton, T, Danilishin, S, Da Silva Costa, C, Datrier, L, Daw, E, Pozzo, W, Demarchi, L, Diaz, M, Fiore, L, Giovanni, M, Girolamo, T, Lieto, A, Pace, S, Palma, I, Renzo, F, Dooley, K, Downes, T, Driggers, J, Ducoin, J, Dwyer, S, Easter, P, Edo, T, Edwards, M, Eisenstein, R, Essick, R, Etienne, Z, Evans, T, Farr, W, Fauchon-Jones, E, Fejer, M, Ferreira, E, Ferreira, T, Fisher, R, Fishner, J, Font, J, Forsyth, P, Fournier, J, Frolov, V, Gabbard, H, Gadre, B, Gaebel, S, Gair, J, Ganija, M, Gaonkar, S, Ge, G, Giaime, J, Giardina, K, Gonzalez, G, Castro, J, Gorodetsky, M, Gossan, S, Green, A, Gretarsson, E, Guidi, G, Gulati, H, Gupta, M, Gustafson, E, Hall, B, Hall, E, Hamilton, E, Hanke, M, Hannam, M, Hannuksela, O, Harry, G, Harry, I, Haster, C, Hayes, F, Heintze, M, Heptonstall, A, Holgado, A, Holland, N, Holz, D, Howell, E, Hoy, C, Hsieh, B, Huang, G, Huang, P, Huang, Y, Huerta, E, Huttner, S, Isa, H, Isac, J, Iyer, B, Jadhav, S, Janthalur, N, Jenkins, A, Jones, A, Jones, D, Jonker, R, Kalaghatgi, C, Kang, G, Kanner, J, Kapadia, S, Keerthana, N, Khalili, F, Khazanov, E, Kim, Y, King, E, King, P, Klika, J, Knowles, T, Koehlenbeck, S, Kong, A, Korth, W, Kozak, D, Kuo, C, Lackey, B, Lai, K, Lam, T, Lane, B, Lang, R, Lanza, R, Lasky, P, Lecoeuche, Y, Lee, C, Lee, H, Lee, R, Li, K, Li, T, Lin, C, Lin, L, Linker, S, Littenberg, T, Liu, G, Lo, R, Lockerbie, N, London, L, Lough, J, Lousto, C, Lower, M, Luck, H, Lundgren, A, Luo, L, Macleod, D, Zertuche, L, Magee, R, Mansell, G, Martin, I, Martin, R, Martynov, D, Massinger, T, Mccann, J, Mcclelland, D, Mcguire, S, Mcmanus, D, Mcwilliams, S, Meadors, G, Mehta, A, Mercer, R, Merilh, E, Meyers, P, Mikhailov, E, Mills, J, Milovich-Goff, M, Mitrofanov, V, Mohapatra, S, Moore, C, Mow-Lowry, C, Muniz, E, Murray, P, Nayak, R, Nelson, T, Ng, K, Ni, W, Nuttall, L, O'Brien, B, O'Dea, G, Ogin, G, Oh, J, Oh, S, Okada, M, Ooi, C, Oram, R, Ormiston, R, Ortega, L, Ottaway, D, Owen, B, Pace, A, Page, M, Pai, S, Palamos, J, Pan, H, Pan, K, Pang, H, Pang, P, Pant, B, Papa, M, Pearlstone, B, Arellano, F, Perez, C, Pfeiffer, H, Piccinni, O, Pong, D, Porter, E, Prajapati, A, Prodi, G, Prokhorov, L, Purrer, M, Quinonez, P, Quintero, E, Raab, F, Ramirez, K, Reitze, D, Richardson, C, Richardson, J, Ricker, P, Robertson, N, Rollins, J, Roma, V, Romel, C, Romie, J, Rosofsky, S, Ross, M, Rudiger, A, Sanchez, E, Sanchez, L, Sanders, J, Santiago, K, Savage, R, Schofield, R, Schulte, B, Schutz, B, Schwalbe, S, Scott, S, Shaddock, D, Shaner, M, Shoemaker, D, Silva, A, Singer, L, Sintes, A, Slagmolen, B, Slaven-Blair, T, Smith, J, Smith, R, Son, E, Spencer, A, Srivastava, A, Steer, D, Stevenson, S, Stops, D, Strain, K, Strigin, S, Stuver, A, Summerscales, T, Sutton, P, Swinkels, B, Szczepanczyk, M, Tait, S, Tanner, D, Martin, E, Tasson, J, Thondapu, S, Thorne, K, Torrie, C, Tringali, M, Tsang, K, Tsang, T, Urban, A, Usman, S, Bakel, N, Beuzekom, M, Brand, J, Broeck, C, Vander-Hyde, D, Schaaf, L, Heijningen, J, Putten, M, Veggel, A, Veitch, P, Viets, A, Vine, D, Vinet, J, Vivanco, F, Vyatchanin, S, Wade, A, Wade, L, Wang, W, Wang, Y, Ward, R, Warden, Z, Wei, L, Weinstein, A, Wessel, E, Westhouse, J, Whelan, J, Whiting, B, Wilken, D, Williamson, A, Willis, J, Wimmer, M, Wipf, C, Wofford, J, Wright, J, Wu, C, Wu, H, Wu, S, Wysocki, D, Xu, W, Yancey, C, Yap, M, Yeeles, D, Yuen, S, Zadrozny, A, Zendri, J, Zhu, X, Zhu, Z, Zimmerman, A, Zucker, M, Abbott, B. P., Abbott, R., Abbott, T. D., Abraham, S., Acernese, F., Ackley, K., Adams, C., Adya, V. B., Affeldt, C., Agathos, M., Agatsuma, K., Aggarwal, N., Aguiar, O. D., Aiello, L., Ain, A., Ajith, P., Akutsu, T., Allen, G., Allocca, A., Aloy, M. A., Altin, P. A., Amato, A., Ananyeva, A., Anderson, S. B., Anderson, W. G., Ando, M., Angelova, S. V., Antier, S., Appert, S., Arai, K., Arai, Y., Araki, S., Araya, A., Araya, M. C., Areeda, J. S., Arene, M., Aritomi, N., Arnaud, N., Arun, K. G., Ascenzi, S., Ashton, G., Aso, Y., Aston, S. M., Astone, P., Aubin, F., Aufmuth, P., Aultoneal, K., Austin, C., Avendano, V., Avila-Alvarez, A., Babak, S., Bacon, P., Badaracco, F., Bader, M. K. M., Bae, S. W., Bae, Y. B., Baiotti, L., Bajpai, R., Baker, P. T., Baldaccini, F., Ballardin, G., Ballmer, S. W., Banagiri, S., Barayoga, J. C., Barclay, S. E., Barish, B. C., Barker, D., Barkett, K., Barnum, S., Barone, F., Barr, B., Barsotti, L., Barsuglia, M., Barta, D., Bartlett, J., Barton, M. A., Bartos, I., Bassiri, R., Basti, A., Bawaj, M., Bayley, J. C., Bazzan, M., Becsy, B., Bejger, M., Belahcene, I., Bell, A. S., Beniwal, D., Berger, B. K., Bergmann, G., Bernuzzi, S., Bero, J. J., Berry, C. P. L., Bersanetti, D., Bertolini, A., Betzwieser, J., Bhandare, R., Bidler, J., Bilenko, I. A., Bilgili, S. A., Billingsley, G., Birch, J., Birney, R., Birnholtz, O., Biscans, S., Biscoveanu, S., Bisht, A., Bitossi, M., Bizouard, M. A., Blackburn, J. K., Blair, C. D., Blair, D. G., Blair, R. M., Bloemen, S., Bode, N., Boer, M., Boetzel, Y., Bogaert, G., Bondu, F., Bonilla, E., Bonnand, R., Booker, P., Boom, B. A., Booth, C. D., Bork, R., Boschi, V., Bose, S., Bossie, K., Bossilkov, V., Bosveld, J., Bouffanais, Y., Bozzi, A., Bradaschia, C., Brady, P. R., Bramley, A., Branchesi, M., Brau, J. E., Briant, T., Briggs, J. H., Brighenti, F., Brillet, A., Brinkmann, M., Brisson, V., Brockill, P., Brooks, A. F., Brown, D. A., Brown, D. D., Brunett, S., Buikema, A., Bulik, T., Bulten, H. J., Buonanno, A., Buskulic, D., Buy, C., Byer, R. L., Cabero, M., Cadonati, L., Cagnoli, G., Cahillane, C., Bustillo, J. C., Callister, T. A., Calloni, E., Camp, J. B., Campbell, W. A., Canepa, M., Cannon, K., Cannon, K. C., Cao, H., Cao, J., Capocasa, E., Carbognani, F., Caride, S., Carney, M. F., Carullo, G., Diaz, J. C., Casentini, C., Caudill, S., Cavaglia, M., Cavalier, F., Cavalieri, R., Cella, G., Cerda-Duran, P., Cerretani, G., Cesarini, E., Chaibi, O., Chakravarti, K., Chamberlin, S. J., Chan, M., Chan, M. L., Chao, S., Charlton, P., Chase, E. A., Chassande-Mottin, E., Chatterjee, D., Chaturvedi, M., Chatziioannou, K., Cheeseboro, B. D., Chen, C. S., Chen, H. Y., Chen, K. H., Chen, X., Chen, Y., Chen, Y. R., Cheng, H. -P., Cheong, C. K., Chia, H. Y., Chincarini, A., Chiummo, A., Cho, G., Cho, H. S., Cho, M., Christensen, N., Chu, H. Y., Chu, Q., Chu, Y. K., Chua, S., Chung, K. W., Chung, S., Ciani, G., Ciobanu, A. A., Ciolfi, R., Cipriano, F., Cirone, A., Clara, F., Clark, J. A., Clearwater, P., Cleva, F., Cocchieri, C., Coccia, E., Cohadon, P. -F., Cohen, D., Colgan, R., Colleoni, M., Collette, C. G., Collins, C., Cominsky, L. R., Constancio, M., Conti, L., Cooper, S. J., Corban, P., Corbitt, T. R., Cordero-Carrion, I., Corley, K. R., Cornish, N., Corsi, A., Cortese, S., Costa, C. A., Cotesta, R., Coughlin, M. W., Coughlin, S. B., Coulon, J. -P., Countryman, S. T., Couvares, P., Covas, P. B., Cowan, E. E., Coward, D. M., Cowart, M. J., Coyne, D. C., Coyne, R., Creighton, J. D. E., Creighton, T. D., Cripe, J., Croquette, M., Crowder, S. G., Cullen, T. J., Cumming, A., Cunningham, L., Cuoco, E., Canton, T. D., Dalya, G., Danilishin, S. L., D'Antonio, S., Danzmann, K., Dasgupta, A., Da Silva Costa, C. F., Datrier, L. E. H., Dattilo, V., Dave, I., Davier, M., Davis, D., Daw, E. J., Debra, D., Deenadayalan, M., Degallaix, J., De Laurentis, M., Deleglise, S., Pozzo, W. D., Demarchi, L. M., Demos, N., Dent, T., De Pietri, R., Derby, J., De Rosa, R., De Rossi, C., Desalvo, R., de Varona, O., Dhurandhar, S., Diaz, M. C., Dietrich, T., Fiore, L. D., Giovanni, M. D., Girolamo, T. D., Lieto, A. D., Ding, B., Pace, S. D., Palma, I. D., Renzo, F. D., Dmitriev, A., Doctor, Z., Doi, K., Donovan, F., Dooley, K. L., Doravari, S., Dorrington, I., Downes, T. P., Drago, M., Driggers, J. C., Du, Z., Ducoin, J. -G., Dupej, P., Dwyer, S. E., Easter, P. J., Edo, T. B., Edwards, M. C., Effler, A., Eguchi, S., Ehrens, P., Eichholz, J., Eikenberry, S. S., Eisenmann, M., Eisenstein, R. A., Enomoto, Y., Essick, R. C., Estelles, H., Estevez, D., Etienne, Z. B., Etzel, T., Evans, M., Evans, T. M., Fafone, V., Fair, H., Fairhurst, S., Fan, X., Farinon, S., Farr, B., Farr, W. M., Fauchon-Jones, E. J., Favata, M., Fays, M., Fazio, M., Fee, C., Feicht, J., Fejer, M. M., Feng, F., Fernandez-Galiana, A., Ferrante, I., Ferreira, E. C., Ferreira, T. A., Ferrini, F., Fidecaro, F., Fiori, I., Fiorucci, D., Fishbach, M., Fisher, R. P., Fishner, J. M., Fitz-Axen, M., Flaminio, R., Fletcher, M., Flynn, E., Fong, H., Font, J. A., Forsyth, P. W. F., Fournier, J. -D., Frasca, S., Frasconi, F., Frei, Z., Freise, A., Frey, R., Frey, V., Fritschel, P., Frolov, V. V., Fujii, Y., Fukunaga, M., Fukushima, M., Fulda, P., Fyffe, M., Gabbard, H. A., Gadre, B. U., Gaebel, S. M., Gair, J. R., Gammaitoni, L., Ganija, M. R., Gaonkar, S. G., Garcia, A., Garcia-Quiros, C., Garufi, F., Gateley, B., Gaudio, S., Gaur, G., Gayathri, V., Ge, G. G., Gemme, G., Genin, E., Gennai, A., George, D., George, J., Gergely, L., Germain, V., Ghonge, S., Ghosh, A., Ghosh, S., Giacomazzo, B., Giaime, J. A., Giardina, K. D., Giazotto, A., Gill, K., Giordano, G., Glover, L., Godwin, P., Goetz, E., Goetz, R., Goncharov, B., Gonzalez, G., Castro, J. M. G., Gopakumar, A., Gorodetsky, M. L., Gossan, S. E., Gosselin, M., Gouaty, R., Grado, A., Graef, C., Granata, M., Grant, A., Gras, S., Grassia, P., Gray, C., Gray, R., Greco, G., Green, A. C., Green, R., Gretarsson, E. M., Groot, P., Grote, H., Grunewald, S., Gruning, P., Guidi, G. M., Gulati, H. K., Guo, Y., Gupta, A., Gupta, M. K., Gustafson, E. K., Gustafson, R., Haegel, L., Hagiwara, A., Haino, S., Halim, O., Hall, B. R., Hall, E. D., Hamilton, E. Z., Hammond, G., Haney, M., Hanke, M. M., Hanks, J., Hanna, C., Hannam, M. D., Hannuksela, O. A., Hanson, J., Hardwick, T., Haris, K., Harms, J., Harry, G. M., Harry, I. W., Hasegawa, K., Haster, C. -J., Haughian, K., Hayakawa, H., Hayama, K., Hayes, F. J., Healy, J., Heidmann, A., Heintze, M. C., Heitmann, H., Hello, P., Hemming, G., Hendry, M., Heng, I. S., Hennig, J., Heptonstall, A. W., Heurs, M., Hild, S., Himemoto, Y., Hinderer, T., Hiranuma, Y., Hirata, N., Hirose, E., Hoak, D., Hochheim, S., Hofman, D., Holgado, A. M., Holland, N. A., Holt, K., Holz, D. E., Hong, Z., Hopkins, P., Horst, C., Hough, J., Howell, E. J., Hoy, C. G., Hreibi, A., Hsieh, B. H., Huang, G. Z., Huang, P. W., Huang, Y. J., Huerta, E. A., Huet, D., Hughey, B., Hulko, M., Husa, S., Huttner, S. H., Huynh-Dinh, T., Idzkowski, B., Iess, A., Ikenoue, B., Imam, S., Inayoshi, K., Ingram, C., Inoue, Y., Inta, R., Intini, G., Ioka, K., Irwin, B., Isa, H. N., Isac, J. -M., Isi, M., Itoh, Y., Iyer, B. R., Izumi, K., Jacqmin, T., Jadhav, S. J., Jani, K., Janthalur, N. N., Jaranowski, P., Jenkins, A. C., Jiang, J., Johnson, D. S., Jones, A. W., Jones, D. I., Jones, R., Jonker, R. J. G., Ju, L., Jung, K., Jung, P., Junker, J., Kajita, T., Kalaghatgi, C. V., Kalogera, V., Kamai, B., Kamiizumi, M., Kanda, N., Kandhasamy, S., Kang, G. W., Kanner, J. B., Kapadia, S. J., Karki, S., Karvinen, K. S., Kashyap, R., Kasprzack, M., Katsanevas, S., Katsavounidis, E., Katzman, W., Kaufer, S., Kawabe, K., Kawaguchi, K., Kawai, N., Kawasaki, T., Keerthana, N. V., Kefelian, F., Keitel, D., Kennedy, R., Key, J. S., Khalili, F. Y., Khan, H., Khan, I., Khan, S., Khan, Z., Khazanov, E. A., Khursheed, M., Kijbunchoo, N., Kim, C., Kim, J. C., Kim, J., Kim, K., Kim, W., Kim, W. S., Kim, Y. -M., Kimball, C., Kimura, N., King, E. J., King, P. J., Kinley-Hanlon, M., Kirchhoff, R., Kissel, J. S., Kita, N., Kitazawa, H., Kleybolte, L., Klika, J. H., Klimenko, S., Knowles, T. D., Knyazev, E., Koch, P., Koehlenbeck, S. M., Koekoek, G., Kojima, Y., Kokeyama, K., Koley, S., Komori, K., Kondrashov, V., Kong, A. K. H., Kontos, A., Koper, N., Korobko, M., Korth, W. Z., Kotake, K., Kowalska, I., Kozak, D. B., Kozakai, C., Kozu, R., Kringel, V., Krishnendu, N., Krolak, A., Kuehn, G., Kumar, A., Kumar, P., Kumar, R., Kumar, S., Kume, J., Kuo, C. M., Kuo, H. S., Kuo, L., Kuroyanagi, S., Kusayanagi, K., Kutynia, A., Kwak, K., Kwang, S., Lackey, B. D., Lai, K. H., Lam, T. L., Landry, M., Lane, B. B., Lang, R. N., Lange, J., Lantz, B., Lanza, R. K., Lartaux-Vollard, A., Lasky, P. D., Laxen, M., Lazzarini, A., Lazzaro, C., Leaci, P., Leavey, S., Lecoeuche, Y. K., Lee, C. H., Lee, H. K., Lee, H. M., Lee, H. W., Lee, J., Lee, K., Lee, R. K., Lehmann, J., Lenon, A., Leonardi, M., Leroy, N., Letendre, N., Levin, Y., Li, J., Li, K. J. L., Li, T. G. F., Li, X., Lin, C. Y., Lin, F., Lin, F. L., Lin, L. C. C., Linde, F., Linker, S. D., Littenberg, T. B., Liu, G. C., Liu, J., Liu, X., Lo, R. K. L., Lockerbie, N. A., London, L. T., Longo, A., Lorenzini, M., Loriette, V., Lormand, M., Losurdo, G., Lough, J. D., Lousto, C. O., Lovelace, G., Lower, M. E., Luck, H., Lumaca, D., Lundgren, A. P., Luo, L. W., Lynch, R., Ma, Y., Macas, R., Macfoy, S., Macinnis, M., Macleod, D. M., Macquet, A., Magana-Sandoval, F., Zertuche, L. M., Magee, R. M., Majorana, E., Maksimovic, I., Malik, A., Man, N., Mandic, V., Mangano, V., Mansell, G. L., Manske, M., Mantovani, M., Marchesoni, F., Marchio, M., Marion, F., Marka, S., Marka, Z., Markakis, C., Markosyan, A. S., Markowitz, A., Maros, E., Marquina, A., Marsat, S., Martelli, F., Martin, I. W., Martin, R. M., Martynov, D. V., Mason, K., Massera, E., Masserot, A., Massinger, T. J., Masso-Reid, M., Mastrogiovanni, S., Matas, A., Matichard, F., Matone, L., Mavalvala, N., Mazumder, N., Mccann, J. J., Mccarthy, R., Mcclelland, D. E., Mccormick, S., Mcculler, L., Mcguire, S. C., Mciver, J., Mcmanus, D. J., Mcrae, T., Mcwilliams, S. T., Meacher, D., Meadors, G. D., Mehmet, M., Mehta, A. K., Meidam, J., Melatos, A., Mendell, G., Mercer, R. A., Mereni, L., Merilh, E. L., Merzougui, M., Meshkov, S., Messenger, C., Messick, C., Metzdorff, R., Meyers, P. M., Miao, H., Michel, C., Michimura, Y., Middleton, H., Mikhailov, E. E., Milano, L., Miller, A. L., Miller, A., Millhouse, M., Mills, J. C., Milovich-Goff, M. C., Minazzoli, O., Minenkov, Y., Mio, N., Mishkin, A., Mishra, C., Mistry, T., Mitra, S., Mitrofanov, V. P., Mitselmakher, G., Mittleman, R., Miyakawa, O., Miyamoto, A., Miyazaki, Y., Miyo, K., Miyoki, S., Mo, G., Moffa, D., Mogushi, K., Mohapatra, S. R. P., Montani, M., Moore, C. J., Moraru, D., Moreno, G., Morisaki, S., Moriwaki, Y., Mours, B., Mow-Lowry, C. M., Mukherjee, A., Mukherjee, D., Mukherjee, S., Mukund, N., Mullavey, A., Munch, J., Muniz, E. A., Muratore, M., Murray, P. G., Nagano, K., Nagano, S., Nagar, A., Nakamura, K., Nakano, H., Nakano, M., Nakashima, R., Nardecchia, I., Narikawa, T., Naticchioni, L., Nayak, R. K., Negishi, R., Neilson, J., Nelemans, G., Nelson, T. J. N., Nery, M., Neunzert, A., Ng, K. Y., Ng, S., Nguyen, P., Ni, W. T., Nichols, D., Nishizawa, A., Nissanke, S., Nocera, F., North, C., Nuttall, L. K., Obergaulinger, M., Oberling, J., O'Brien, B. D., Obuchi, Y., O'Dea, G. D., Ogaki, W., Ogin, G. H., Oh, J. J., Oh, S. H., Ohashi, M., Ohishi, N., Ohkawa, M., Ohme, F., Ohta, H., Okada, M. A., Okutomi, K., Oliver, M., Oohara, K., Ooi, C. P., Oppermann, P., Oram, R. J., O'Reilly, B., Ormiston, R. G., Ortega, L. F., O'Shaughnessy, R., Oshino, S., Ossokine, S., Ottaway, D. J., Overmier, H., Owen, B. J., Pace, A. E., Pagano, G., Page, M. A., Pai, A., Pai, S. A., Palamos, J. R., Palashov, O., Palomba, C., Pal-Singh, A., Pan, H. -W., Pan, K. C., Pang, B., Pang, H. F., Pang, P. T. H., Pankow, C., Pannarale, F., Pant, B. C., Paoletti, F., Paoli, A., Papa, M. A., Parida, A., Park, J., Parker, W., Pascucci, D., Pasqualetti, A., Passaquieti, R., Passuello, D., Patil, M., Patricelli, B., Pearlstone, B. L., Pedersen, C., Pedraza, M., Pedurand, R., Pele, A., Arellano, F. E. P., Penn, S., Perez, C. J., Perreca, A., Pfeiffer, H. P., Phelps, M., Phukon, K. S., Piccinni, O. J., Pichot, M., Piergiovanni, F., Pillant, G., Pinard, L., Pinto, I., Pirello, M., Pitkin, M., Poggiani, R., Pong, D. Y. T., Ponrathnam, S., Popolizio, P., Porter, E. K., Powell, J., Prajapati, A. K., Prasad, J., Prasai, K., Prasanna, R., Pratten, G., Prestegard, T., Privitera, S., Prodi, G. A., Prokhorov, L. G., Puncken, O., Punturo, M., Puppo, P., Purrer, M., Qi, H., Quetschke, V., Quinonez, P. J., Quintero, E. A., Quitzow-James, R., Raab, F. J., Radkins, H., Radulescu, N., Raffai, P., Raja, S., Rajan, C., Rajbhandari, B., Rakhmanov, M., Ramirez, K. E., Ramos-Buades, A., Rana, J., Rao, K., Rapagnani, P., Raymond, V., Razzano, M., Read, J., Regimbau, T., Rei, L., Reid, S., Reitze, D. H., Ren, W., Ricci, F., Richardson, C. J., Richardson, J. W., Ricker, P. M., Riles, K., Rizzo, M., Robertson, N. A., Robie, R., Robinet, F., Rocchi, A., Rolland, L., Rollins, J. G., Roma, V. J., Romanelli, M., Romano, R., Romel, C. L., Romie, J. H., Rose, K., Rosinska, D., Rosofsky, S. G., Ross, M. P., Rowan, S., Rudiger, A., Ruggi, P., Rutins, G., Ryan, K., Sachdev, S., Sadecki, T., Sago, N., Saito, S., Saito, Y., Sakai, K., Sakai, Y., Sakamoto, H., Sakellariadou, M., Sakuno, Y., Salconi, L., Saleem, M., Samajdar, A., Sammut, L., Sanchez, E. J., Sanchez, L. E., Sanchis-Gual, N., Sandberg, V., Sanders, J. R., Santiago, K. A., Sarin, N., Sassolas, B., Sathyaprakash, B. S., Sato, S., Sato, T., Sauter, O., Savage, R. L., Sawada, T., Schale, P., Scheel, M., Scheuer, J., Schmidt, P., Schnabel, R., Schofield, R. M. S., Schonbeck, A., Schreiber, E., Schulte, B. W., Schutz, B. F., Schwalbe, S. G., Scott, J., Scott, S. M., Seidel, E., Sekiguchi, T., Sekiguchi, Y., Sellers, D., Sengupta, A. S., Sennett, N., Sentenac, D., Sequino, V., Sergeev, A., Setyawati, Y., Shaddock, D. A., Shaffer, T., Shahriar, M. S., Shaner, M. B., Shao, L., Sharma, P., Shawhan, P., Shen, H., Shibagaki, S., Shimizu, R., Shimoda, T., Shimode, K., Shink, R., Shinkai, H., Shishido, T., Shoda, A., Shoemaker, D. H., Shoemaker, D. M., Shyamsundar, S., Siellez, K., Sieniawska, M., Sigg, D., Silva, A. D., Singer, L. P., Singh, N., Singhal, A., Sintes, A. M., Sitmukhambetov, S., Skliris, V., Slagmolen, B. J. J., Slaven-Blair, T. J., Smith, J. R., Smith, R. J. E., Somala, S., Somiya, K., Son, E. J., Sorazu, B., Sorrentino, F., Sotani, H., Souradeep, T., Sowell, E., Spencer, A. P., Srivastava, A. K., Srivastava, V., Staats, K., Stachie, C., Standke, M., Steer, D. A., Steinke, M., Steinlechner, J., Steinlechner, S., Steinmeyer, D., Stevenson, S. P., Stocks, D., Stone, R., Stops, D. J., Strain, K. A., Stratta, G., Strigin, S. E., Strunk, A., Sturani, R., Stuver, A. L., Sudhir, V., Sugimoto, R., Summerscales, T. Z., Sun, L., Sunil, S., Suresh, J., Sutton, P. J., Suzuki, T., Swinkels, B. L., Szczepanczyk, M. J., Tacca, M., Tagoshi, H., Tait, S. C., Takahashi, H., Takahashi, R., Takamori, A., Takano, S., Takeda, H., Takeda, M., Talbot, C., Talukder, D., Tanaka, H., Tanaka, K., Tanaka, T., Tanioka, S., Tanner, D. B., Tapai, M., Martin, E. N. T. S., Taracchini, A., Tasson, J. D., Taylor, R., Telada, S., Thies, F., Thomas, M., Thomas, P., Thondapu, S. R., Thorne, K. A., Thrane, E., Tiwari, S., Tiwari, V., Toland, K., Tomaru, T., Tomigami, Y., Tomura, T., Tonelli, M., Tornasi, Z., Torres-Forne, A., Torrie, C. I., Toyra, D., Travasso, F., Traylor, G., Tringali, M. C., Trovato, A., Trozzo, L., Trudeau, R., Tsang, K. W., Tsang, T. T. L., Tse, M., Tso, R., Tsubono, K., Tsuchida, S., Tsukada, L., Tsuna, D., Tsuzuki, T., Tuyenbayev, D., Uchikata, N., Uchiyama, T., Ueda, A., Uehara, T., Ueno, K., Ueshima, G., Ugolini, D., Unnikrishnan, C. S., Uraguchi, F., Urban, A. L., Ushiba, T., Usman, S. A., Vahlbruch, H., Vajente, G., Valdes, G., Bakel, N., Beuzekom, M., Brand, J. F. J., Broeck, C. V. D., Vander-Hyde, D. C., Schaaf, L., Heijningen, J. V., Putten, M. H. P. M., Veggel, A. A., Vardaro, M., Varma, V., Vass, S., Vasuth, M., Vecchio, A., Vedovato, G., Veitch, J., Veitch, P. J., Venkateswara, K., Venugopalan, G., Verkindt, D., Vetrano, F., Vicere, A., Viets, A. D., Vine, D. J., Vinet, J. -Y., Vitale, S., Vivanco, F. H., Vo, T., Vocca, H., Vorvick, C., Vyatchanin, S. P., Wade, A. R., Wade, L. E., Wade, M., Walet, R., Walker, M., Wallace, L., Walsh, S., Wang, G., Wang, H., Wang, J., Wang, J. Z., Wang, W. H., Wang, Y. F., Ward, R. L., Warden, Z. A., Warner, J., Was, M., Watchi, J., Weaver, B., Wei, L. -W., Weinert, M., Weinstein, A. J., Weiss, R., Wellmann, F., Wen, L., Wessel, E. K., Wessels, P., Westhouse, J. W., Wette, K., Whelan, J. T., Whiting, B. F., Whittle, C., Wilken, D. M., Williams, D., Williamson, A. R., Willis, J. L., Willke, B., Wimmer, M. H., Winkler, W., Wipf, C. C., Wittel, H., Woan, G., Woehler, J., Wofford, J. K., Worden, J., Wright, J. L., Wu, C. M., Wu, D. S., Wu, H. C., Wu, S. R., Wysocki, D. M., Xiao, L., Xu, W. R., Yamada, T., Yamamoto, H., Yamamoto, K., Yamamoto, T., Yancey, C. C., Yang, L., Yap, M. J., Yazback, M., Yeeles, D. W., Yokogawa, K., Yokoyama, J., Yokozawa, T., Yoshioka, T., Yu, H., Yuen, S. H. R., Yuzurihara, H., Yvert, M., Zadrozny, A. K., Zanolin, M., Zeidler, S., Zelenova, T., Zendri, J. -P., Zevin, M., Zhang, J., Zhang, L., Zhang, T., Zhao, C., Zhao, Y., Zhou, M., Zhou, Z., Zhu, X. J., Zhu, Z. H., Zimmerman, A. B., Zucker, M. E., Zweizig, J., Abernathy, M. R., Adams, T., Addesso, P., Adhikari, R. X., Allen, B., Asada, H., Ast, M., Atsuta, S., Aulbert, C., Awai, K., Batch, J. C., Baune, C., Bavigadda, V., Bécsy, B., Beer, C., Belgin, M., Bhagwat, S., Billman, C. R., Biwer, C., Blackman, J., Bock, O., Bohe, A., Braginsky, V. B., Broida, J. E., Buchanan, C. C., Calderón bustillo, J., Capano, C. D., Casanueva diaz, J., Cavaglià, M., Cepeda, C. B., Cerboni baiardi, L., Chmiel, T., Chow, J. H., Chua, A. J. K., Colla, A., Cominsky, L., Canton, T. Dal, D’Antonio, S., Davies, G. S., Day, B., Day, R., De, S., Debreczeni, G., Deléglise, S., Del Pozzo, W., Denker, T., Dergachev, V., De Rosa, Rosario., Derosa, R. T., Devine, R. C., Díaz, M. C., Fiore, L. Di, Giovanni, M. Di, Di Girolamo, T., Lieto, A. Di, Pace, S. Di, Palma, I. Di, Virgilio, A. Di, Dolique, V., Douglas, R., Dovale álvarez, M., Drever, R. W. P., Ducrot, M., Eda, K., Eggenstein, H. -B., Etienne, Z., Everett, R., Factourovich, M., Fehrmann, H., Fernández galiana, A., Forsyth, S. S., Fries, E. M., Fujimoto, M. -K., Gabbard, H., Gehrels, N., Ghosh, Abhirup, Ghosh, Archisman, Glaefke, A., Gondan, L., González, G., Gonzalez castro, J. M., Guo, X., Gushwa, K. E., Hacker, J. J., Hart, M. J., Hartman, M. T., Henry, J., Houston, E. A., Hu, Y. M., Indik, N., Ingram, D. R., Isogai, T., Jawahar, S., Jiménez-Forteza, F., Johnson, W. W., Kagawa, T., Kakizaki, M., Kanemura, S., Kaneyama, M., Kang, G., Kataoka, Y., Kaur, T., Kawamura, S., Kéfélian, F., Kelley, D. B., Kim, H., Kimbrell, S. J., Klein, B., Krämer, C., Krishnan, B., Królak, A., Kumar, Rahul, Kumar, Rakesh, Kuroda, K., Kuwahara, Y., Lebigot, E. O., Leong, J. R., Libson, A., Lombardi, A. L., Lord, J. E., Lück, H., Machenschalk, B., Magaña-Sandoval, F., Malvezzi, V., Mano, S., Márka, S., Márka, Z., Martellini, L., Matsumoto, N., Matsushima, F., Mcgrath, C., Mcintyre, G., Mendoza-Gandara, D., Mezzani, F., Miller, B. B., Ming, J., Mirshekari, S., Miyamoto, T., Moggi, A., Mohan, M., Moore, B. C., Morii, W., Morriss, S. R., Mueller, G., Muir, A. W., Mukherjee, Arunava, Muniz, E. A. M., Mytidis, A., Nakamura, T., Nakano, Masaya, Nakano, Masayuki, Nakao, K., Napier, K., Neri, M., Newport, J. M., Newton, G., Nguyen, T. T., Ni, W. -T., Nielsen, A. B., Nitz, A., Noack, A., Nolting, D., Normandin, M. E. N., Ochsner, E., Oelker, E., Ono, K., Ono, Y., Oram, Richard J., O’Reilly, B., O’Shaughnessy, R., Page, J., Pan, H., Paris, H. R., Pekowsky, L., Peña arellano, F. E., Perri, L. M., Pierro, V., Pinto, I. M., Poe, M., Post, A., Pratt, J. W. W., Predoi, V., Prijatelj, M., Principe, M., Pürrer, M., Qin, J., Qiu, S., Rabeling, D. S., Re, V., Rew, H., Reyes, S. D., Rhoades, E., Rosińska, D., Rüdiger, A., Sadeghian, L., Saijo, M., Salemi, F., Sampson, L. M., Sasaki, Y., Saulson, P. R., Sawadsky, A., Schmidt, E., Schmidt, J., Schönbeck, A., Schuette, D., Shaffer, T. J., Shapiro, B., Sheperd, A., Shibata, M., Shikano, Y., Siemens, X., Singer, A., Singh, A., Singh, R., Smith, B., Staley, A., Stephens, B. C., Straniero, N., Sugimoto, Y., Szczepańczyk, M. J., Takada, S., Tápai, M., Tatsumi, D., Theeg, T., Thomas, E. G., Tippens, T., Tokmakov, K. V., Tomlinson, C., Töyrä, D., Trifirò, D., Trinastic, J., Turconi, M., Ueki, S., van Bakel, N., van Beuzekom, M., van den Brand, J. F. J., Van Den Broeck, C., van der Schaaf, L., van Heijningen, J. V., van Putten, M. H. P. M., van Veggel, A. A., Vasúth, M., Viceré, A., Vinciguerra, S., Voss, D. V., Vousden, W. D., Wakamatsu, T., Wang, M., Wang, Y., Weßels, P., Westphal, T., Williams, R. D., Wu, G., Yam, W., Yano, K., Yoon, T. H., Zadrożny, A., Zangrando, L., Zhang, M., Zhang, Y., and Zhu, S. J.

Subjects
neutron star: binary, EVENTS GW150914, Gravitational-wave observatory, Physics and Astronomy (miscellaneous), Astronomy, Binary number, Astrophysics, detector: network, Review Article, BLACK-HOLE BINARIES, 01 natural sciences, General Relativity and Quantum Cosmology, localization, Physics, Particles & Fields, Gravitational waves, Gravitational-wave detectors, Electromagnetic counterparts, Data analysis, Observatory, Gravitational-wave detector, NEUTRON-STAR, LIGO, 010303 astronomy & astrophysics, ELECTROMAGNETIC SIGNALS, QC, QB, media_common, Settore FIS/01, Physics, High Energy Astrophysical Phenomena (astro-ph.HE), NUCLEOSYNTHESIS, GAMMA-RAY BURSTS, star merger rate, COMPACT BINARIES, Detector, Astrophysics::Instrumentation and Methods for Astrophysics, Data analysi, Physical Sciences, Physique des particules élémentaires, [PHYS.GRQC]Physics [physics]/General Relativity and Quantum Cosmology [gr-qc], Astrophysics - High Energy Astrophysical Phenomena, Gravitational wave, BLACK-HOLE MERGERS, data analysis method, LONG-TERM, media_common.quotation_subject, Astrophysics::High Energy Astrophysical Phenomena, FOS: Physical sciences, counterparts, General Relativity and Quantum Cosmology (gr-qc), Astrophysics::Cosmology and Extragalactic Astrophysics, MASS, lcsh:Atomic physics. Constitution and properties of matter, Electromagnetic counterpart, Gravitational-wave astronomy, electromagnetic field: production, binary: coalescence, SEARCH, evolution, 0103 physical sciences, KAGRA, RATES, Luminosity distance, Astrophysics::Galaxy Astrophysics, Science & Technology, IDENTIFICATION, 010308 nuclear & particles physics, Physique, COUNTERPART, gravitational radiation, black hole: mass, binary: compact, gravitational radiation detector, EVOLUTION, lcsh:QC170-197, Electromagnetic, detector: sensitivity, VIRGO, black hole: binary, Physics and Astronomy, Sky, Intermediate-mass black hole, STAR MERGER RATE, gravitational radiation: emission, SWIFT FOLLOW-UP
Abstract

We present our current best estimate of the plausible observing scenarios for the Advanced LIGO, Advanced Virgo and KAGRA gravitational-wave detectors over the next several years, with the intention of providing information to facilitate planning for multi-messenger astronomy with gravitational waves. We estimate the sensitivity of the network to transient gravitational-wave signals for the third (O3), fourth (O4) and fifth observing (O5) runs, including the planned upgrades of the Advanced LIGO and Advanced Virgo detectors. We study the capability of the network to determine the sky location of the source for gravitational-wave signals from the inspiral of binary systems of compact objects, that is binary neutron star, neutron star–black hole, and binary black hole systems. The ability to localize the sources is given as a sky-area probability, luminosity distance, and comoving volume. The median sky localization area (90% credible region) is expected to be a few hundreds of square degrees for all types of binary systems during O3 with the Advanced LIGO and Virgo (HLV) network. The median sky localization area will improve to a few tens of square degrees during O4 with the Advanced LIGO, Virgo, and KAGRA (HLVK) network. During O3, the median localization volume (90% credible region) is expected to be on the order of 105,106,107Mpc3 for binary neutron star, neutron star–black hole, and binary black hole systems, respectively. The localization volume in O4 is expected to be about a factor two smaller than in O3. We predict a detection count of 1-1+12(10-10+52) for binary neutron star mergers, of 0-0+19(1-1+91) for neutron star–black hole mergers, and 17-11+22(79-44+89) for binary black hole mergers in a one-calendar-year observing run of the HLV network during O3 (HLVK network during O4). We evaluate sensitivity and localization expectations for unmodeled signal searches, including the search for intermediate mass black hole binary mergers., 0, info:eu-repo/semantics/inPress

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results